Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs</title><author><name sortKey="Hassan, Zurina" sort="Hassan, Zurina" uniqKey="Hassan Z" first="Zurina" last="Hassan">Zurina Hassan</name><affiliation><nlm:aff id="aff1"><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Bosch, Oliver G" sort="Bosch, Oliver G" uniqKey="Bosch O" first="Oliver G." last="Bosch">Oliver G. Bosch</name><affiliation><nlm:aff id="aff2"><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Singh, Darshan" sort="Singh, Darshan" uniqKey="Singh D" first="Darshan" last="Singh">Darshan Singh</name><affiliation><nlm:aff id="aff1"><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Narayanan, Suresh" sort="Narayanan, Suresh" uniqKey="Narayanan S" first="Suresh" last="Narayanan">Suresh Narayanan</name><affiliation><nlm:aff id="aff3"><institution>School of Social Sciences, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Kasinather, B Vicknasingam" sort="Kasinather, B Vicknasingam" uniqKey="Kasinather B" first="B. Vicknasingam" last="Kasinather">B. Vicknasingam Kasinather</name><affiliation><nlm:aff id="aff1"><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Seifritz, Erich" sort="Seifritz, Erich" uniqKey="Seifritz E" first="Erich" last="Seifritz">Erich Seifritz</name><affiliation><nlm:aff id="aff2"><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Kornhuber, Johannes" sort="Kornhuber, Johannes" uniqKey="Kornhuber J" first="Johannes" last="Kornhuber">Johannes Kornhuber</name><affiliation><nlm:aff id="aff4"><institution>Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Quednow, Boris B" sort="Quednow, Boris B" uniqKey="Quednow B" first="Boris B." last="Quednow">Boris B. Quednow</name><affiliation><nlm:aff id="aff5"><institution>Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Muller, Christian P" sort="Muller, Christian P" uniqKey="Muller C" first="Christian P." last="Müller">Christian P. Müller</name><affiliation><nlm:aff id="aff4"><institution>Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28868040</idno><idno type="pmc">5563308</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563308</idno><idno type="RBID">PMC:5563308</idno><idno type="doi">10.3389/fpsyt.2017.00152</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">001004</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001004</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs</title><author><name sortKey="Hassan, Zurina" sort="Hassan, Zurina" uniqKey="Hassan Z" first="Zurina" last="Hassan">Zurina Hassan</name><affiliation><nlm:aff id="aff1"><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Bosch, Oliver G" sort="Bosch, Oliver G" uniqKey="Bosch O" first="Oliver G." last="Bosch">Oliver G. Bosch</name><affiliation><nlm:aff id="aff2"><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Singh, Darshan" sort="Singh, Darshan" uniqKey="Singh D" first="Darshan" last="Singh">Darshan Singh</name><affiliation><nlm:aff id="aff1"><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Narayanan, Suresh" sort="Narayanan, Suresh" uniqKey="Narayanan S" first="Suresh" last="Narayanan">Suresh Narayanan</name><affiliation><nlm:aff id="aff3"><institution>School of Social Sciences, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Kasinather, B Vicknasingam" sort="Kasinather, B Vicknasingam" uniqKey="Kasinather B" first="B. Vicknasingam" last="Kasinather">B. Vicknasingam Kasinather</name><affiliation><nlm:aff id="aff1"><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></nlm:aff></affiliation></author><author><name sortKey="Seifritz, Erich" sort="Seifritz, Erich" uniqKey="Seifritz E" first="Erich" last="Seifritz">Erich Seifritz</name><affiliation><nlm:aff id="aff2"><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Kornhuber, Johannes" sort="Kornhuber, Johannes" uniqKey="Kornhuber J" first="Johannes" last="Kornhuber">Johannes Kornhuber</name><affiliation><nlm:aff id="aff4"><institution>Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Quednow, Boris B" sort="Quednow, Boris B" uniqKey="Quednow B" first="Boris B." last="Quednow">Boris B. Quednow</name><affiliation><nlm:aff id="aff5"><institution>Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Muller, Christian P" sort="Muller, Christian P" uniqKey="Muller C" first="Christian P." last="Müller">Christian P. Müller</name><affiliation><nlm:aff id="aff4"><institution>Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></nlm:aff></affiliation></author></analytic><series><title level="j">Frontiers in Psychiatry</title><idno type="eISSN">1664-0640</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects. These drugs change the mental state and/or the behavioral performance of an individual and can be instrumentalized for various purposes. After the emergence of a novel psychoactive substance (NPS) and a period of experimental consumption, personal and medical benefits and harm potential of the NPS can be estimated on evidence base. This may lead to a legal classification of the NPS, which may range from limited medical use, controlled availability up to a complete ban of the drug form publically accepted use. With these measures, however, a drug does not disappear, but frequently continues to be used, which eventually allows an even better estimate of the drug’s properties. Thus, only in rare cases, there is a final verdict that is no more questioned. Instead, the view on a drug can change from tolerable to harmful but may also involve the new establishment of a desired medical application to a previously harmful drug. Here, we provide a summary review on a number of NPS for which the neuropharmacological evaluation has made important progress in recent years. They include mitragynine (“Kratom”), synthetic cannabinoids (e.g., “Spice”), dimethyltryptamine and novel serotonergic hallucinogens, the cathinones mephedrone and methylone, ketamine and novel dissociative drugs, γ-hydroxybutyrate, γ-butyrolactone, and 1,4-butanediol. This review shows not only emerging harm potentials but also some potential medical applications.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Jay, M" uniqKey="Jay M">M Jay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wadley, G" uniqKey="Wadley G">G Wadley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hagen, Eh" uniqKey="Hagen E">EH Hagen</name></author><author><name sortKey="Sullivan, Rj" uniqKey="Sullivan R">RJ Sullivan</name></author><author><name sortKey="Schmidt, R" uniqKey="Schmidt R">R Schmidt</name></author><author><name sortKey="Morris, G" uniqKey="Morris G">G Morris</name></author><author><name sortKey="Kempter, R" uniqKey="Kempter R">R Kempter</name></author><author><name sortKey="Hammerstein, P" uniqKey="Hammerstein P">P Hammerstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dellu, F" uniqKey="Dellu F">F Dellu</name></author><author><name sortKey="Piazza, Pv" uniqKey="Piazza P">PV Piazza</name></author><author><name sortKey="Mayo, W" uniqKey="Mayo W">W Mayo</name></author><author><name sortKey="Le Moal, M" uniqKey="Le Moal M">M Le Moal</name></author><author><name sortKey="Simon, H" uniqKey="Simon H">H Simon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bidwell, Lc" uniqKey="Bidwell L">LC Bidwell</name></author><author><name sortKey="Knopik, Vs" uniqKey="Knopik V">VS Knopik</name></author><author><name sortKey="Audrain Mcgovern, J" uniqKey="Audrain Mcgovern J">J Audrain-McGovern</name></author><author><name sortKey="Glynn, Tr" uniqKey="Glynn T">TR Glynn</name></author><author><name sortKey="Spillane, Ns" uniqKey="Spillane N">NS Spillane</name></author><author><name sortKey="Ray, La" uniqKey="Ray L">LA Ray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Schumann, G" uniqKey="Schumann G">G Schumann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Schumann, G" uniqKey="Schumann G">G Schumann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brand, R" uniqKey="Brand R">R Brand</name></author><author><name sortKey="Wolff, W" uniqKey="Wolff W">W Wolff</name></author><author><name sortKey="Ziegler, M" uniqKey="Ziegler M">M Ziegler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mccreary, Ac" uniqKey="Mccreary A">AC McCreary</name></author><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Filip, M" uniqKey="Filip M">M Filip</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmed, Sh" uniqKey="Ahmed S">SH Ahmed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chick, J" uniqKey="Chick J">J Chick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heath, Db" uniqKey="Heath D">DB Heath</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peele, S" uniqKey="Peele S">S Peele</name></author><author><name sortKey="Brodsky, A" uniqKey="Brodsky A">A Brodsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lende, Dh" uniqKey="Lende D">DH Lende</name></author><author><name sortKey="Leonard, T" uniqKey="Leonard T">T Leonard</name></author><author><name sortKey="Sterk, Ce" uniqKey="Sterk C">CE Sterk</name></author><author><name sortKey="Elifson, K" uniqKey="Elifson K">K Elifson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spear, Lp" uniqKey="Spear L">LP Spear</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuntsche, E" uniqKey="Kuntsche E">E Kuntsche</name></author><author><name sortKey="Knibbe, R" uniqKey="Knibbe R">R Knibbe</name></author><author><name sortKey="Gmel, G" uniqKey="Gmel G">G Gmel</name></author><author><name sortKey="Engels, R" uniqKey="Engels R">R Engels</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Kalinichenko, Ls" uniqKey="Kalinichenko L">LS Kalinichenko</name></author><author><name sortKey="Tiesel, J" uniqKey="Tiesel J">J Tiesel</name></author><author><name sortKey="Witt, M" uniqKey="Witt M">M Witt</name></author><author><name sortKey="Stockl, T" uniqKey="Stockl T">T Stöckl</name></author><author><name sortKey="Sprenger, E" uniqKey="Sprenger E">E Sprenger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonn Miller, Mo" uniqKey="Bonn Miller M">MO Bonn-Miller</name></author><author><name sortKey="Zvolensky, Mj" uniqKey="Zvolensky M">MJ Zvolensky</name></author><author><name sortKey="Bernstein, A" uniqKey="Bernstein A">A Bernstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fattore, L" uniqKey="Fattore L">L Fattore</name></author><author><name sortKey="Fratta, W" uniqKey="Fratta W">W Fratta</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author><author><name sortKey="Orsolini, L" uniqKey="Orsolini L">L Orsolini</name></author><author><name sortKey="Duccio Papanti, G" uniqKey="Duccio Papanti G">G Duccio Papanti</name></author><author><name sortKey="Corkery, Jm" uniqKey="Corkery J">JM Corkery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, D" uniqKey="Singh D">D Singh</name></author><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Vicknasingam, Bk" uniqKey="Vicknasingam B">BK Vicknasingam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Frederiksen, Nj" uniqKey="Frederiksen N">NJ Frederiksen</name></author><author><name sortKey="Bakke, Sl" uniqKey="Bakke S">SL Bakke</name></author><author><name sortKey="Dalum, P" uniqKey="Dalum P">P Dalum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kornhuber, J" uniqKey="Kornhuber J">J Kornhuber</name></author><author><name sortKey="Weller, M" uniqKey="Weller M">M Weller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Lin, D" uniqKey="Lin D">D Lin</name></author><author><name sortKey="Wu, B" uniqKey="Wu B">B Wu</name></author><author><name sortKey="Zhou, W" uniqKey="Zhou W">W Zhou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Romeo, B" uniqKey="Romeo B">B Romeo</name></author><author><name sortKey="Choucha, W" uniqKey="Choucha W">W Choucha</name></author><author><name sortKey="Fossati, P" uniqKey="Fossati P">P Fossati</name></author><author><name sortKey="Rotge, Jy" uniqKey="Rotge J">JY Rotge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Hassan, Z" uniqKey="Hassan Z">Z Hassan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hassan, Z" uniqKey="Hassan Z">Z Hassan</name></author><author><name sortKey="Muzaimi, M" uniqKey="Muzaimi M">M Muzaimi</name></author><author><name sortKey="Navaratnam, V" uniqKey="Navaratnam V">V Navaratnam</name></author><author><name sortKey="Yusoff, Nhm" uniqKey="Yusoff N">NHM Yusoff</name></author><author><name sortKey="Suhaimi, Fw" uniqKey="Suhaimi F">FW Suhaimi</name></author><author><name sortKey="Vadivelu, R" uniqKey="Vadivelu R">R Vadivelu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, D" uniqKey="Singh D">D Singh</name></author><author><name sortKey="Narayanan, S" uniqKey="Narayanan S">S Narayanan</name></author><author><name sortKey="Vicknasingam, B" uniqKey="Vicknasingam B">B Vicknasingam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brown, Pn" uniqKey="Brown P">PN Brown</name></author><author><name sortKey="Lund, Ja" uniqKey="Lund J">JA Lund</name></author><author><name sortKey="Murch, Sj" uniqKey="Murch S">SJ Murch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saingam, D" uniqKey="Saingam D">D Saingam</name></author><author><name sortKey="Assanangkornchai, S" uniqKey="Assanangkornchai S">S Assanangkornchai</name></author><author><name sortKey="Geater, Af" uniqKey="Geater A">AF Geater</name></author><author><name sortKey="Lerkiatbundit, S" uniqKey="Lerkiatbundit S">S Lerkiatbundit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vicknasingam, B" uniqKey="Vicknasingam B">B Vicknasingam</name></author><author><name sortKey="Narayanan, S" uniqKey="Narayanan S">S Narayanan</name></author><author><name sortKey="Beng, Gt" uniqKey="Beng G">GT Beng</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boyer, Ew" uniqKey="Boyer E">EW Boyer</name></author><author><name sortKey="Babu, Km" uniqKey="Babu K">KM Babu</name></author><author><name sortKey="Adkins, Je" uniqKey="Adkins J">JE Adkins</name></author><author><name sortKey="Mccurdy, Cr" uniqKey="Mccurdy C">CR McCurdy</name></author><author><name sortKey="Halpern, Jh" uniqKey="Halpern J">JH Halpern</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prozialeck, Wc" uniqKey="Prozialeck W">WC Prozialeck</name></author><author><name sortKey="Jivan, Jk" uniqKey="Jivan J">JK Jivan</name></author><author><name sortKey="Andurkar, Sv" uniqKey="Andurkar S">SV Andurkar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cinosi, E" uniqKey="Cinosi E">E Cinosi</name></author><author><name sortKey="Martinotti, G" uniqKey="Martinotti G">G Martinotti</name></author><author><name sortKey="Simonato, P" uniqKey="Simonato P">P Simonato</name></author><author><name sortKey="Singh, D" uniqKey="Singh D">D Singh</name></author><author><name sortKey="Demetrovics, Z" uniqKey="Demetrovics Z">Z Demetrovics</name></author><author><name sortKey="Roman Urrestarazu, A" uniqKey="Roman Urrestarazu A">A Roman-Urrestarazu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Warner, Ml" uniqKey="Warner M">ML Warner</name></author><author><name sortKey="Kaufman, Nc" uniqKey="Kaufman N">NC Kaufman</name></author><author><name sortKey="Grundmann, O" uniqKey="Grundmann O">O Grundmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Swogger, Mt" uniqKey="Swogger M">MT Swogger</name></author><author><name sortKey="Hart, E" uniqKey="Hart E">E Hart</name></author><author><name sortKey="Erowid, F" uniqKey="Erowid F">F Erowid</name></author><author><name sortKey="Erowid, E" uniqKey="Erowid E">E Erowid</name></author><author><name sortKey="Trabold, N" uniqKey="Trabold N">N Trabold</name></author><author><name sortKey="Yee, K" uniqKey="Yee K">K Yee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suhaimi, Fw" uniqKey="Suhaimi F">FW Suhaimi</name></author><author><name sortKey="Yusoff, Nhm" uniqKey="Yusoff N">NHM Yusoff</name></author><author><name sortKey="Hassan, R" uniqKey="Hassan R">R Hassan</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author><author><name sortKey="Navaratnam, V" uniqKey="Navaratnam V">V Navaratnam</name></author><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmad, K" uniqKey="Ahmad K">K Ahmad</name></author><author><name sortKey="Aziz, Z" uniqKey="Aziz Z">Z Aziz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saingam, D" uniqKey="Saingam D">D Saingam</name></author><author><name sortKey="Assanangkornchai, S" uniqKey="Assanangkornchai S">S Assanangkornchai</name></author><author><name sortKey="Geater, Af" uniqKey="Geater A">AF Geater</name></author><author><name sortKey="Balthip, Q" uniqKey="Balthip Q">Q Balthip</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanguay, P" uniqKey="Tanguay P">P Tanguay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assanangkornchai, S" uniqKey="Assanangkornchai S">S Assanangkornchai</name></author><author><name sortKey="Muekthong, A" uniqKey="Muekthong A">A Muekthong</name></author><author><name sortKey="Sam Angsri, N" uniqKey="Sam Angsri N">N Sam-Angsri</name></author><author><name sortKey="Pattanasattayawong, U" uniqKey="Pattanasattayawong U">U Pattanasattayawong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Singh, D" uniqKey="Singh D">D Singh</name></author><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Vicknasingam, Bk" uniqKey="Vicknasingam B">BK Vicknasingam</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trakulsrichai, S" uniqKey="Trakulsrichai S">S Trakulsrichai</name></author><author><name sortKey="Tongpo, A" uniqKey="Tongpo A">A Tongpo</name></author><author><name sortKey="Sriapha, C" uniqKey="Sriapha C">C Sriapha</name></author><author><name sortKey="Wongvisawakorn, S" uniqKey="Wongvisawakorn S">S Wongvisawakorn</name></author><author><name sortKey="Rittilert, P" uniqKey="Rittilert P">P Rittilert</name></author><author><name sortKey="Kaojarern, S" uniqKey="Kaojarern S">S Kaojarern</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ward, J" uniqKey="Ward J">J Ward</name></author><author><name sortKey="Rosenbaum, C" uniqKey="Rosenbaum C">C Rosenbaum</name></author><author><name sortKey="Hernon, C" uniqKey="Hernon C">C Hernon</name></author><author><name sortKey="Mccurdy, Cr" uniqKey="Mccurdy C">CR McCurdy</name></author><author><name sortKey="Boyer, Ew" uniqKey="Boyer E">EW Boyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suwanlert, S" uniqKey="Suwanlert S">S Suwanlert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prozialeck, Wc" uniqKey="Prozialeck W">WC Prozialeck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schmidt, Mm" uniqKey="Schmidt M">MM Schmidt</name></author><author><name sortKey="Sharma, A" uniqKey="Sharma A">A Sharma</name></author><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author><author><name sortKey="Feinmann, C" uniqKey="Feinmann C">C Feinmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kronstrand, R" uniqKey="Kronstrand R">R Kronstrand</name></author><author><name sortKey="Roman, M" uniqKey="Roman M">M Roman</name></author><author><name sortKey="Thelander, G" uniqKey="Thelander G">G Thelander</name></author><author><name sortKey="Eriksson, A" uniqKey="Eriksson A">A Eriksson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anwar, M" uniqKey="Anwar M">M Anwar</name></author><author><name sortKey="Law, R" uniqKey="Law R">R Law</name></author><author><name sortKey="Schier, J" uniqKey="Schier J">J Schier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lydecker, Ag" uniqKey="Lydecker A">AG Lydecker</name></author><author><name sortKey="Sharma, A" uniqKey="Sharma A">A Sharma</name></author><author><name sortKey="Mccurdy, Cr" uniqKey="Mccurdy C">CR McCurdy</name></author><author><name sortKey="Avery, Ba" uniqKey="Avery B">BA Avery</name></author><author><name sortKey="Babu, Km" uniqKey="Babu K">KM Babu</name></author><author><name sortKey="Boyer, Ew" uniqKey="Boyer E">EW Boyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shellard, Ej" uniqKey="Shellard E">EJ Shellard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yusoff, Nhm" uniqKey="Yusoff N">NHM Yusoff</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Hassan, Z" uniqKey="Hassan Z">Z Hassan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takayama, H" uniqKey="Takayama H">H Takayama</name></author><author><name sortKey="Maeda, M" uniqKey="Maeda M">M Maeda</name></author><author><name sortKey="Ohbayashi, S" uniqKey="Ohbayashi S">S Ohbayashi</name></author><author><name sortKey="Kitajima, M" uniqKey="Kitajima M">M Kitajima</name></author><author><name sortKey="Sakai, Si" uniqKey="Sakai S">SI Sakai</name></author><author><name sortKey="Aimi, N" uniqKey="Aimi N">N Aimi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ma, J" uniqKey="Ma J">J Ma</name></author><author><name sortKey="Yin, W" uniqKey="Yin W">W Yin</name></author><author><name sortKey="Zhou, H" uniqKey="Zhou H">H Zhou</name></author><author><name sortKey="Cook, Jm" uniqKey="Cook J">JM Cook</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ma, J" uniqKey="Ma J">J Ma</name></author><author><name sortKey="Yin, Wy" uniqKey="Yin W">WY Yin</name></author><author><name sortKey="Zhou, H" uniqKey="Zhou H">H Zhou</name></author><author><name sortKey="Liao, Xb" uniqKey="Liao X">XB Liao</name></author><author><name sortKey="Cook, Jm" uniqKey="Cook J">JM Cook</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Isabel, K" uniqKey="Isabel K">K Isabel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parthasarathy, S" uniqKey="Parthasarathy S">S Parthasarathy</name></author><author><name sortKey="Ramanathan, S" uniqKey="Ramanathan S">S Ramanathan</name></author><author><name sortKey="Ismail, S" uniqKey="Ismail S">S Ismail</name></author><author><name sortKey="Adenan, Mi" uniqKey="Adenan M">MI Adenan</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author><author><name sortKey="Murugaiyah, V" uniqKey="Murugaiyah V">V Murugaiyah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Janchawee, B" uniqKey="Janchawee B">B Janchawee</name></author><author><name sortKey="Keawpradub, N" uniqKey="Keawpradub N">N Keawpradub</name></author><author><name sortKey="Chittrakarn, S" uniqKey="Chittrakarn S">S Chittrakarn</name></author><author><name sortKey="Prasettho, S" uniqKey="Prasettho S">S Prasettho</name></author><author><name sortKey="Wararatananurak, P" uniqKey="Wararatananurak P">P Wararatananurak</name></author><author><name sortKey="Sawangjareon, K" uniqKey="Sawangjareon K">K Sawangjareon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Moraes, Nv" uniqKey="De Moraes N">NV de Moraes</name></author><author><name sortKey="Moretti, Ra" uniqKey="Moretti R">RA Moretti</name></author><author><name sortKey="Furr, Eb" uniqKey="Furr E">EB Furr</name></author><author><name sortKey="Mccurdy, Cr" uniqKey="Mccurdy C">CR McCurdy</name></author><author><name sortKey="Lanchote, Vl" uniqKey="Lanchote V">VL Lanchote</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramanathan, S" uniqKey="Ramanathan S">S Ramanathan</name></author><author><name sortKey="Parthasarathy, S" uniqKey="Parthasarathy S">S Parthasarathy</name></author><author><name sortKey="Murugaiyah, V" uniqKey="Murugaiyah V">V Murugaiyah</name></author><author><name sortKey="Magosso, E" uniqKey="Magosso E">E Magosso</name></author><author><name sortKey="Tan, Sc" uniqKey="Tan S">SC Tan</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Philipp, Aa" uniqKey="Philipp A">AA Philipp</name></author><author><name sortKey="Wissenbach, Dk" uniqKey="Wissenbach D">DK Wissenbach</name></author><author><name sortKey="Zoerntlein, Sw" uniqKey="Zoerntlein S">SW Zoerntlein</name></author><author><name sortKey="Klein, On" uniqKey="Klein O">ON Klein</name></author><author><name sortKey="Kanogsunthornrat, J" uniqKey="Kanogsunthornrat J">J Kanogsunthornrat</name></author><author><name sortKey="Maurer, Hh" uniqKey="Maurer H">HH Maurer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Philipp, Aa" uniqKey="Philipp A">AA Philipp</name></author><author><name sortKey="Wissenbach, Dk" uniqKey="Wissenbach D">DK Wissenbach</name></author><author><name sortKey="Weber, Aa" uniqKey="Weber A">AA Weber</name></author><author><name sortKey="Zapp, J" uniqKey="Zapp J">J Zapp</name></author><author><name sortKey="Maurer, Hh" uniqKey="Maurer H">HH Maurer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Philipp, Aa" uniqKey="Philipp A">AA Philipp</name></author><author><name sortKey="Wissenbach, Dk" uniqKey="Wissenbach D">DK Wissenbach</name></author><author><name sortKey="Weber, Aa" uniqKey="Weber A">AA Weber</name></author><author><name sortKey="Zapp, J" uniqKey="Zapp J">J Zapp</name></author><author><name sortKey="Zoerntlein, Sw" uniqKey="Zoerntlein S">SW Zoerntlein</name></author><author><name sortKey="Kanogsunthornrat, J" uniqKey="Kanogsunthornrat J">J Kanogsunthornrat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taufik Hidayat, M" uniqKey="Taufik Hidayat M">M Taufik Hidayat</name></author><author><name sortKey="Apryani, E" uniqKey="Apryani E">E Apryani</name></author><author><name sortKey="Nabishah, Bm" uniqKey="Nabishah B">BM Nabishah</name></author><author><name sortKey="Moklas, Maa" uniqKey="Moklas M">MAA Moklas</name></author><author><name sortKey="Sharida, F" uniqKey="Sharida F">F Sharida</name></author><author><name sortKey="Farhan, Ma" uniqKey="Farhan M">MA Farhan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamamoto, Lt" uniqKey="Yamamoto L">LT Yamamoto</name></author><author><name sortKey="Horie, S" uniqKey="Horie S">S Horie</name></author><author><name sortKey="Takayama, H" uniqKey="Takayama H">H Takayama</name></author><author><name sortKey="Aimi, N" uniqKey="Aimi N">N Aimi</name></author><author><name sortKey="Sakai, S" uniqKey="Sakai S">S Sakai</name></author><author><name sortKey="Yano, S" uniqKey="Yano S">S Yano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Watanabe, K" uniqKey="Watanabe K">K Watanabe</name></author><author><name sortKey="Yano, S" uniqKey="Yano S">S Yano</name></author><author><name sortKey="Horie, S" uniqKey="Horie S">S Horie</name></author><author><name sortKey="Yamamoto, Lt" uniqKey="Yamamoto L">LT Yamamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shamima, Ar" uniqKey="Shamima A">AR Shamima</name></author><author><name sortKey="Fakurazi, S" uniqKey="Fakurazi S">S Fakurazi</name></author><author><name sortKey="Hidayat, Mt" uniqKey="Hidayat M">MT Hidayat</name></author><author><name sortKey="Hairuszah, I" uniqKey="Hairuszah I">I Hairuszah</name></author><author><name sortKey="Moklas, Ma" uniqKey="Moklas M">MA Moklas</name></author><author><name sortKey="Arulselvan, P" uniqKey="Arulselvan P">P Arulselvan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matsumoto, K" uniqKey="Matsumoto K">K Matsumoto</name></author><author><name sortKey="Yamamoto, Lt" uniqKey="Yamamoto L">LT Yamamoto</name></author><author><name sortKey="Watanabe, K" uniqKey="Watanabe K">K Watanabe</name></author><author><name sortKey="Yano, S" uniqKey="Yano S">S Yano</name></author><author><name sortKey="Shan, J" uniqKey="Shan J">J Shan</name></author><author><name sortKey="Pang, Pk" uniqKey="Pang P">PK Pang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tohda, M" uniqKey="Tohda M">M Tohda</name></author><author><name sortKey="Thongpraditchote, S" uniqKey="Thongpraditchote S">S Thongpraditchote</name></author><author><name sortKey="Matsumoto, K" uniqKey="Matsumoto K">K Matsumoto</name></author><author><name sortKey="Murakami, Y" uniqKey="Murakami Y">Y Murakami</name></author><author><name sortKey="Sakai, S" uniqKey="Sakai S">S Sakai</name></author><author><name sortKey="Aimi, N" uniqKey="Aimi N">N Aimi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jamil, Mf" uniqKey="Jamil M">MF Jamil</name></author><author><name sortKey="Subki, Mf" uniqKey="Subki M">MF Subki</name></author><author><name sortKey="Lan, Tm" uniqKey="Lan T">TM Lan</name></author><author><name sortKey="Majid, Mi" uniqKey="Majid M">MI Majid</name></author><author><name sortKey="Adenan, Mi" uniqKey="Adenan M">MI Adenan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fakurazi, S" uniqKey="Fakurazi S">S Fakurazi</name></author><author><name sortKey="Rahman, Sa" uniqKey="Rahman S">SA Rahman</name></author><author><name sortKey="Hidayat, Mt" uniqKey="Hidayat M">MT Hidayat</name></author><author><name sortKey="Ithnin, H" uniqKey="Ithnin H">H Ithnin</name></author><author><name sortKey="Moklas, Ma" uniqKey="Moklas M">MA Moklas</name></author><author><name sortKey="Arulselvan, P" uniqKey="Arulselvan P">P Arulselvan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reanmongkol, W" uniqKey="Reanmongkol W">W Reanmongkol</name></author><author><name sortKey="Keawpradub, N" uniqKey="Keawpradub N">N Keawpradub</name></author><author><name sortKey="Sawangjaroen, K" uniqKey="Sawangjaroen K">K Sawangjaroen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sabetghadam, A" uniqKey="Sabetghadam A">A Sabetghadam</name></author><author><name sortKey="Ramanathan, S" uniqKey="Ramanathan S">S Ramanathan</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shaik Mossadeq, Wm" uniqKey="Shaik Mossadeq W">WM Shaik Mossadeq</name></author><author><name sortKey="Sulaiman, Mr" uniqKey="Sulaiman M">MR Sulaiman</name></author><author><name sortKey="Tengku Mohamad, Ta" uniqKey="Tengku Mohamad T">TA Tengku Mohamad</name></author><author><name sortKey="Chiong, Hs" uniqKey="Chiong H">HS Chiong</name></author><author><name sortKey="Zakaria, Za" uniqKey="Zakaria Z">ZA Zakaria</name></author><author><name sortKey="Jabit, Ml" uniqKey="Jabit M">ML Jabit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Criddle, Ca" uniqKey="Criddle C">CA Criddle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carpenter, Jm" uniqKey="Carpenter J">JM Carpenter</name></author><author><name sortKey="Criddle, Ca" uniqKey="Criddle C">CA Criddle</name></author><author><name sortKey="Craig, Hk" uniqKey="Craig H">HK Craig</name></author><author><name sortKey="Ali, Z" uniqKey="Ali Z">Z Ali</name></author><author><name sortKey="Zhang, Z" uniqKey="Zhang Z">Z Zhang</name></author><author><name sortKey="Khan, Ia" uniqKey="Khan I">IA Khan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Farah Idayu, N" uniqKey="Farah Idayu N">N Farah Idayu</name></author><author><name sortKey="Hidayat, Mt" uniqKey="Hidayat M">MT Hidayat</name></author><author><name sortKey="Moklas, Ma" uniqKey="Moklas M">MA Moklas</name></author><author><name sortKey="Sharida, F" uniqKey="Sharida F">F Sharida</name></author><author><name sortKey="Raudzah, Ar" uniqKey="Raudzah A">AR Raudzah</name></author><author><name sortKey="Shamima, Ar" uniqKey="Shamima A">AR Shamima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kumarnsit, E" uniqKey="Kumarnsit E">E Kumarnsit</name></author><author><name sortKey="Vongvatcharanon, U" uniqKey="Vongvatcharanon U">U Vongvatcharanon</name></author><author><name sortKey="Keawpradub, N" uniqKey="Keawpradub N">N Keawpradub</name></author><author><name sortKey="Intasaro, P" uniqKey="Intasaro P">P Intasaro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saitoh, A" uniqKey="Saitoh A">A Saitoh</name></author><author><name sortKey="Yamada, M" uniqKey="Yamada M">M Yamada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yusoff, Nhm" uniqKey="Yusoff N">NHM Yusoff</name></author><author><name sortKey="Suhaimi, Fw" uniqKey="Suhaimi F">FW Suhaimi</name></author><author><name sortKey="Vadivelu, Rk" uniqKey="Vadivelu R">RK Vadivelu</name></author><author><name sortKey="Hassan, Z" uniqKey="Hassan Z">Z Hassan</name></author><author><name sortKey="Rumler, A" uniqKey="Rumler A">A Rümler</name></author><author><name sortKey="Rotter, A" uniqKey="Rotter A">A Rotter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Apryani, E" uniqKey="Apryani E">E Apryani</name></author><author><name sortKey="Hidayat, Mt" uniqKey="Hidayat M">MT Hidayat</name></author><author><name sortKey="Moklas, Ma" uniqKey="Moklas M">MA Moklas</name></author><author><name sortKey="Fakurazi, S" uniqKey="Fakurazi S">S Fakurazi</name></author><author><name sortKey="Idayu, Nf" uniqKey="Idayu N">NF Idayu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hazim, Ai" uniqKey="Hazim A">AI Hazim</name></author><author><name sortKey="Mustapha, M" uniqKey="Mustapha M">M Mustapha</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Senik, Mh" uniqKey="Senik M">MH Senik</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author><author><name sortKey="John Tharakan, Kj" uniqKey="John Tharakan K">KJ John Tharakan</name></author><author><name sortKey="Abdullah, Jm" uniqKey="Abdullah J">JM Abdullah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ismail, Niw" uniqKey="Ismail N">NIW Ismail</name></author><author><name sortKey="Jayabalan, N" uniqKey="Jayabalan N">N Jayabalan</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Muzaimi, M" uniqKey="Muzaimi M">M Muzaimi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harun, N" uniqKey="Harun N">N Harun</name></author><author><name sortKey="Hassan, Z" uniqKey="Hassan Z">Z Hassan</name></author><author><name sortKey="Navaratnam, V" uniqKey="Navaratnam V">V Navaratnam</name></author><author><name sortKey="Mansor, Sm" uniqKey="Mansor S">SM Mansor</name></author><author><name sortKey="Shoaib, M" uniqKey="Shoaib M">M Shoaib</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Davies, S" uniqKey="Davies S">S Davies</name></author><author><name sortKey="Wood, Dm" uniqKey="Wood D">DM Wood</name></author><author><name sortKey="Smith, G" uniqKey="Smith G">G Smith</name></author><author><name sortKey="Button, J" uniqKey="Button J">J Button</name></author><author><name sortKey="Ramsey, J" uniqKey="Ramsey J">J Ramsey</name></author><author><name sortKey="Archer, R" uniqKey="Archer R">R Archer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kemp, A" uniqKey="Kemp A">A Kemp</name></author><author><name sortKey="Clark, M" uniqKey="Clark M">M Clark</name></author><author><name sortKey="Dobbs, T" uniqKey="Dobbs T">T Dobbs</name></author><author><name sortKey="Galli, R" uniqKey="Galli R">R Galli</name></author><author><name sortKey="Sherman, J" uniqKey="Sherman J">J Sherman</name></author><author><name sortKey="Cox, R" uniqKey="Cox R">R Cox</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Hall, W" uniqKey="Hall W">W Hall</name></author><author><name sortKey="Degenhardt, L" uniqKey="Degenhardt L">L Degenhardt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Torjesen, I" uniqKey="Torjesen I">I Torjesen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Di Forti, M" uniqKey="Di Forti M">M Di Forti</name></author><author><name sortKey="Morgan, C" uniqKey="Morgan C">C Morgan</name></author><author><name sortKey="Dazzan, P" uniqKey="Dazzan P">P Dazzan</name></author><author><name sortKey="Pariante, C" uniqKey="Pariante C">C Pariante</name></author><author><name sortKey="Mondelli, V" uniqKey="Mondelli V">V Mondelli</name></author><author><name sortKey="Marques, Tr" uniqKey="Marques T">TR Marques</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Di Forti, M" uniqKey="Di Forti M">M Di Forti</name></author><author><name sortKey="Sallis, H" uniqKey="Sallis H">H Sallis</name></author><author><name sortKey="Allegri, F" uniqKey="Allegri F">F Allegri</name></author><author><name sortKey="Trotta, A" uniqKey="Trotta A">A Trotta</name></author><author><name sortKey="Ferraro, L" uniqKey="Ferraro L">L Ferraro</name></author><author><name sortKey="Stilo, Sa" uniqKey="Stilo S">SA Stilo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forrester, Mb" uniqKey="Forrester M">MB Forrester</name></author><author><name sortKey="Kleinschmidt, K" uniqKey="Kleinschmidt K">K Kleinschmidt</name></author><author><name sortKey="Schwarz, E" uniqKey="Schwarz E">E Schwarz</name></author><author><name sortKey="Young, A" uniqKey="Young A">A Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Debruyne, D" uniqKey="Debruyne D">D Debruyne</name></author><author><name sortKey="Le Boisselier, R" uniqKey="Le Boisselier R">R Le Boisselier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barratt, Mj" uniqKey="Barratt M">MJ Barratt</name></author><author><name sortKey="Potter, Gr" uniqKey="Potter G">GR Potter</name></author><author><name sortKey="Wouters, M" uniqKey="Wouters M">M Wouters</name></author><author><name sortKey="Wilkins, C" uniqKey="Wilkins C">C Wilkins</name></author><author><name sortKey="Werse, B" uniqKey="Werse B">B Werse</name></author><author><name sortKey="Per L, J" uniqKey="Per L J">J Perälä</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gurdal, F" uniqKey="Gurdal F">F Gurdal</name></author><author><name sortKey="Asirdizer, M" uniqKey="Asirdizer M">M Asirdizer</name></author><author><name sortKey="Aker, Rg" uniqKey="Aker R">RG Aker</name></author><author><name sortKey="Korkut, S" uniqKey="Korkut S">S Korkut</name></author><author><name sortKey="Gocer, Y" uniqKey="Gocer Y">Y Gocer</name></author><author><name sortKey="Kucukibrahimoglu, Ee" uniqKey="Kucukibrahimoglu E">EE Kucukibrahimoglu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mills, B" uniqKey="Mills B">B Mills</name></author><author><name sortKey="Yepes, A" uniqKey="Yepes A">A Yepes</name></author><author><name sortKey="Nugent, K" uniqKey="Nugent K">K Nugent</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kadaria, D" uniqKey="Kadaria D">D Kadaria</name></author><author><name sortKey="Sinclair, Se" uniqKey="Sinclair S">SE Sinclair</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weaver, Mf" uniqKey="Weaver M">MF Weaver</name></author><author><name sortKey="Hopper, Ja" uniqKey="Hopper J">JA Hopper</name></author><author><name sortKey="Gunderson, Ew" uniqKey="Gunderson E">EW Gunderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khullar, V" uniqKey="Khullar V">V Khullar</name></author><author><name sortKey="Jain, A" uniqKey="Jain A">A Jain</name></author><author><name sortKey="Sattari, M" uniqKey="Sattari M">M Sattari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forrester, Mb" uniqKey="Forrester M">MB Forrester</name></author><author><name sortKey="Kleinschmidt, K" uniqKey="Kleinschmidt K">K Kleinschmidt</name></author><author><name sortKey="Schwarz, E" uniqKey="Schwarz E">E Schwarz</name></author><author><name sortKey="Young, A" uniqKey="Young A">A Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, H" uniqKey="Muller H">H Müller</name></author><author><name sortKey="Huttner, Hb" uniqKey="Huttner H">HB Huttner</name></author><author><name sortKey="Kohrmann, M" uniqKey="Kohrmann M">M Köhrmann</name></author><author><name sortKey="Wielopolski, Je" uniqKey="Wielopolski J">JE Wielopolski</name></author><author><name sortKey="Kornhuber, J" uniqKey="Kornhuber J">J Kornhuber</name></author><author><name sortKey="Sperling, W" uniqKey="Sperling W">W Sperling</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, H" uniqKey="Muller H">H Müller</name></author><author><name sortKey="Sperling, W" uniqKey="Sperling W">W Sperling</name></author><author><name sortKey="Kohrmann, M" uniqKey="Kohrmann M">M Köhrmann</name></author><author><name sortKey="Huttner, Hb" uniqKey="Huttner H">HB Huttner</name></author><author><name sortKey="Kornhuber, J" uniqKey="Kornhuber J">J Kornhuber</name></author><author><name sortKey="Maler, Jm" uniqKey="Maler J">JM Maler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loeffler, G" uniqKey="Loeffler G">G Loeffler</name></author><author><name sortKey="Delaney, E" uniqKey="Delaney E">E Delaney</name></author><author><name sortKey="Hann, M" uniqKey="Hann M">M Hann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Castaneto, Ms" uniqKey="Castaneto M">MS Castaneto</name></author><author><name sortKey="Gorelick, Da" uniqKey="Gorelick D">DA Gorelick</name></author><author><name sortKey="Desrosiers, Na" uniqKey="Desrosiers N">NA Desrosiers</name></author><author><name sortKey="Hartman, Rl" uniqKey="Hartman R">RL Hartman</name></author><author><name sortKey="Pirard, S" uniqKey="Pirard S">S Pirard</name></author><author><name sortKey="Huestis, Ma" uniqKey="Huestis M">MA Huestis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seely, Ka" uniqKey="Seely K">KA Seely</name></author><author><name sortKey="Lapoint, J" uniqKey="Lapoint J">J Lapoint</name></author><author><name sortKey="Moran, Jh" uniqKey="Moran J">JH Moran</name></author><author><name sortKey="Fattore, L" uniqKey="Fattore L">L Fattore</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trecki, J" uniqKey="Trecki J">J Trecki</name></author><author><name sortKey="Gerona, Rr" uniqKey="Gerona R">RR Gerona</name></author><author><name sortKey="Schwartz, Md" uniqKey="Schwartz M">MD Schwartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiley, Jl" uniqKey="Wiley J">JL Wiley</name></author><author><name sortKey="Marusich, Ja" uniqKey="Marusich J">JA Marusich</name></author><author><name sortKey="Martin, Br" uniqKey="Martin B">BR Martin</name></author><author><name sortKey="Huffman, Jw" uniqKey="Huffman J">JW Huffman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ernst, L" uniqKey="Ernst L">L Ernst</name></author><author><name sortKey="Schiebel, Hm" uniqKey="Schiebel H">HM Schiebel</name></author><author><name sortKey="Theuring, C" uniqKey="Theuring C">C Theuring</name></author><author><name sortKey="Lindigkeit, R" uniqKey="Lindigkeit R">R Lindigkeit</name></author><author><name sortKey="Beuerle, T" uniqKey="Beuerle T">T Beuerle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Musshoff, F" uniqKey="Musshoff F">F Musshoff</name></author><author><name sortKey="Hottmann, L" uniqKey="Hottmann L">L Hottmann</name></author><author><name sortKey="Hess, C" uniqKey="Hess C">C Hess</name></author><author><name sortKey="Madea, B" uniqKey="Madea B">B Madea</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hillebrand, J" uniqKey="Hillebrand J">J Hillebrand</name></author><author><name sortKey="Olszewski, D" uniqKey="Olszewski D">D Olszewski</name></author><author><name sortKey="Sedefov, R" uniqKey="Sedefov R">R Sedefov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moller, I" uniqKey="Moller I">I Möller</name></author><author><name sortKey="Wintermeyer, A" uniqKey="Wintermeyer A">A Wintermeyer</name></author><author><name sortKey="Bender, K" uniqKey="Bender K">K Bender</name></author><author><name sortKey="Jubner, M" uniqKey="Jubner M">M Jübner</name></author><author><name sortKey="Thomas, A" uniqKey="Thomas A">A Thomas</name></author><author><name sortKey="Krug, O" uniqKey="Krug O">O Krug</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strano Rossi, S" uniqKey="Strano Rossi S">S Strano-Rossi</name></author><author><name sortKey="Anzillotti, L" uniqKey="Anzillotti L">L Anzillotti</name></author><author><name sortKey="Castrignan, E" uniqKey="Castrignan E">E Castrignanò</name></author><author><name sortKey="Romolo, Fs" uniqKey="Romolo F">FS Romolo</name></author><author><name sortKey="Chiarotti, M" uniqKey="Chiarotti M">M Chiarotti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hudson, S" uniqKey="Hudson S">S Hudson</name></author><author><name sortKey="Ramsey, J" uniqKey="Ramsey J">J Ramsey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sundstrom, M" uniqKey="Sundstrom M">M Sundström</name></author><author><name sortKey="Pelander, A" uniqKey="Pelander A">A Pelander</name></author><author><name sortKey="Angerer, V" uniqKey="Angerer V">V Angerer</name></author><author><name sortKey="Hutter, M" uniqKey="Hutter M">M Hutter</name></author><author><name sortKey="Kneisel, S" uniqKey="Kneisel S">S Kneisel</name></author><author><name sortKey="Ojanper, I" uniqKey="Ojanper I">I Ojanperä</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grabenauer, M" uniqKey="Grabenauer M">M Grabenauer</name></author><author><name sortKey="Krol, Wl" uniqKey="Krol W">WL Krol</name></author><author><name sortKey="Wiley, Jl" uniqKey="Wiley J">JL Wiley</name></author><author><name sortKey="Thomas, Bf" uniqKey="Thomas B">BF Thomas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller Vahl, K" uniqKey="Muller Vahl K">K Muller-Vahl</name></author><author><name sortKey="Grotenhermen, F" uniqKey="Grotenhermen F">F Grotenhermen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grotenhermen, F" uniqKey="Grotenhermen F">F Grotenhermen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grotenhermen, F" uniqKey="Grotenhermen F">F Grotenhermen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gunderson, Ew" uniqKey="Gunderson E">EW Gunderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rosenbaum, Cd" uniqKey="Rosenbaum C">CD Rosenbaum</name></author><author><name sortKey="Carreiro, Sp" uniqKey="Carreiro S">SP Carreiro</name></author><author><name sortKey="Babu, Km" uniqKey="Babu K">KM Babu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Penders, T" uniqKey="Penders T">T Penders</name></author><author><name sortKey="Saeed, S" uniqKey="Saeed S">S Saeed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcguinness, Tm" uniqKey="Mcguinness T">TM McGuinness</name></author><author><name sortKey="Newell, D" uniqKey="Newell D">D Newell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bhanushali, Gk" uniqKey="Bhanushali G">GK Bhanushali</name></author><author><name sortKey="Jain, G" uniqKey="Jain G">G Jain</name></author><author><name sortKey="Fatima, H" uniqKey="Fatima H">H Fatima</name></author><author><name sortKey="Leisch, Lj" uniqKey="Leisch L">LJ Leisch</name></author><author><name sortKey="Thornley Brown, D" uniqKey="Thornley Brown D">D Thornley-Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Veer, N" uniqKey="Van Der Veer N">N Van der Veer</name></author><author><name sortKey="Friday, J" uniqKey="Friday J">J Friday</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brakoulias, V" uniqKey="Brakoulias V">V Brakoulias</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jinwala, Fn" uniqKey="Jinwala F">FN Jinwala</name></author><author><name sortKey="Gupta, M" uniqKey="Gupta M">M Gupta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harris, Cr" uniqKey="Harris C">CR Harris</name></author><author><name sortKey="Brown, A" uniqKey="Brown A">A Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oluwabusi, Oo" uniqKey="Oluwabusi O">OO Oluwabusi</name></author><author><name sortKey="Lobach, L" uniqKey="Lobach L">L Lobach</name></author><author><name sortKey="Akhtar, U" uniqKey="Akhtar U">U Akhtar</name></author><author><name sortKey="Youngman, B" uniqKey="Youngman B">B Youngman</name></author><author><name sortKey="Ambrosini, Pj" uniqKey="Ambrosini P">PJ Ambrosini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goshgarian, Am" uniqKey="Goshgarian A">AM Goshgarian</name></author><author><name sortKey="Benford, Dm" uniqKey="Benford D">DM Benford</name></author><author><name sortKey="Caplan, Jp" uniqKey="Caplan J">JP Caplan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benford, Dm" uniqKey="Benford D">DM Benford</name></author><author><name sortKey="Caplan, Jp" uniqKey="Caplan J">JP Caplan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forrester, Mb" uniqKey="Forrester M">MB Forrester</name></author><author><name sortKey="Haywood, T" uniqKey="Haywood T">T Haywood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forrester, Mb" uniqKey="Forrester M">MB Forrester</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Durand, D" uniqKey="Durand D">D Durand</name></author><author><name sortKey="Delgado, Ll" uniqKey="Delgado L">LL Delgado</name></author><author><name sortKey="De La Parra Pellot, Dm" uniqKey="De La Parra Pellot D">DM de la Parra-Pellot</name></author><author><name sortKey="Nichols Vinueza, D" uniqKey="Nichols Vinueza D">D Nichols-Vinueza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hurst, D" uniqKey="Hurst D">D Hurst</name></author><author><name sortKey="Loeffler, G" uniqKey="Loeffler G">G Loeffler</name></author><author><name sortKey="Mclay, R" uniqKey="Mclay R">R McLay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marshell, R" uniqKey="Marshell R">R Marshell</name></author><author><name sortKey="Kearney Ramos, T" uniqKey="Kearney Ramos T">T Kearney-Ramos</name></author><author><name sortKey="Brents, Lk" uniqKey="Brents L">LK Brents</name></author><author><name sortKey="Hyatt, Ws" uniqKey="Hyatt W">WS Hyatt</name></author><author><name sortKey="Tai, S" uniqKey="Tai S">S Tai</name></author><author><name sortKey="Prather, Pl" uniqKey="Prather P">PL Prather</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brents, Lk" uniqKey="Brents L">LK Brents</name></author><author><name sortKey="Prather, Pl" uniqKey="Prather P">PL Prather</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Auw Rter, V" uniqKey="Auw Rter V">V Auwärter</name></author><author><name sortKey="Dresen, S" uniqKey="Dresen S">S Dresen</name></author><author><name sortKey="Weinmann, W" uniqKey="Weinmann W">W Weinmann</name></author><author><name sortKey="Muller, M" uniqKey="Muller M">M Müller</name></author><author><name sortKey="Putz, M" uniqKey="Putz M">M Pütz</name></author><author><name sortKey="Ferreir S, N" uniqKey="Ferreir S N">N Ferreirós</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grigoryev, A" uniqKey="Grigoryev A">A Grigoryev</name></author><author><name sortKey="Savchuk, S" uniqKey="Savchuk S">S Savchuk</name></author><author><name sortKey="Melnik, A" uniqKey="Melnik A">A Melnik</name></author><author><name sortKey="Moskaleva, N" uniqKey="Moskaleva N">N Moskaleva</name></author><author><name sortKey="Dzhurko, J" uniqKey="Dzhurko J">J Dzhurko</name></author><author><name sortKey="Ershov, M" uniqKey="Ershov M">M Ershov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grigoryev, A" uniqKey="Grigoryev A">A Grigoryev</name></author><author><name sortKey="Kavanagh, P" uniqKey="Kavanagh P">P Kavanagh</name></author><author><name sortKey="Melnik, A" uniqKey="Melnik A">A Melnik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grigoryev, A" uniqKey="Grigoryev A">A Grigoryev</name></author><author><name sortKey="Kavanagh, P" uniqKey="Kavanagh P">P Kavanagh</name></author><author><name sortKey="Melnik, A" uniqKey="Melnik A">A Melnik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ortega, A" uniqKey="Ortega A">A Ortega</name></author><author><name sortKey="Rangel L Pez, E" uniqKey="Rangel L Pez E">E Rangel-López</name></author><author><name sortKey="Hidalgo Miranda, A" uniqKey="Hidalgo Miranda A">A Hidalgo-Miranda</name></author><author><name sortKey="Morales, A" uniqKey="Morales A">A Morales</name></author><author><name sortKey="Ruiz Garcia, E" uniqKey="Ruiz Garcia E">E Ruiz-García</name></author><author><name sortKey="Meneses Garcia, A" uniqKey="Meneses Garcia A">A Meneses-García</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Latorre, Jg" uniqKey="Latorre J">JG Latorre</name></author><author><name sortKey="Schmidt, Eb" uniqKey="Schmidt E">EB Schmidt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soderstrom, K" uniqKey="Soderstrom K">K Soderstrom</name></author><author><name sortKey="Tian, Q" uniqKey="Tian Q">Q Tian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cui, Yy" uniqKey="Cui Y">YY Cui</name></author><author><name sortKey="D Gostino, B" uniqKey="D Gostino B">B D’Agostino</name></author><author><name sortKey="Risse, Pa" uniqKey="Risse P">PA Risse</name></author><author><name sortKey="Marrocco, G" uniqKey="Marrocco G">G Marrocco</name></author><author><name sortKey="Naline, E" uniqKey="Naline E">E Naline</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cox, Ml" uniqKey="Cox M">ML Cox</name></author><author><name sortKey="Haller, Vl" uniqKey="Haller V">VL Haller</name></author><author><name sortKey="Welch, Sp" uniqKey="Welch S">SP Welch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Darmani, Na" uniqKey="Darmani N">NA Darmani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Acquas, E" uniqKey="Acquas E">E Acquas</name></author><author><name sortKey="Pisanu, A" uniqKey="Pisanu A">A Pisanu</name></author><author><name sortKey="Marrocu, P" uniqKey="Marrocu P">P Marrocu</name></author><author><name sortKey="Di Chiara, G" uniqKey="Di Chiara G">G Di Chiara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buckley, Ne" uniqKey="Buckley N">NE Buckley</name></author><author><name sortKey="Mccoy, Kl" uniqKey="Mccoy K">KL McCoy</name></author><author><name sortKey="Mezey, E" uniqKey="Mezey E">E Mezey</name></author><author><name sortKey="Bonner, T" uniqKey="Bonner T">T Bonner</name></author><author><name sortKey="Zimmer, A" uniqKey="Zimmer A">A Zimmer</name></author><author><name sortKey="Felder, Cc" uniqKey="Felder C">CC Felder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Underwood, E" uniqKey="Underwood E">E Underwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carbonaro, Tm" uniqKey="Carbonaro T">TM Carbonaro</name></author><author><name sortKey="Gatch, Mb" uniqKey="Gatch M">MB Gatch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strassman, R" uniqKey="Strassman R">R Strassman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Callaway, Jc" uniqKey="Callaway J">JC Callaway</name></author><author><name sortKey="Raymon, Lp" uniqKey="Raymon L">LP Raymon</name></author><author><name sortKey="Hearn, Wl" uniqKey="Hearn W">WL Hearn</name></author><author><name sortKey="Mckenna, Dj" uniqKey="Mckenna D">DJ McKenna</name></author><author><name sortKey="Grob, Cs" uniqKey="Grob C">CS Grob</name></author><author><name sortKey="Brito, Gs" uniqKey="Brito G">GS Brito</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ott, J" uniqKey="Ott J">J Ott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wallach, Jv" uniqKey="Wallach J">JV Wallach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barker, Sa" uniqKey="Barker S">SA Barker</name></author><author><name sortKey="Borjigin, J" uniqKey="Borjigin J">J Borjigin</name></author><author><name sortKey="Lomnicka, I" uniqKey="Lomnicka I">I Lomnicka</name></author><author><name sortKey="Strassman, R" uniqKey="Strassman R">R Strassman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Christian, St" uniqKey="Christian S">ST Christian</name></author><author><name sortKey="Harrison, R" uniqKey="Harrison R">R Harrison</name></author><author><name sortKey="Quayle, E" uniqKey="Quayle E">E Quayle</name></author><author><name sortKey="Pagel, J" uniqKey="Pagel J">J Pagel</name></author><author><name sortKey="Monti, J" uniqKey="Monti J">J Monti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keiser, Mj" uniqKey="Keiser M">MJ Keiser</name></author><author><name sortKey="Setola, V" uniqKey="Setola V">V Setola</name></author><author><name sortKey="Irwin, Jj" uniqKey="Irwin J">JJ Irwin</name></author><author><name sortKey="Laggner, C" uniqKey="Laggner C">C Laggner</name></author><author><name sortKey="Abbas, Ai" uniqKey="Abbas A">AI Abbas</name></author><author><name sortKey="Hufeisen, Sj" uniqKey="Hufeisen S">SJ Hufeisen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mckenna, Dj" uniqKey="Mckenna D">DJ McKenna</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dos Santos, Rg" uniqKey="Dos Santos R">RG Dos Santos</name></author><author><name sortKey="Valle, M" uniqKey="Valle M">M Valle</name></author><author><name sortKey="Bouso, Jc" uniqKey="Bouso J">JC Bouso</name></author><author><name sortKey="Nomdedeu, Jf" uniqKey="Nomdedeu J">JF Nomdedéu</name></author><author><name sortKey="Rodriguez Espinosa, J" uniqKey="Rodriguez Espinosa J">J Rodríguez-Espinosa</name></author><author><name sortKey="Mcilhenny, Eh" uniqKey="Mcilhenny E">EH McIlhenny</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dos Santos, Rg" uniqKey="Dos Santos R">RG Dos Santos</name></author><author><name sortKey="Grasa, E" uniqKey="Grasa E">E Grasa</name></author><author><name sortKey="Valle, M" uniqKey="Valle M">M Valle</name></author><author><name sortKey="Ballester, Mr" uniqKey="Ballester M">MR Ballester</name></author><author><name sortKey="Bouso, Jc" uniqKey="Bouso J">JC Bouso</name></author><author><name sortKey="Nomdedeu, Jf" uniqKey="Nomdedeu J">JF Nomdedéu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Halberstadt, Al" uniqKey="Halberstadt A">AL Halberstadt</name></author><author><name sortKey="Nichols, De" uniqKey="Nichols D">DE Nichols</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carbonaro, Tm" uniqKey="Carbonaro T">TM Carbonaro</name></author><author><name sortKey="Eshleman, Aj" uniqKey="Eshleman A">AJ Eshleman</name></author><author><name sortKey="Forster, Mj" uniqKey="Forster M">MJ Forster</name></author><author><name sortKey="Cheng, K" uniqKey="Cheng K">K Cheng</name></author><author><name sortKey="Rice, Kc" uniqKey="Rice K">KC Rice</name></author><author><name sortKey="Gatch, Mb" uniqKey="Gatch M">MB Gatch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cole, Jm" uniqKey="Cole J">JM Cole</name></author><author><name sortKey="Pieper, Wa" uniqKey="Pieper W">WA Pieper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strassman, Rj" uniqKey="Strassman R">RJ Strassman</name></author><author><name sortKey="Qualls, Cr" uniqKey="Qualls C">CR Qualls</name></author><author><name sortKey="Berg, Lm" uniqKey="Berg L">LM Berg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glennon, Ra" uniqKey="Glennon R">RA Glennon</name></author><author><name sortKey="Young, R" uniqKey="Young R">R Young</name></author><author><name sortKey="Jacyno, Jm" uniqKey="Jacyno J">JM Jacyno</name></author><author><name sortKey="Slusher, M" uniqKey="Slusher M">M Slusher</name></author><author><name sortKey="Rosecrans, Ja" uniqKey="Rosecrans J">JA Rosecrans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glennon, Ra" uniqKey="Glennon R">RA Glennon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riba, J" uniqKey="Riba J">J Riba</name></author><author><name sortKey="Rodriguez Fornells, A" uniqKey="Rodriguez Fornells A">A Rodríguez-Fornells</name></author><author><name sortKey="Urbano, G" uniqKey="Urbano G">G Urbano</name></author><author><name sortKey="Morte, A" uniqKey="Morte A">A Morte</name></author><author><name sortKey="Antonijoan, R" uniqKey="Antonijoan R">R Antonijoan</name></author><author><name sortKey="Montero, M" uniqKey="Montero M">M Montero</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Frecska, E" uniqKey="Frecska E">E Frecska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Frecska, E" uniqKey="Frecska E">E Frecska</name></author><author><name sortKey="Bokor, P" uniqKey="Bokor P">P Bokor</name></author><author><name sortKey="Winkelman, M" uniqKey="Winkelman M">M Winkelman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Szabo, A" uniqKey="Szabo A">A Szabo</name></author><author><name sortKey="Frecska, E" uniqKey="Frecska E">E Frecska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pal, A" uniqKey="Pal A">A Pal</name></author><author><name sortKey="Fontanilla, D" uniqKey="Fontanilla D">D Fontanilla</name></author><author><name sortKey="Gopalakrishnan, A" uniqKey="Gopalakrishnan A">A Gopalakrishnan</name></author><author><name sortKey="Chae, Yk" uniqKey="Chae Y">YK Chae</name></author><author><name sortKey="Markley, Jl" uniqKey="Markley J">JL Markley</name></author><author><name sortKey="Ruoho, Ae" uniqKey="Ruoho A">AE Ruoho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Frecska, E" uniqKey="Frecska E">E Frecska</name></author><author><name sortKey="Szabo, A" uniqKey="Szabo A">A Szabo</name></author><author><name sortKey="Winkelman, Mj" uniqKey="Winkelman M">MJ Winkelman</name></author><author><name sortKey="Luna, Le" uniqKey="Luna L">LE Luna</name></author><author><name sortKey="Mckenna, Dj" uniqKey="Mckenna D">DJ McKenna</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Quednow, Bb" uniqKey="Quednow B">BB Quednow</name></author><author><name sortKey="Geyer, Ma" uniqKey="Geyer M">MA Geyer</name></author><author><name sortKey="Halberstadt, Al" uniqKey="Halberstadt A">AL Halberstadt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Checkley, Sa" uniqKey="Checkley S">SA Checkley</name></author><author><name sortKey="Murray, Rm" uniqKey="Murray R">RM Murray</name></author><author><name sortKey="Oon, Mc" uniqKey="Oon M">MC Oon</name></author><author><name sortKey="Rodnight, R" uniqKey="Rodnight R">R Rodnight</name></author><author><name sortKey="Birley, Jl" uniqKey="Birley J">JL Birley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Os Rio Fde, L" uniqKey="Os Rio Fde L">L Osório Fde</name></author><author><name sortKey="Sanches, Rf" uniqKey="Sanches R">RF Sanches</name></author><author><name sortKey="Macedo, Lr" uniqKey="Macedo L">LR Macedo</name></author><author><name sortKey="Santos, Rg" uniqKey="Santos R">RG Santos</name></author><author><name sortKey="Maia De Oliveira, Jp" uniqKey="Maia De Oliveira J">JP Maia-de-Oliveira</name></author><author><name sortKey="Wichert Ana, L" uniqKey="Wichert Ana L">L Wichert-Ana</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jacob, Ms" uniqKey="Jacob M">MS Jacob</name></author><author><name sortKey="Presti, De" uniqKey="Presti D">DE Presti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schenberg, Ee" uniqKey="Schenberg E">EE Schenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Derocq, Jm" uniqKey="Derocq J">JM Derocq</name></author><author><name sortKey="Bourrie, B" uniqKey="Bourrie B">B Bourrié</name></author><author><name sortKey="Segui, M" uniqKey="Segui M">M Ségui</name></author><author><name sortKey="Le Fur, G" uniqKey="Le Fur G">G Le Fur</name></author><author><name sortKey="Casellas, P" uniqKey="Casellas P">P Casellas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Metzner, R" uniqKey="Metzner R">R Metzner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="El Mallakh, Rs" uniqKey="El Mallakh R">RS El-Mallakh</name></author><author><name sortKey="Halpern, Jh" uniqKey="Halpern J">JH Halpern</name></author><author><name sortKey="Abraham, Hd" uniqKey="Abraham H">HD Abraham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nichols, De" uniqKey="Nichols D">DE Nichols</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vollenweider, Fx" uniqKey="Vollenweider F">FX Vollenweider</name></author><author><name sortKey="Kometer, M" uniqKey="Kometer M">M Kometer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hollister, Le" uniqKey="Hollister L">LE Hollister</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nichols, De" uniqKey="Nichols D">DE Nichols</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fantegrossi, We" uniqKey="Fantegrossi W">WE Fantegrossi</name></author><author><name sortKey="Murnane, Ks" uniqKey="Murnane K">KS Murnane</name></author><author><name sortKey="Reissig, Cj" uniqKey="Reissig C">CJ Reissig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Halberstadt, Al" uniqKey="Halberstadt A">AL Halberstadt</name></author><author><name sortKey="Geyer, Ma" uniqKey="Geyer M">MA Geyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Preller, Kh" uniqKey="Preller K">KH Preller</name></author><author><name sortKey="Herdener, M" uniqKey="Herdener M">M Herdener</name></author><author><name sortKey="Pokorny, T" uniqKey="Pokorny T">T Pokorny</name></author><author><name sortKey="Planzer, A" uniqKey="Planzer A">A Planzer</name></author><author><name sortKey="Kraehenmann, R" uniqKey="Kraehenmann R">R Kraehenmann</name></author><author><name sortKey="Stampfli, P" uniqKey="Stampfli P">P Stampfli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Quednow, Bb" uniqKey="Quednow B">BB Quednow</name></author><author><name sortKey="Kometer, M" uniqKey="Kometer M">M Kometer</name></author><author><name sortKey="Geyer, Ma" uniqKey="Geyer M">MA Geyer</name></author><author><name sortKey="Vollenweider, Fx" uniqKey="Vollenweider F">FX Vollenweider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vollenweider, Fx" uniqKey="Vollenweider F">FX Vollenweider</name></author><author><name sortKey="Vollenweider Scherpenhuyzen, Mf" uniqKey="Vollenweider Scherpenhuyzen M">MF Vollenweider-Scherpenhuyzen</name></author><author><name sortKey="Babler, A" uniqKey="Babler A">A Babler</name></author><author><name sortKey="Vogel, H" uniqKey="Vogel H">H Vogel</name></author><author><name sortKey="Hell, D" uniqKey="Hell D">D Hell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rickli, A" uniqKey="Rickli A">A Rickli</name></author><author><name sortKey="Luethi, D" uniqKey="Luethi D">D Luethi</name></author><author><name sortKey="Reinisch, J" uniqKey="Reinisch J">J Reinisch</name></author><author><name sortKey="Buchy, D" uniqKey="Buchy D">D Buchy</name></author><author><name sortKey="Hoener, Mc" uniqKey="Hoener M">MC Hoener</name></author><author><name sortKey="Liechti, Me" uniqKey="Liechti M">ME Liechti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gonzalez Maeso, J" uniqKey="Gonzalez Maeso J">J Gonzalez-Maeso</name></author><author><name sortKey="Ang, Rl" uniqKey="Ang R">RL Ang</name></author><author><name sortKey="Yuen, T" uniqKey="Yuen T">T Yuen</name></author><author><name sortKey="Chan, P" uniqKey="Chan P">P Chan</name></author><author><name sortKey="Weisstaub, Nv" uniqKey="Weisstaub N">NV Weisstaub</name></author><author><name sortKey="Lopez Gimenez, Jf" uniqKey="Lopez Gimenez J">JF Lopez-Gimenez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Delille, Hk" uniqKey="Delille H">HK Delille</name></author><author><name sortKey="Mezler, M" uniqKey="Mezler M">M Mezler</name></author><author><name sortKey="Marek, Gj" uniqKey="Marek G">GJ Marek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hofmann, A" uniqKey="Hofmann A">A Hofmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shulgin, At" uniqKey="Shulgin A">AT Shulgin</name></author><author><name sortKey="Shulgin, A" uniqKey="Shulgin A">A Shulgin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shulgin, At" uniqKey="Shulgin A">AT Shulgin</name></author><author><name sortKey="Shulgin, A" uniqKey="Shulgin A">A Shulgin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dean, Bv" uniqKey="Dean B">BV Dean</name></author><author><name sortKey="Stellpflug, Sj" uniqKey="Stellpflug S">SJ Stellpflug</name></author><author><name sortKey="Burnett, Am" uniqKey="Burnett A">AM Burnett</name></author><author><name sortKey="Engebretsen, Km" uniqKey="Engebretsen K">KM Engebretsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beharry, S" uniqKey="Beharry S">S Beharry</name></author><author><name sortKey="Gibbons, S" uniqKey="Gibbons S">S Gibbons</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liechti, M" uniqKey="Liechti M">M Liechti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zawilska, Jb" uniqKey="Zawilska J">JB Zawilska</name></author><author><name sortKey="Andrzejczak, D" uniqKey="Andrzejczak D">D Andrzejczak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author><author><name sortKey="Papanti, Gd" uniqKey="Papanti G">GD Papanti</name></author><author><name sortKey="Orsolini, L" uniqKey="Orsolini L">L Orsolini</name></author><author><name sortKey="Corkery, Jm" uniqKey="Corkery J">JM Corkery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawn, W" uniqKey="Lawn W">W Lawn</name></author><author><name sortKey="Barratt, M" uniqKey="Barratt M">M Barratt</name></author><author><name sortKey="Williams, M" uniqKey="Williams M">M Williams</name></author><author><name sortKey="Horne, A" uniqKey="Horne A">A Horne</name></author><author><name sortKey="Winstock, A" uniqKey="Winstock A">A Winstock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simmler, Ld" uniqKey="Simmler L">LD Simmler</name></author><author><name sortKey="Rickli, A" uniqKey="Rickli A">A Rickli</name></author><author><name sortKey="Schramm, Y" uniqKey="Schramm Y">Y Schramm</name></author><author><name sortKey="Hoener, Mc" uniqKey="Hoener M">MC Hoener</name></author><author><name sortKey="Liechti, Me" uniqKey="Liechti M">ME Liechti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Palamar, Jj" uniqKey="Palamar J">JJ Palamar</name></author><author><name sortKey="Martins, Ss" uniqKey="Martins S">SS Martins</name></author><author><name sortKey="Su, Mk" uniqKey="Su M">MK Su</name></author><author><name sortKey="Ompad, Dc" uniqKey="Ompad D">DC Ompad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vallersnes, Om" uniqKey="Vallersnes O">OM Vallersnes</name></author><author><name sortKey="Dines, Am" uniqKey="Dines A">AM Dines</name></author><author><name sortKey="Wood, Dm" uniqKey="Wood D">DM Wood</name></author><author><name sortKey="Yates, C" uniqKey="Yates C">C Yates</name></author><author><name sortKey="Heyerdahl, F" uniqKey="Heyerdahl F">F Heyerdahl</name></author><author><name sortKey="Hovda, Ke" uniqKey="Hovda K">KE Hovda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Logan, Bk" uniqKey="Logan B">BK Logan</name></author><author><name sortKey="Mohr, Ala" uniqKey="Mohr A">ALA Mohr</name></author><author><name sortKey="Friscia, M" uniqKey="Friscia M">M Friscia</name></author><author><name sortKey="Krotulski, Aj" uniqKey="Krotulski A">AJ Krotulski</name></author><author><name sortKey="Papsun, Dm" uniqKey="Papsun D">DM Papsun</name></author><author><name sortKey="Kacinko, Sl" uniqKey="Kacinko S">SL Kacinko</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burish, Mj" uniqKey="Burish M">MJ Burish</name></author><author><name sortKey="Thoren, Kl" uniqKey="Thoren K">KL Thoren</name></author><author><name sortKey="Madou, M" uniqKey="Madou M">M Madou</name></author><author><name sortKey="Toossi, S" uniqKey="Toossi S">S Toossi</name></author><author><name sortKey="Shah, M" uniqKey="Shah M">M Shah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Halberstadt, Al" uniqKey="Halberstadt A">AL Halberstadt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hieger, Ma" uniqKey="Hieger M">MA Hieger</name></author><author><name sortKey="Rose, Sr" uniqKey="Rose S">SR Rose</name></author><author><name sortKey="Cumpston, Kl" uniqKey="Cumpston K">KL Cumpston</name></author><author><name sortKey="Stromberg, Pe" uniqKey="Stromberg P">PE Stromberg</name></author><author><name sortKey="Miller, S" uniqKey="Miller S">S Miller</name></author><author><name sortKey="Wills, Bk" uniqKey="Wills B">BK Wills</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Srisuma, S" uniqKey="Srisuma S">S Srisuma</name></author><author><name sortKey="Bronstein, Ac" uniqKey="Bronstein A">AC Bronstein</name></author><author><name sortKey="Hoyte, Co" uniqKey="Hoyte C">CO Hoyte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baggott, Mj" uniqKey="Baggott M">MJ Baggott</name></author><author><name sortKey="Coyle, Jr" uniqKey="Coyle J">JR Coyle</name></author><author><name sortKey="Erowid, E" uniqKey="Erowid E">E Erowid</name></author><author><name sortKey="Erowid, F" uniqKey="Erowid F">F Erowid</name></author><author><name sortKey="Robertson, Lc" uniqKey="Robertson L">LC Robertson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Litjens, Rp" uniqKey="Litjens R">RP Litjens</name></author><author><name sortKey="Brunt, Tm" uniqKey="Brunt T">TM Brunt</name></author><author><name sortKey="Alderliefste, Gj" uniqKey="Alderliefste G">GJ Alderliefste</name></author><author><name sortKey="Westerink, Rh" uniqKey="Westerink R">RH Westerink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buckholtz, Ns" uniqKey="Buckholtz N">NS Buckholtz</name></author><author><name sortKey="Zhou, Df" uniqKey="Zhou D">DF Zhou</name></author><author><name sortKey="Freedman, Dx" uniqKey="Freedman D">DX Freedman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buckholtz, Ns" uniqKey="Buckholtz N">NS Buckholtz</name></author><author><name sortKey="Zhou, Df" uniqKey="Zhou D">DF Zhou</name></author><author><name sortKey="Freedman, Dx" uniqKey="Freedman D">DX Freedman</name></author><author><name sortKey="Potter, Wz" uniqKey="Potter W">WZ Potter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roth, Bl" uniqKey="Roth B">BL Roth</name></author><author><name sortKey="Willins, Dl" uniqKey="Willins D">DL Willins</name></author><author><name sortKey="Kroeze, Wk" uniqKey="Kroeze W">WK Kroeze</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aloyo, Vj" uniqKey="Aloyo V">VJ Aloyo</name></author><author><name sortKey="Dave, Kd" uniqKey="Dave K">KD Dave</name></author><author><name sortKey="Rahman, T" uniqKey="Rahman T">T Rahman</name></author><author><name sortKey="Harvey, Ja" uniqKey="Harvey J">JA Harvey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gresch, Pj" uniqKey="Gresch P">PJ Gresch</name></author><author><name sortKey="Smith, Rl" uniqKey="Smith R">RL Smith</name></author><author><name sortKey="Barrett, Rj" uniqKey="Barrett R">RJ Barrett</name></author><author><name sortKey="Sanders Bush, E" uniqKey="Sanders Bush E">E Sanders-Bush</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buchborn, T" uniqKey="Buchborn T">T Buchborn</name></author><author><name sortKey="Schroder, H" uniqKey="Schroder H">H Schroder</name></author><author><name sortKey="Dieterich, Dc" uniqKey="Dieterich D">DC Dieterich</name></author><author><name sortKey="Grecksch, G" uniqKey="Grecksch G">G Grecksch</name></author><author><name sortKey="Hollt, V" uniqKey="Hollt V">V Hollt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Capela, Jp" uniqKey="Capela J">JP Capela</name></author><author><name sortKey="Fernandes, E" uniqKey="Fernandes E">E Fernandes</name></author><author><name sortKey="Remiao, F" uniqKey="Remiao F">F Remiao</name></author><author><name sortKey="Bastos, Ml" uniqKey="Bastos M">ML Bastos</name></author><author><name sortKey="Meisel, A" uniqKey="Meisel A">A Meisel</name></author><author><name sortKey="Carvalho, F" uniqKey="Carvalho F">F Carvalho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Capela, Jp" uniqKey="Capela J">JP Capela</name></author><author><name sortKey="Da Costa Araujo, S" uniqKey="Da Costa Araujo S">S da Costa Araujo</name></author><author><name sortKey="Costa, Vm" uniqKey="Costa V">VM Costa</name></author><author><name sortKey="Ruscher, K" uniqKey="Ruscher K">K Ruscher</name></author><author><name sortKey="Fernandes, E" uniqKey="Fernandes E">E Fernandes</name></author><author><name sortKey="Bastos Mde, L" uniqKey="Bastos Mde L">L Bastos Mde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Capela, Jp" uniqKey="Capela J">JP Capela</name></author><author><name sortKey="Ruscher, K" uniqKey="Ruscher K">K Ruscher</name></author><author><name sortKey="Lautenschlager, M" uniqKey="Lautenschlager M">M Lautenschlager</name></author><author><name sortKey="Freyer, D" uniqKey="Freyer D">D Freyer</name></author><author><name sortKey="Dirnagl, U" uniqKey="Dirnagl U">U Dirnagl</name></author><author><name sortKey="Gaio, Ar" uniqKey="Gaio A">AR Gaio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Noworyta Sokolowska, K" uniqKey="Noworyta Sokolowska K">K Noworyta-Sokolowska</name></author><author><name sortKey="Kaminska, K" uniqKey="Kaminska K">K Kaminska</name></author><author><name sortKey="Kreiner, G" uniqKey="Kreiner G">G Kreiner</name></author><author><name sortKey="Rogoz, Z" uniqKey="Rogoz Z">Z Rogoz</name></author><author><name sortKey="Golembiowska, K" uniqKey="Golembiowska K">K Golembiowska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="King, W" uniqKey="King W">W King</name></author><author><name sortKey="Ellison, G" uniqKey="Ellison G">G Ellison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karila, L" uniqKey="Karila L">L Karila</name></author><author><name sortKey="Reynaud, M" uniqKey="Reynaud M">M Reynaud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanchez, S" uniqKey="Sanchez S">S Sanchez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Green, Ar" uniqKey="Green A">AR Green</name></author><author><name sortKey="King, Mv" uniqKey="King M">MV King</name></author><author><name sortKey="Shortall, Se" uniqKey="Shortall S">SE Shortall</name></author><author><name sortKey="Fone, Kc" uniqKey="Fone K">KC Fone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karila, L" uniqKey="Karila L">L Karila</name></author><author><name sortKey="Billieux, J" uniqKey="Billieux J">J Billieux</name></author><author><name sortKey="Benyamina, A" uniqKey="Benyamina A">A Benyamina</name></author><author><name sortKey="Lancon, C" uniqKey="Lancon C">C Lancon</name></author><author><name sortKey="Cottencin, O" uniqKey="Cottencin O">O Cottencin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brunt, Tm" uniqKey="Brunt T">TM Brunt</name></author><author><name sortKey="Poortman, A" uniqKey="Poortman A">A Poortman</name></author><author><name sortKey="Niesink, Rj" uniqKey="Niesink R">RJ Niesink</name></author><author><name sortKey="Van Den Brink, W" uniqKey="Van Den Brink W">W van den Brink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cottencin, O" uniqKey="Cottencin O">O Cottencin</name></author><author><name sortKey="Rolland, B" uniqKey="Rolland B">B Rolland</name></author><author><name sortKey="Karila, L" uniqKey="Karila L">L Karila</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Debruyne, D" uniqKey="Debruyne D">D Debruyne</name></author><author><name sortKey="Courne, Ma" uniqKey="Courne M">MA Courné</name></author><author><name sortKey="Le Boisselier, R" uniqKey="Le Boisselier R">R Le Boisselier</name></author><author><name sortKey="Djezzar, S" uniqKey="Djezzar S">S Djezzar</name></author><author><name sortKey="Gerardin, M" uniqKey="Gerardin M">M Gérardin</name></author><author><name sortKey="Boucher, A" uniqKey="Boucher A">A Boucher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vardakou, I" uniqKey="Vardakou I">I Vardakou</name></author><author><name sortKey="Pistos, C" uniqKey="Pistos C">C Pistos</name></author><author><name sortKey="Spiliopoulou, C" uniqKey="Spiliopoulou C">C Spiliopoulou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinotti, G" uniqKey="Martinotti G">G Martinotti</name></author><author><name sortKey="Lupi, M" uniqKey="Lupi M">M Lupi</name></author><author><name sortKey="Carlucci, L" uniqKey="Carlucci L">L Carlucci</name></author><author><name sortKey="Cinosi, E" uniqKey="Cinosi E">E Cinosi</name></author><author><name sortKey="Santacroce, R" uniqKey="Santacroce R">R Santacroce</name></author><author><name sortKey="Acciavatti, T" uniqKey="Acciavatti T">T Acciavatti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zawilska, Jb" uniqKey="Zawilska J">JB Zawilska</name></author><author><name sortKey="Wojcieszak, J" uniqKey="Wojcieszak J">J Wojcieszak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Glennon, Ra" uniqKey="Glennon R">RA Glennon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author><author><name sortKey="Albanese, A" uniqKey="Albanese A">A Albanese</name></author><author><name sortKey="Fergus, S" uniqKey="Fergus S">S Fergus</name></author><author><name sortKey="Stair, Jl" uniqKey="Stair J">JL Stair</name></author><author><name sortKey="Deluca, P" uniqKey="Deluca P">P Deluca</name></author><author><name sortKey="Corazza, O" uniqKey="Corazza O">O Corazza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kelly, Jp" uniqKey="Kelly J">JP Kelly</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karila, L" uniqKey="Karila L">L Karila</name></author><author><name sortKey="Megarbane, B" uniqKey="Megarbane B">B Megarbane</name></author><author><name sortKey="Cottencin, O" uniqKey="Cottencin O">O Cottencin</name></author><author><name sortKey="Lejoyeux, M" uniqKey="Lejoyeux M">M Lejoyeux</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wood, Dm" uniqKey="Wood D">DM Wood</name></author><author><name sortKey="Dargan, Pi" uniqKey="Dargan P">PI Dargan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="German, Cl" uniqKey="German C">CL German</name></author><author><name sortKey="Fleckenstein, Ae" uniqKey="Fleckenstein A">AE Fleckenstein</name></author><author><name sortKey="Hanson, Gr" uniqKey="Hanson G">GR Hanson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kapitany Foveny, M" uniqKey="Kapitany Foveny M">M Kapitány-Fövény</name></author><author><name sortKey="Merv, B" uniqKey="Merv B">B Mervó</name></author><author><name sortKey="Kertesz, M" uniqKey="Kertesz M">M Kertész</name></author><author><name sortKey="Corazza, O" uniqKey="Corazza O">O Corazza</name></author><author><name sortKey="Farkas, J" uniqKey="Farkas J">J Farkas</name></author><author><name sortKey="Kokonyei, G" uniqKey="Kokonyei G">G Kökönyei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Hout, Mc" uniqKey="Van Hout M">MC Van Hout</name></author><author><name sortKey="Bingham, T" uniqKey="Bingham T">T Bingham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wood, Dm" uniqKey="Wood D">DM Wood</name></author><author><name sortKey="Greene, Sl" uniqKey="Greene S">SL Greene</name></author><author><name sortKey="Dargan, Pi" uniqKey="Dargan P">PI Dargan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="John, Me" uniqKey="John M">ME John</name></author><author><name sortKey="Thomas Rozea, C" uniqKey="Thomas Rozea C">C Thomas-Rozea</name></author><author><name sortKey="Hahn, D" uniqKey="Hahn D">D Hahn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dragogna, F" uniqKey="Dragogna F">F Dragogna</name></author><author><name sortKey="Oldani, L" uniqKey="Oldani L">L Oldani</name></author><author><name sortKey="Buoli, M" uniqKey="Buoli M">M Buoli</name></author><author><name sortKey="Altamura, Ac" uniqKey="Altamura A">AC Altamura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bajaj, N" uniqKey="Bajaj N">N Bajaj</name></author><author><name sortKey="Mullen, D" uniqKey="Mullen D">D Mullen</name></author><author><name sortKey="Wylie, S" uniqKey="Wylie S">S Wylie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loi, B" uniqKey="Loi B">B Loi</name></author><author><name sortKey="Corkery, Jm" uniqKey="Corkery J">JM Corkery</name></author><author><name sortKey="Claridge, H" uniqKey="Claridge H">H Claridge</name></author><author><name sortKey="Goodair, C" uniqKey="Goodair C">C Goodair</name></author><author><name sortKey="Chiappini, S" uniqKey="Chiappini S">S Chiappini</name></author><author><name sortKey="Gimeno Clemente, C" uniqKey="Gimeno Clemente C">C Gimeno Clemente</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gustavsson, D" uniqKey="Gustavsson D">D Gustavsson</name></author><author><name sortKey="Escher, C" uniqKey="Escher C">C Escher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author><author><name sortKey="Corkery, J" uniqKey="Corkery J">J Corkery</name></author><author><name sortKey="Ghodse, A" uniqKey="Ghodse A">A Ghodse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Busard, Fp" uniqKey="Busard F">FP Busardò</name></author><author><name sortKey="Kyriakou, C" uniqKey="Kyriakou C">C Kyriakou</name></author><author><name sortKey="Napoletano, S" uniqKey="Napoletano S">S Napoletano</name></author><author><name sortKey="Marinelli, E" uniqKey="Marinelli E">E Marinelli</name></author><author><name sortKey="Zaami, S" uniqKey="Zaami S">S Zaami</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prosser, Jm" uniqKey="Prosser J">JM Prosser</name></author><author><name sortKey="Nelson, Ls" uniqKey="Nelson L">LS Nelson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morris, H" uniqKey="Morris H">H Morris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winder, Gs" uniqKey="Winder G">GS Winder</name></author><author><name sortKey="Stern, N" uniqKey="Stern N">N Stern</name></author><author><name sortKey="Hosanagar, A" uniqKey="Hosanagar A">A Hosanagar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carhart Harris, Rl" uniqKey="Carhart Harris R">RL Carhart-Harris</name></author><author><name sortKey="King, La" uniqKey="King L">LA King</name></author><author><name sortKey="Nutt, Dj" uniqKey="Nutt D">DJ Nutt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winstock, Ar" uniqKey="Winstock A">AR Winstock</name></author><author><name sortKey="Mitcheson, Lr" uniqKey="Mitcheson L">LR Mitcheson</name></author><author><name sortKey="Deluca, P" uniqKey="Deluca P">P Deluca</name></author><author><name sortKey="Davey, Z" uniqKey="Davey Z">Z Davey</name></author><author><name sortKey="Corazza, O" uniqKey="Corazza O">O Corazza</name></author><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simmler, Ld" uniqKey="Simmler L">LD Simmler</name></author><author><name sortKey="Buser, Ta" uniqKey="Buser T">TA Buser</name></author><author><name sortKey="Donzelli, M" uniqKey="Donzelli M">M Donzelli</name></author><author><name sortKey="Schramm, Y" uniqKey="Schramm Y">Y Schramm</name></author><author><name sortKey="Dieu, Lh" uniqKey="Dieu L">LH Dieu</name></author><author><name sortKey="Huwyler, J" uniqKey="Huwyler J">J Huwyler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meyer, Mr" uniqKey="Meyer M">MR Meyer</name></author><author><name sortKey="Maurer, Hh" uniqKey="Maurer H">HH Maurer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jacob, P" uniqKey="Jacob P">P Jacob</name></author><author><name sortKey="Shulgin, A" uniqKey="Shulgin A">A Shulgin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meyer, Mr" uniqKey="Meyer M">MR Meyer</name></author><author><name sortKey="Wilhelm, J" uniqKey="Wilhelm J">J Wilhelm</name></author><author><name sortKey="Peters, Ft" uniqKey="Peters F">FT Peters</name></author><author><name sortKey="Maurer, Hh" uniqKey="Maurer H">HH Maurer</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Mcnamara, S" uniqKey="Mcnamara S">S McNamara</name></author><author><name sortKey="Stokes, S" uniqKey="Stokes S">S Stokes</name></author><author><name sortKey="Coleman, N" uniqKey="Coleman N">N Coleman</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="De Felice, Lj" uniqKey="De Felice L">LJ De Felice</name></author><author><name sortKey="Glennon, Ra" uniqKey="Glennon R">RA Glennon</name></author><author><name sortKey="Negus, Ss" uniqKey="Negus S">SS Negus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shimizu, E" uniqKey="Shimizu E">E Shimizu</name></author><author><name sortKey="Watanabe, H" uniqKey="Watanabe H">H Watanabe</name></author><author><name sortKey="Kojima, T" uniqKey="Kojima T">T Kojima</name></author><author><name sortKey="Hagiwara, H" uniqKey="Hagiwara H">H Hagiwara</name></author><author><name sortKey="Fujisaki, M" uniqKey="Fujisaki M">M Fujisaki</name></author><author><name sortKey="Miyatake, R" uniqKey="Miyatake R">R Miyatake</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boulanger Gobeil, C" uniqKey="Boulanger Gobeil C">C Boulanger-Gobeil</name></author><author><name sortKey="St Onge, M" uniqKey="St Onge M">M St-Onge</name></author><author><name sortKey="Laliberte, M" uniqKey="Laliberte M">M Laliberté</name></author><author><name sortKey="Auger, Pl" uniqKey="Auger P">PL Auger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Piao, Ys" uniqKey="Piao Y">YS Piao</name></author><author><name sortKey="Hall, Fs" uniqKey="Hall F">FS Hall</name></author><author><name sortKey="Moriya, Y" uniqKey="Moriya Y">Y Moriya</name></author><author><name sortKey="Ito, M" uniqKey="Ito M">M Ito</name></author><author><name sortKey="Ohara, A" uniqKey="Ohara A">A Ohara</name></author><author><name sortKey="Kikura Hanajiri, R" uniqKey="Kikura Hanajiri R">R Kikura-Hanajiri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pearson, Jm" uniqKey="Pearson J">JM Pearson</name></author><author><name sortKey="Hargraves, Tl" uniqKey="Hargraves T">TL Hargraves</name></author><author><name sortKey="Hair, Ls" uniqKey="Hair L">LS Hair</name></author><author><name sortKey="Massucci, Cj" uniqKey="Massucci C">CJ Massucci</name></author><author><name sortKey="Frazee, Cc" uniqKey="Frazee C">CC Frazee</name></author><author><name sortKey="Garg, U" uniqKey="Garg U">U Garg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Warrick, Bj" uniqKey="Warrick B">BJ Warrick</name></author><author><name sortKey="Wilson, J" uniqKey="Wilson J">J Wilson</name></author><author><name sortKey="Hedge, M" uniqKey="Hedge M">M Hedge</name></author><author><name sortKey="Freeman, S" uniqKey="Freeman S">S Freeman</name></author><author><name sortKey="Leonard, K" uniqKey="Leonard K">K Leonard</name></author><author><name sortKey="Aaron, C" uniqKey="Aaron C">C Aaron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carbone, Pn" uniqKey="Carbone P">PN Carbone</name></author><author><name sortKey="Carbone, Dl" uniqKey="Carbone D">DL Carbone</name></author><author><name sortKey="Carstairs, Sd" uniqKey="Carstairs S">SD Carstairs</name></author><author><name sortKey="Luzi, Sa" uniqKey="Luzi S">SA Luzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barrios, L" uniqKey="Barrios L">L Barrios</name></author><author><name sortKey="Grison Hernando, H" uniqKey="Grison Hernando H">H Grison-Hernando</name></author><author><name sortKey="Boels, D" uniqKey="Boels D">D Boels</name></author><author><name sortKey="Bouquie, R" uniqKey="Bouquie R">R Bouquie</name></author><author><name sortKey="Monteil Ganiere, C" uniqKey="Monteil Ganiere C">C Monteil-Ganiere</name></author><author><name sortKey="Clement, R" uniqKey="Clement R">R Clement</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bossong, Mg" uniqKey="Bossong M">MG Bossong</name></author><author><name sortKey="Van Dijk, Jp" uniqKey="Van Dijk J">JP Van Dijk</name></author><author><name sortKey="Niesink, Rj" uniqKey="Niesink R">RJ Niesink</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koob, Gf" uniqKey="Koob G">GF Koob</name></author><author><name sortKey="Volkow, Nd" uniqKey="Volkow N">ND Volkow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Homberg, Jr" uniqKey="Homberg J">JR Homberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morris, H" uniqKey="Morris H">H Morris</name></author><author><name sortKey="Wallach, J" uniqKey="Wallach J">J Wallach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Breen, C" uniqKey="Breen C">C Breen</name></author><author><name sortKey="Degenhardt, L" uniqKey="Degenhardt L">L Degenhardt</name></author><author><name sortKey="White, B" uniqKey="White B">B White</name></author><author><name sortKey="Bruno, R" uniqKey="Bruno R">R Bruno</name></author><author><name sortKey="Chanteloup, F" uniqKey="Chanteloup F">F Chanteloup</name></author><author><name sortKey="Fisher, J" uniqKey="Fisher J">J Fisher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kurdi, Ms" uniqKey="Kurdi M">MS Kurdi</name></author><author><name sortKey="Theerth, Ka" uniqKey="Theerth K">KA Theerth</name></author><author><name sortKey="Deva, Rs" uniqKey="Deva R">RS Deva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coyle, Cm" uniqKey="Coyle C">CM Coyle</name></author><author><name sortKey="Laws, Kr" uniqKey="Laws K">KR Laws</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rowland, Lm" uniqKey="Rowland L">LM Rowland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sheehy, Ka" uniqKey="Sheehy K">KA Sheehy</name></author><author><name sortKey="Muller, Ea" uniqKey="Muller E">EA Muller</name></author><author><name sortKey="Lippold, C" uniqKey="Lippold C">C Lippold</name></author><author><name sortKey="Nouraie, M" uniqKey="Nouraie M">M Nouraie</name></author><author><name sortKey="Finkel, Jc" uniqKey="Finkel J">JC Finkel</name></author><author><name sortKey="Quezado, Zm" uniqKey="Quezado Z">ZM Quezado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gable, Rs" uniqKey="Gable R">RS Gable</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morgan, Cj" uniqKey="Morgan C">CJ Morgan</name></author><author><name sortKey="Curran, Hv" uniqKey="Curran H">HV Curran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bokor, G" uniqKey="Bokor G">G Bokor</name></author><author><name sortKey="Anderson, Pd" uniqKey="Anderson P">PD Anderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reynaud Maurupt, C" uniqKey="Reynaud Maurupt C">C Reynaud-Maurupt</name></author><author><name sortKey="Bello, Py" uniqKey="Bello P">PY Bello</name></author><author><name sortKey="Akoka, S" uniqKey="Akoka S">S Akoka</name></author><author><name sortKey="Toufik, A" uniqKey="Toufik A">A Toufik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Britt, Gc" uniqKey="Britt G">GC Britt</name></author><author><name sortKey="Mccance Katz, Ef" uniqKey="Mccance Katz E">EF McCance-Katz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, Cp" uniqKey="Muller C">CP Müller</name></author><author><name sortKey="Pum, Me" uniqKey="Pum M">ME Pum</name></author><author><name sortKey="Amato, D" uniqKey="Amato D">D Amato</name></author><author><name sortKey="Schuttler, J" uniqKey="Schuttler J">J Schüttler</name></author><author><name sortKey="Huston, Jp" uniqKey="Huston J">JP Huston</name></author><author><name sortKey="De Souza Silva, Ma" uniqKey="De Souza Silva M">MA de Souza Silva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Powers, Ar" uniqKey="Powers A">AR Powers</name></author><author><name sortKey="Gancsos, Mg" uniqKey="Gancsos M">MG Gancsos</name></author><author><name sortKey="Finn, Es" uniqKey="Finn E">ES Finn</name></author><author><name sortKey="Morgan, Pt" uniqKey="Morgan P">PT Morgan</name></author><author><name sortKey="Corlett, Pr" uniqKey="Corlett P">PR Corlett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhuo, X" uniqKey="Zhuo X">X Zhuo</name></author><author><name sortKey="Cang, Y" uniqKey="Cang Y">Y Cang</name></author><author><name sortKey="Yan, H" uniqKey="Yan H">H Yan</name></author><author><name sortKey="Bu, J" uniqKey="Bu J">J Bu</name></author><author><name sortKey="Shen, B" uniqKey="Shen B">B Shen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giorgetti, R" uniqKey="Giorgetti R">R Giorgetti</name></author><author><name sortKey="Marcotulli, D" uniqKey="Marcotulli D">D Marcotulli</name></author><author><name sortKey="Tagliabracci, A" uniqKey="Tagliabracci A">A Tagliabracci</name></author><author><name sortKey="Schifano, F" uniqKey="Schifano F">F Schifano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Penning, R" uniqKey="Penning R">R Penning</name></author><author><name sortKey="Veldstra, Jl" uniqKey="Veldstra J">JL Veldstra</name></author><author><name sortKey="Daamen, Ap" uniqKey="Daamen A">AP Daamen</name></author><author><name sortKey="Olivier, B" uniqKey="Olivier B">B Olivier</name></author><author><name sortKey="Verster, Jc" uniqKey="Verster J">JC Verster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pappas, Mk" uniqKey="Pappas M">MK Pappas</name></author><author><name sortKey="Halkitis, Pn" uniqKey="Halkitis P">PN Halkitis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, Jj" uniqKey="Xu J">JJ Xu</name></author><author><name sortKey="Zhang, C" uniqKey="Zhang C">C Zhang</name></author><author><name sortKey="Hu, Qh" uniqKey="Hu Q">QH Hu</name></author><author><name sortKey="Chu, Zx" uniqKey="Chu Z">ZX Chu</name></author><author><name sortKey="Zhang, J" uniqKey="Zhang J">J Zhang</name></author><author><name sortKey="Li, Yz" uniqKey="Li Y">YZ Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiner, A" uniqKey="Weiner A">A Weiner</name></author><author><name sortKey="Vieira, L" uniqKey="Vieira L">L Vieira</name></author><author><name sortKey="Mckay, Ca" uniqKey="Mckay C">CA McKay</name></author><author><name sortKey="Bayer, Mj" uniqKey="Bayer M">MJ Bayer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mason, K" uniqKey="Mason K">K Mason</name></author><author><name sortKey="Cottrell, Am" uniqKey="Cottrell A">AM Cottrell</name></author><author><name sortKey="Corrigan, Ag" uniqKey="Corrigan A">AG Corrigan</name></author><author><name sortKey="Gillatt, Da" uniqKey="Gillatt D">DA Gillatt</name></author><author><name sortKey="Mitchelmore, Ae" uniqKey="Mitchelmore A">AE Mitchelmore</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Skeldon, Sc" uniqKey="Skeldon S">SC Skeldon</name></author><author><name sortKey="Goldenberg, Sl" uniqKey="Goldenberg S">SL Goldenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yek, J" uniqKey="Yek J">J Yek</name></author><author><name sortKey="Sundaram, P" uniqKey="Sundaram P">P Sundaram</name></author><author><name sortKey="Aydin, H" uniqKey="Aydin H">H Aydin</name></author><author><name sortKey="Kuo, T" uniqKey="Kuo T">T Kuo</name></author><author><name sortKey="Ng, Lg" uniqKey="Ng L">LG Ng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huang, Lk" uniqKey="Huang L">LK Huang</name></author><author><name sortKey="Wang, Jh" uniqKey="Wang J">JH Wang</name></author><author><name sortKey="Shen, Sh" uniqKey="Shen S">SH Shen</name></author><author><name sortKey="Lin, At" uniqKey="Lin A">AT Lin</name></author><author><name sortKey="Chang, Cy" uniqKey="Chang C">CY Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, S" uniqKey="Wu S">S Wu</name></author><author><name sortKey="Lai, Y" uniqKey="Lai Y">Y Lai</name></author><author><name sortKey="He, Y" uniqKey="He Y">Y He</name></author><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Guan, Z" uniqKey="Guan Z">Z Guan</name></author><author><name sortKey="Cai, Z" uniqKey="Cai Z">Z Cai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Wy" uniqKey="Chen W">WY Chen</name></author><author><name sortKey="Huang, Mc" uniqKey="Huang M">MC Huang</name></author><author><name sortKey="Lin, Sk" uniqKey="Lin S">SK Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tang, J" uniqKey="Tang J">J Tang</name></author><author><name sortKey="Liao, Y" uniqKey="Liao Y">Y Liao</name></author><author><name sortKey="He, H" uniqKey="He H">H He</name></author><author><name sortKey="Deng, Q" uniqKey="Deng Q">Q Deng</name></author><author><name sortKey="Zhang, G" uniqKey="Zhang G">G Zhang</name></author><author><name sortKey="Qi, C" uniqKey="Qi C">C Qi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Costi, S" uniqKey="Costi S">S Costi</name></author><author><name sortKey="Dam, Ntv" uniqKey="Dam N">NTV Dam</name></author><author><name sortKey="Murrough, Jw" uniqKey="Murrough J">JW Murrough</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonnet, U" uniqKey="Bonnet U">U Bonnet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pender, Jw" uniqKey="Pender J">JW Pender</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petersen, Rc" uniqKey="Petersen R">RC Petersen</name></author><author><name sortKey="Stillman, Rc" uniqKey="Stillman R">RC Stillman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morgan, Cj" uniqKey="Morgan C">CJ Morgan</name></author><author><name sortKey="Curran, Hv" uniqKey="Curran H">HV Curran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rocha, A" uniqKey="Rocha A">A Rocha</name></author><author><name sortKey="Hart, N" uniqKey="Hart N">N Hart</name></author><author><name sortKey="Trujillo, Ka" uniqKey="Trujillo K">KA Trujillo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, Hj" uniqKey="Liang H">HJ Liang</name></author><author><name sortKey="Tang, Kl" uniqKey="Tang K">KL Tang</name></author><author><name sortKey="Chan, F" uniqKey="Chan F">F Chan</name></author><author><name sortKey="Ungvari, Gs" uniqKey="Ungvari G">GS Ungvari</name></author><author><name sortKey="Tang, Wk" uniqKey="Tang W">WK Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stone, Jm" uniqKey="Stone J">JM Stone</name></author><author><name sortKey="Pepper, F" uniqKey="Pepper F">F Pepper</name></author><author><name sortKey="Fam, J" uniqKey="Fam J">J Fam</name></author><author><name sortKey="Furby, H" uniqKey="Furby H">H Furby</name></author><author><name sortKey="Hughes, E" uniqKey="Hughes E">E Hughes</name></author><author><name sortKey="Morgan, C" uniqKey="Morgan C">C Morgan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamal, Rm" uniqKey="Kamal R">RM Kamal</name></author><author><name sortKey="Van Noorden, Ms" uniqKey="Van Noorden M">MS Van Noorden</name></author><author><name sortKey="Wannet, W" uniqKey="Wannet W">W Wannet</name></author><author><name sortKey="Beurmajer, H" uniqKey="Beurmajer H">H Beurmajer</name></author><author><name sortKey="Dijkstra, Ba" uniqKey="Dijkstra B">BA Dijkstra</name></author><author><name sortKey="Schellekens, A" uniqKey="Schellekens A">A Schellekens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carai, Ma" uniqKey="Carai M">MA Carai</name></author><author><name sortKey="Colombo, G" uniqKey="Colombo G">G Colombo</name></author><author><name sortKey="Reali, R" uniqKey="Reali R">R Reali</name></author><author><name sortKey="Serra, S" uniqKey="Serra S">S Serra</name></author><author><name sortKey="Mocci, I" uniqKey="Mocci I">I Mocci</name></author><author><name sortKey="Castelli, Mp" uniqKey="Castelli M">MP Castelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Irwing, Rd" uniqKey="Irwing R">RD Irwing</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bessman, Sp" uniqKey="Bessman S">SP Bessman</name></author><author><name sortKey="Fishbein, Wn" uniqKey="Fishbein W">WN Fishbein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Snead, Oc" uniqKey="Snead O">OC Snead</name></author><author><name sortKey="Morley, Bj" uniqKey="Morley B">BJ Morley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Engberg, G" uniqKey="Engberg G">G Engberg</name></author><author><name sortKey="Nissbrandt, H" uniqKey="Nissbrandt H">H Nissbrandt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benavides, J" uniqKey="Benavides J">J Benavides</name></author><author><name sortKey="Rumigny, Jf" uniqKey="Rumigny J">JF Rumigny</name></author><author><name sortKey="Bourguignon, Jj" uniqKey="Bourguignon J">JJ Bourguignon</name></author><author><name sortKey="Cash, C" uniqKey="Cash C">C Cash</name></author><author><name sortKey="Wermuth, Cg" uniqKey="Wermuth C">CG Wermuth</name></author><author><name sortKey="Mandel, P" uniqKey="Mandel P">P Mandel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Snead, Oc" uniqKey="Snead O">OC Snead</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Lp" uniqKey="Carter L">LP Carter</name></author><author><name sortKey="Koek, W" uniqKey="Koek W">W Koek</name></author><author><name sortKey="France, Cp" uniqKey="France C">CP France</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Andresen, H" uniqKey="Andresen H">H Andresen</name></author><author><name sortKey="Aydin, Be" uniqKey="Aydin B">BE Aydin</name></author><author><name sortKey="Mueller, A" uniqKey="Mueller A">A Mueller</name></author><author><name sortKey="Iwersen Bergmann, S" uniqKey="Iwersen Bergmann S">S Iwersen-Bergmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liechti, Me" uniqKey="Liechti M">ME Liechti</name></author><author><name sortKey="Quednow, Bb" uniqKey="Quednow B">BB Quednow</name></author><author><name sortKey="Liakoni, E" uniqKey="Liakoni E">E Liakoni</name></author><author><name sortKey="Dornbierer, D" uniqKey="Dornbierer D">D Dornbierer</name></author><author><name sortKey="Von Rotz, R" uniqKey="Von Rotz R">R von Rotz</name></author><author><name sortKey="Gachet, Ms" uniqKey="Gachet M">MS Gachet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schep, Lj" uniqKey="Schep L">LJ Schep</name></author><author><name sortKey="Knudsen, K" uniqKey="Knudsen K">K Knudsen</name></author><author><name sortKey="Slaughter, Rj" uniqKey="Slaughter R">RJ Slaughter</name></author><author><name sortKey="Vale, Ja" uniqKey="Vale J">JA Vale</name></author><author><name sortKey="Megarbane, B" uniqKey="Megarbane B">B Mégarbane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaufman, Ee" uniqKey="Kaufman E">EE Kaufman</name></author><author><name sortKey="Nelson, T" uniqKey="Nelson T">T Nelson</name></author><author><name sortKey="Miller, D" uniqKey="Miller D">D Miller</name></author><author><name sortKey="Stadlan, N" uniqKey="Stadlan N">N Stadlan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abanades, S" uniqKey="Abanades S">S Abanades</name></author><author><name sortKey="Farre, M" uniqKey="Farre M">M Farre</name></author><author><name sortKey="Segura, M" uniqKey="Segura M">M Segura</name></author><author><name sortKey="Pichini, S" uniqKey="Pichini S">S Pichini</name></author><author><name sortKey="Barral, D" uniqKey="Barral D">D Barral</name></author><author><name sortKey="Pacifici, R" uniqKey="Pacifici R">R Pacifici</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bosch, Og" uniqKey="Bosch O">OG Bosch</name></author><author><name sortKey="Eisenegger, C" uniqKey="Eisenegger C">C Eisenegger</name></author><author><name sortKey="Gertsch, J" uniqKey="Gertsch J">J Gertsch</name></author><author><name sortKey="Von Rotz, R" uniqKey="Von Rotz R">R von Rotz</name></author><author><name sortKey="Dornbierer, D" uniqKey="Dornbierer D">D Dornbierer</name></author><author><name sortKey="Gachet, Ms" uniqKey="Gachet M">MS Gachet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miotto, K" uniqKey="Miotto K">K Miotto</name></author><author><name sortKey="Darakjian, J" uniqKey="Darakjian J">J Darakjian</name></author><author><name sortKey="Basch, J" uniqKey="Basch J">J Basch</name></author><author><name sortKey="Murray, S" uniqKey="Murray S">S Murray</name></author><author><name sortKey="Zogg, J" uniqKey="Zogg J">J Zogg</name></author><author><name sortKey="Rawson, R" uniqKey="Rawson R">R Rawson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Sassenbroeck, Dk" uniqKey="Van Sassenbroeck D">DK Van Sassenbroeck</name></author><author><name sortKey="De Neve, N" uniqKey="De Neve N">N De Neve</name></author><author><name sortKey="De Paepe, P" uniqKey="De Paepe P">P De Paepe</name></author><author><name sortKey="Belpaire, Fm" uniqKey="Belpaire F">FM Belpaire</name></author><author><name sortKey="Verstraete, Ag" uniqKey="Verstraete A">AG Verstraete</name></author><author><name sortKey="Calle, Pa" uniqKey="Calle P">PA Calle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Donjacour, Ce" uniqKey="Donjacour C">CE Donjacour</name></author><author><name sortKey="Aziz, Na" uniqKey="Aziz N">NA Aziz</name></author><author><name sortKey="Overeem, S" uniqKey="Overeem S">S Overeem</name></author><author><name sortKey="Kalsbeek, A" uniqKey="Kalsbeek A">A Kalsbeek</name></author><author><name sortKey="Pijl, H" uniqKey="Pijl H">H Pijl</name></author><author><name sortKey="Lammers, Gj" uniqKey="Lammers G">GJ Lammers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goodwin, Ak" uniqKey="Goodwin A">AK Goodwin</name></author><author><name sortKey="Froestl, W" uniqKey="Froestl W">W Froestl</name></author><author><name sortKey="Weerts, Em" uniqKey="Weerts E">EM Weerts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Husain, Am" uniqKey="Husain A">AM Husain</name></author><author><name sortKey="Ristanovic, Rk" uniqKey="Ristanovic R">RK Ristanovic</name></author><author><name sortKey="Bogan, Rk" uniqKey="Bogan R">RK Bogan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ottani, A" uniqKey="Ottani A">A Ottani</name></author><author><name sortKey="Leone, S" uniqKey="Leone S">S Leone</name></author><author><name sortKey="Vergara, Fb" uniqKey="Vergara F">FB Vergara</name></author><author><name sortKey="Tacchi, R" uniqKey="Tacchi R">R Tacchi</name></author><author><name sortKey="Loche, A" uniqKey="Loche A">A Loche</name></author><author><name sortKey="Bertolini, A" uniqKey="Bertolini A">A Bertolini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcelroy, Sl" uniqKey="Mcelroy S">SL McElroy</name></author><author><name sortKey="Guerdjikova, Ai" uniqKey="Guerdjikova A">AI Guerdjikova</name></author><author><name sortKey="Winstanley, El" uniqKey="Winstanley E">EL Winstanley</name></author><author><name sortKey="O Elia, Am" uniqKey="O Elia A">AM O’Melia</name></author><author><name sortKey="Mori, N" uniqKey="Mori N">N Mori</name></author><author><name sortKey="Keck, Pe" uniqKey="Keck P">PE Keck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kapitany Foveny, M" uniqKey="Kapitany Foveny M">M Kapitány-Fövény</name></author><author><name sortKey="Merv, B" uniqKey="Merv B">B Mervó</name></author><author><name sortKey="Corazza, O" uniqKey="Corazza O">O Corazza</name></author><author><name sortKey="Kokonyei, G" uniqKey="Kokonyei G">G Kökönyei</name></author><author><name sortKey="Farkas, J" uniqKey="Farkas J">J Farkas</name></author><author><name sortKey="Urban, R" uniqKey="Urban R">R Urbán</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sumnall, Hr" uniqKey="Sumnall H">HR Sumnall</name></author><author><name sortKey="Woolfall, K" uniqKey="Woolfall K">K Woolfall</name></author><author><name sortKey="Edwards, S" uniqKey="Edwards S">S Edwards</name></author><author><name sortKey="Cole, Jc" uniqKey="Cole J">JC Cole</name></author><author><name sortKey="Beynon, Cm" uniqKey="Beynon C">CM Beynon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Teltzrow, R" uniqKey="Teltzrow R">R Teltzrow</name></author><author><name sortKey="Bosch, Og" uniqKey="Bosch O">OG Bosch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bosch, Og" uniqKey="Bosch O">OG Bosch</name></author><author><name sortKey="Havranek, Mm" uniqKey="Havranek M">MM Havranek</name></author><author><name sortKey="Baumberger, A" uniqKey="Baumberger A">A Baumberger</name></author><author><name sortKey="Preller, Kh" uniqKey="Preller K">KH Preller</name></author><author><name sortKey="Von Rotz, R" uniqKey="Von Rotz R">R von Rotz</name></author><author><name sortKey="Herdener, M" uniqKey="Herdener M">M Herdener</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mamelak, M" uniqKey="Mamelak M">M Mamelak</name></author><author><name sortKey="Escriu, Jm" uniqKey="Escriu J">JM Escriu</name></author><author><name sortKey="Stokan, O" uniqKey="Stokan O">O Stokan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Black, J" uniqKey="Black J">J Black</name></author><author><name sortKey="Houghton, Wc" uniqKey="Houghton W">WC Houghton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Black, J" uniqKey="Black J">J Black</name></author><author><name sortKey="Pardi, D" uniqKey="Pardi D">D Pardi</name></author><author><name sortKey="Hornfeldt, Cs" uniqKey="Hornfeldt C">CS Hornfeldt</name></author><author><name sortKey="Inhaber, N" uniqKey="Inhaber N">N Inhaber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spaeth, M" uniqKey="Spaeth M">M Spaeth</name></author><author><name sortKey="Bennett, Rm" uniqKey="Bennett R">RM Bennett</name></author><author><name sortKey="Benson, Ba" uniqKey="Benson B">BA Benson</name></author><author><name sortKey="Wang, Yg" uniqKey="Wang Y">YG Wang</name></author><author><name sortKey="Lai, C" uniqKey="Lai C">C Lai</name></author><author><name sortKey="Choy, Eh" uniqKey="Choy E">EH Choy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jime Ez, F" uniqKey="Jime Ez F">F Jimeńez</name></author><author><name sortKey="Lopez Timoneda, F" uniqKey="Lopez Timoneda F">F Lopez Timoneda</name></author><author><name sortKey="Nodal, C" uniqKey="Nodal C">C Nodal</name></author><author><name sortKey="Arrigain, S" uniqKey="Arrigain S">S Arrigain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Metcalf, Dr" uniqKey="Metcalf D">DR Metcalf</name></author><author><name sortKey="Emde, Rn" uniqKey="Emde R">RN Emde</name></author><author><name sortKey="Stripe, Jt" uniqKey="Stripe J">JT Stripe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Cauter, E" uniqKey="Van Cauter E">E Van Cauter</name></author><author><name sortKey="Plat, L" uniqKey="Plat L">L Plat</name></author><author><name sortKey="Scharf, Mb" uniqKey="Scharf M">MB Scharf</name></author><author><name sortKey="Leproult, R" uniqKey="Leproult R">R Leproult</name></author><author><name sortKey="Cespedes, S" uniqKey="Cespedes S">S Cespedes</name></author><author><name sortKey="L Ermite Baleriaux, M" uniqKey="L Ermite Baleriaux M">M L’Hermite-Balériaux</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Von Rotz, R" uniqKey="Von Rotz R">R von Rotz</name></author><author><name sortKey="Kometer, M" uniqKey="Kometer M">M Kometer</name></author><author><name sortKey="Dornbierer, D" uniqKey="Dornbierer D">D Dornbierer</name></author><author><name sortKey="Gertsch, J" uniqKey="Gertsch J">J Gertsch</name></author><author><name sortKey="Salome Gachet, M" uniqKey="Salome Gachet M">M Salomé Gachet</name></author><author><name sortKey="Vollenweider, Fx" uniqKey="Vollenweider F">FX Vollenweider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bosch, Og" uniqKey="Bosch O">OG Bosch</name></author><author><name sortKey="Esposito, F" uniqKey="Esposito F">F Esposito</name></author><author><name sortKey="Havranek, Mm" uniqKey="Havranek M">MM Havranek</name></author><author><name sortKey="Dornbierer, D" uniqKey="Dornbierer D">D Dornbierer</name></author><author><name sortKey="Von Rotz, R" uniqKey="Von Rotz R">R von Rotz</name></author><author><name sortKey="Staempfli, P" uniqKey="Staempfli P">P Staempfli</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Lp" uniqKey="Carter L">LP Carter</name></author><author><name sortKey="Pardi, D" uniqKey="Pardi D">D Pardi</name></author><author><name sortKey="Gorsline, J" uniqKey="Gorsline J">J Gorsline</name></author><author><name sortKey="Griffiths, Rr" uniqKey="Griffiths R">RR Griffiths</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Nemeth, Z" uniqKey="Nemeth Z">Z Nemeth</name></author><author><name sortKey="Kun, B" uniqKey="Kun B">B Kun</name></author><author><name sortKey="Demetrovics, Z" uniqKey="Demetrovics Z">Z Demetrovics</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boscolo Berto, R" uniqKey="Boscolo Berto R">R Boscolo-Berto</name></author><author><name sortKey="Viel, G" uniqKey="Viel G">G Viel</name></author><author><name sortKey="Montagnese, S" uniqKey="Montagnese S">S Montagnese</name></author><author><name sortKey="Raduazzo, Di" uniqKey="Raduazzo D">DI Raduazzo</name></author><author><name sortKey="Ferrara, Sd" uniqKey="Ferrara S">SD Ferrara</name></author><author><name sortKey="Dauvilliers, Y" uniqKey="Dauvilliers Y">Y Dauvilliers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Caputo, F" uniqKey="Caputo F">F Caputo</name></author><author><name sortKey="Mirijello, A" uniqKey="Mirijello A">A Mirijello</name></author><author><name sortKey="Cibin, M" uniqKey="Cibin M">M Cibin</name></author><author><name sortKey="Mosti, A" uniqKey="Mosti A">A Mosti</name></author><author><name sortKey="Ceccanti, M" uniqKey="Ceccanti M">M Ceccanti</name></author><author><name sortKey="Domenicali, M" uniqKey="Domenicali M">M Domenicali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russell, Ij" uniqKey="Russell I">IJ Russell</name></author><author><name sortKey="Perkins, At" uniqKey="Perkins A">AT Perkins</name></author><author><name sortKey="Michalek, Je" uniqKey="Michalek J">JE Michalek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russell, Ij" uniqKey="Russell I">IJ Russell</name></author><author><name sortKey="Holman, Aj" uniqKey="Holman A">AJ Holman</name></author><author><name sortKey="Swick, Tj" uniqKey="Swick T">TJ Swick</name></author><author><name sortKey="Alvarez Horine, S" uniqKey="Alvarez Horine S">S Alvarez-Horine</name></author><author><name sortKey="Wang, Yg" uniqKey="Wang Y">YG Wang</name></author><author><name sortKey="Guinta, D" uniqKey="Guinta D">D Guinta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spaeth, M" uniqKey="Spaeth M">M Spaeth</name></author><author><name sortKey="Alegre, C" uniqKey="Alegre C">C Alegre</name></author><author><name sortKey="Perrot, S" uniqKey="Perrot S">S Perrot</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y Wang</name></author><author><name sortKey="Guinta, Dr" uniqKey="Guinta D">DR Guinta</name></author><author><name sortKey="Alvarez Horine, S" uniqKey="Alvarez Horine S">S Alvarez-Horine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kantrowitz, Jt" uniqKey="Kantrowitz J">JT Kantrowitz</name></author><author><name sortKey="Citrome, L" uniqKey="Citrome L">L Citrome</name></author><author><name sortKey="Javitt, Dc" uniqKey="Javitt D">DC Javitt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ondo, Wg" uniqKey="Ondo W">WG Ondo</name></author><author><name sortKey="Perkins, T" uniqKey="Perkins T">T Perkins</name></author><author><name sortKey="Swick, T" uniqKey="Swick T">T Swick</name></author><author><name sortKey="Hull, Kl" uniqKey="Hull K">KL Hull</name></author><author><name sortKey="Jimenez, Je" uniqKey="Jimenez J">JE Jimenez</name></author><author><name sortKey="Garris, Ts" uniqKey="Garris T">TS Garris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hidalgo, H" uniqKey="Hidalgo H">H Hidalgo</name></author><author><name sortKey="Uhl, V" uniqKey="Uhl V">V Uhl</name></author><author><name sortKey="Gantenbein, Ar" uniqKey="Gantenbein A">AR Gantenbein</name></author><author><name sortKey="Sandor, Ps" uniqKey="Sandor P">PS Sándor</name></author><author><name sortKey="Kallweit, U" uniqKey="Kallweit U">U Kallweit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khatami, R" uniqKey="Khatami R">R Khatami</name></author><author><name sortKey="Tartarotti, S" uniqKey="Tartarotti S">S Tartarotti</name></author><author><name sortKey="Siccoli, Mm" uniqKey="Siccoli M">MM Siccoli</name></author><author><name sortKey="Bassetti, Cl" uniqKey="Bassetti C">CL Bassetti</name></author><author><name sortKey="Sandor, Ps" uniqKey="Sandor P">PS Sándor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bosch, Og" uniqKey="Bosch O">OG Bosch</name></author><author><name sortKey="Quednow, Bb" uniqKey="Quednow B">BB Quednow</name></author><author><name sortKey="Seifritz, E" uniqKey="Seifritz E">E Seifritz</name></author><author><name sortKey="Wetter, Tc" uniqKey="Wetter T">TC Wetter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mamelak, M" uniqKey="Mamelak M">M Mamelak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Lp" uniqKey="Carter L">LP Carter</name></author><author><name sortKey="Richards, Bd" uniqKey="Richards B">BD Richards</name></author><author><name sortKey="Mintzer, Mz" uniqKey="Mintzer M">MZ Mintzer</name></author><author><name sortKey="Griffiths, Rr" uniqKey="Griffiths R">RR Griffiths</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chin, My" uniqKey="Chin M">MY Chin</name></author><author><name sortKey="Kreutzer, Ra" uniqKey="Kreutzer R">RA Kreutzer</name></author><author><name sortKey="Dyer, Je" uniqKey="Dyer J">JE Dyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="George, Cf" uniqKey="George C">CF George</name></author><author><name sortKey="Feldman, N" uniqKey="Feldman N">N Feldman</name></author><author><name sortKey="Inhaber, N" uniqKey="Inhaber N">N Inhaber</name></author><author><name sortKey="Steininger, Tl" uniqKey="Steininger T">TL Steininger</name></author><author><name sortKey="Grzeschik, Sm" uniqKey="Grzeschik S">SM Grzeschik</name></author><author><name sortKey="Lai, C" uniqKey="Lai C">C Lai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bosch, Og" uniqKey="Bosch O">OG Bosch</name></author><author><name sortKey="Seifritz, E" uniqKey="Seifritz E">E Seifritz</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28868040</article-id><article-id pub-id-type="pmc">5563308</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2017.00152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hassan</surname><given-names>Zurina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/67780"></uri></contrib><contrib contrib-type="author"><name><surname>Bosch</surname><given-names>Oliver G.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/244400"></uri></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Darshan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/466404"></uri></contrib><contrib contrib-type="author"><name><surname>Narayanan</surname><given-names>Suresh</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/466352"></uri></contrib><contrib contrib-type="author"><name><surname>Kasinather</surname><given-names>B. Vicknasingam</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/466330"></uri></contrib><contrib contrib-type="author"><name><surname>Seifritz</surname><given-names>Erich</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/69053"></uri></contrib><contrib contrib-type="author"><name><surname>Kornhuber</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/290550"></uri></contrib><contrib contrib-type="author"><name><surname>Quednow</surname><given-names>Boris B.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/7300"></uri></contrib><contrib contrib-type="author"><name><surname>Müller</surname><given-names>Christian P.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/62460"></uri></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Centre for Drug Research, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></aff><aff id="aff3"><sup>3</sup><institution>School of Social Sciences, Universiti Sains Malaysia</institution>,<addr-line>Minden</addr-line>,<country>Malaysia</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></aff><aff id="aff5"><sup>5</sup><institution>Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>,<addr-line>Zurich</addr-line>,<country>Switzerland</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Liana Fattore, Consiglio Nazionale Delle Ricerche (CNR), Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Tod Edward Kippin, University of California, Santa Barbara, United States; Mercedes Lovrecic, National Institute of Public Health, Slovenia</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Christian P. Müller, <email>christian.mueller@uk-erlangen.de</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Addictive Disorders, a section of the journal Frontiers in Psychiatry</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>152</elocation-id><history><date date-type="received"><day>01</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>02</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 Hassan, Bosch, Singh, Narayanan, Kasinather, Seifritz, Kornhuber, Quednow and Müller.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Hassan, Bosch, Singh, Narayanan, Kasinather, Seifritz, Kornhuber, Quednow and Müller</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects. These drugs change the mental state and/or the behavioral performance of an individual and can be instrumentalized for various purposes. After the emergence of a novel psychoactive substance (NPS) and a period of experimental consumption, personal and medical benefits and harm potential of the NPS can be estimated on evidence base. This may lead to a legal classification of the NPS, which may range from limited medical use, controlled availability up to a complete ban of the drug form publically accepted use. With these measures, however, a drug does not disappear, but frequently continues to be used, which eventually allows an even better estimate of the drug’s properties. Thus, only in rare cases, there is a final verdict that is no more questioned. Instead, the view on a drug can change from tolerable to harmful but may also involve the new establishment of a desired medical application to a previously harmful drug. Here, we provide a summary review on a number of NPS for which the neuropharmacological evaluation has made important progress in recent years. They include mitragynine (“Kratom”), synthetic cannabinoids (e.g., “Spice”), dimethyltryptamine and novel serotonergic hallucinogens, the cathinones mephedrone and methylone, ketamine and novel dissociative drugs, γ-hydroxybutyrate, γ-butyrolactone, and 1,4-butanediol. This review shows not only emerging harm potentials but also some potential medical applications.</p></abstract><kwd-group><kwd>Kratom</kwd><kwd>synthetic cannabinoids</kwd><kwd>dimethyltryptamine</kwd><kwd>serotonergic hallucinogens</kwd><kwd>mephedrone</kwd><kwd>ketamine</kwd><kwd>γ-hydroxybutyrate</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content></funding-source><award-id rid="cn01">MU 2789/8-1 and KO 947/15-1</award-id></award-group></funding-group><counts><fig-count count="0"></fig-count><table-count count="0"></table-count><equation-count count="0"></equation-count><ref-count count="368"></ref-count><page-count count="21"></page-count><word-count count="20161"></word-count></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>It appears to be a human trait to constantly seek for new psychoactive substances and to explore potential use of them. As long as human record keeping dates back, humans consume psychoactive plant preparations. Since centuries they isolated single compounds yielding “natural drugs,” while since decades synthetic chemistry allowed the innovation of completely new compounds that are not available from natural resources (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Despite the risk of being toxic upon single or chronic consumption, there are constantly new drugs that find their way into drug-taking communities (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Novel stimuli and novel information about the external world have an incentive salience and maintain seeking behavior in animals and in humans (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). The search for novel external stimuli may translate to novel “mental states,” as an experience of new interoceptive states. Human brains generate distinct working modes that are subjectively perceived as mental states. This is at the neurobiological side believed to be organized by the summatory tonic activity of modulatory transmitter systems. Mental states can determine how an organism perceives, processes, and stores external and internal information. It also affects how efficiently behavior is generated (<xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B8" ref-type="bibr">8</xref>). Mental states change spontaneously or as a consequence of environmental influences, thereby some mental states are perceived as more pleasurable and useful for goal-directed behavior than others. The rewarding value of novelty may, thus, be expanded to novel mental states, which have never been incurred by natural means. Psychoactive substances can induce and maintain a desired mental state. Some of them may also provoke novel mental states. Only a few of the well-established psychoactive substances induce “euphoria” or a sense of “well-being,” which directly reinforces drug-seeking and consumption behaviors. Most psychoactive substances, however, induce mental states that are primarily useful for other purposes. In that, they exert complex reinforcing effects during drug instrumentalization (<xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B10" ref-type="bibr">10</xref>). Thus, the mental state that is induced by a psychoactive drug and for which humans develop a memory (<xref rid="B11" ref-type="bibr">11</xref>) may facilitate other behaviors with positive or negative reinforcing outcome, such as the facilitation of social interaction, mating behavior, coping with stress, and cognitive enhancement (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B12" ref-type="bibr">12</xref>–<xref rid="B16" ref-type="bibr">16</xref>). When a new drug is discovered and experimentally used, the new user may not only judge the novelty and emotional impact of the newly experienced mental state but subsequently decide for what purposes this new mental state may serve (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Once a new drug is made available, an experimental consumption starts that determines individual subjective effects as well as context and possibility of instrumentalization. This may not only work in humans but also for a newly experienced psychoactive drug in animals (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>A major factor that fuels continuous search for new psychoactive drugs is the need to replace existing ones in routine use. Once a long known drug has been criminalized and banned, availability of the drug becomes limited. Legal control imposes punishment on drug possession, trade, and use, which limits its instrumentalization for frequently performed behavior, such as coping with stress (<xref rid="B20" ref-type="bibr">20</xref>). If the drug was useful for this behavior, e.g., to better relax after stressful work, users may start looking for a legal replacement of the banned drug and, thus, be motivated for testing new drugs (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Novel psychoactive substances (NPSs) had been defined by the United Nations as new narcotic or psychotropic drugs that are not controlled by the United Nations’ 1961 Single Convention on Narcotic Drugs or by Psychotropic Substances Conventions (<xref rid="B22" ref-type="bibr">22</xref>). NPSs are by definition those psychoactive drugs used for intoxication which are not already prohibited by UN Single Convention on Narcotic Drugs or Misuse of Drugs Act (<xref rid="B23" ref-type="bibr">23</xref>), thereby “novel” does not necessarily mean that the drug has been developed completely new recently. It may also refer to substances that have lately become popular and/or more widely available, constituting a reason of current or potential public health concerns (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>The way of a NPS in society, from its introduction, experimental use, instrumentalization, habitual abuse, up to its legal control, depends essentially on the relationship of adverse side effects and potential medical use. The adverse side effects are those effects of the drug that threaten the physiological integrity and behavioral repertoire of the whole organism, beyond the desired psychoactive action. Many known psychoactive drugs are strong toxins and harm the user. This can occur after acute consumption or after chronic intake (<xref rid="B3" ref-type="bibr">3</xref>). Humans establish cultural rules for the consumption and the control of side effects of psychoactive drugs (<xref rid="B25" ref-type="bibr">25</xref>). This keeps even highly dangerous drugs, such as alcohol, legal and limits their harm potential when incorporated in cultural activities (<xref rid="B26" ref-type="bibr">26</xref>). But establishing those initially “non-written” rules requires a certain amount of experience and a user/non-user discourse. One result of this discourse is the possibility of legal control, and a “written down” law on where, when, and how a psychoactive substance can be used. Drugs can be labeled as addictive drugs and made illicit. However, many new substances are at the same time tested for a potential beneficial application, e.g., to treat pain, or even as substitutes for well-known addictive drugs, thereby the verdict may be that a NPS might have some addiction- and harm potential but also beneficial effects, which may actually dominate the use profile. There is occasionally also a reversal of the discourse decision in that addictive drugs may receive an additional medical application, e.g., ketamine, which was discussed as an abuse drug (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>), but is now also considered as a useful treatment for depression (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>Newly introduced psychoactive substances do not usually arise from controlled pharmacodevelopment. In that, these drugs initially have the status of a “legal high” and virtually everybody is allowed to possess, distribute, and consume them. Only when after consumption accidents with physical- and/or behavioral impairments occur, or in the worst case drug fatalities, a NPS can be classified and legally controlled or its medical use defined (<xref rid="B21" ref-type="bibr">21</xref>). However, the drug discourse requires evidence, ideally scientific, arising from controlled experimentation. This evidence should go well beyond the accumulation of single cases. Quite naturally, during the information collecting period, the NPS is used, and thus, not brand new anymore. What is new afterward is the certainty with which sufficiently reliable statements about the drug can be made (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>It has to be admitted that the legal status discourse is in practice way more complicated and also culturally selective, which shall not be the focus of this review that rather focuses on the neurobiological evidence that feeds into this discourse. In this article, we review the state of knowledge on a number of NPS for which now a considerable penetration of society has developed in distinct cultural or geographical regions and for which sufficient evidence has been gathered to allow for evidence-based statements. This should provide a comprehensive overview on some of the currently most relevant NPS, thereby the choice of substances discussed was driven by the perceived progress in the understanding of their neuropharmacological action by the authors. In that, the review does not provide a complete coverage of all currently available NPS.</p></sec><sec id="S2"><title>Kratom and Mitragynine</title><p><italic>Mitragyna speciosa Korth</italic>. (<italic>M. speciosa</italic>), from the Rubiaceae family, is a tropical medicinal plant native to Southeast Asia (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). In Malaysia, <italic>M. speciosa</italic> leaves are known as Ketum or Biak (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>), and in Thailand as Kratom (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). <italic>M. speciosa</italic> has been historically used in Southeast Asia as a stimulant drug and in its traditional context as a remedy for various symptoms (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Previous studies mainly described the traditional uses of Kratom among rural folk, peasants, and laborers in Southeast Asia (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). More recently, studies on Kratom use are emerging from Europe and the US (<xref rid="B37" ref-type="bibr">37</xref>–<xref rid="B40" ref-type="bibr">40</xref>). They suggest that Kratom is now also used outside its traditional context. In the West, it is still considered a “safe” herbal drug with potential medicinal application (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>).</p><p>In Southeast Asia, manual laborers commonly chew fresh Kratom leaves and ingest brewed Kratom tea/juice to reduce fatigue, promote work desire, and enhance physical tolerance to debilitating work (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Kratom leaves are also used as an opium substitute to treat morphine addiction in Malaysia and Thailand (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Because of its unique healing properties, rural inhabitants use Kratom leaves to treat various medical conditions such as cough, fever, pain, diarrhea, diabetes, and hypertension (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>). However, Kratom is potentially addictive and chronic users find it difficult to refrain from prolonged Kratom use (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B43" ref-type="bibr">43</xref>). The common side effects of long-term use include constipation, weight loss, hyperpigmentation, dehydration, fatigue, insomnia, and increased urination (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B46" ref-type="bibr">46</xref>). The majority of Kratom users believe its use is not as harmful as those of other illicit substances, such as methamphetamine and heroin, and that Kratom dependence carries little or no health risks (<xref rid="B45" ref-type="bibr">45</xref>–<xref rid="B47" ref-type="bibr">47</xref>). So far, there have been no deleterious incidents directly related to Kratom use in Southeast Asia. Only one study from Thailand has reported Kratom poisoning cases, with palpitation, seizure, and nausea. However, these effects may have been arisen from coadministration of other illicit substances (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>Regular users are more likely to increase the quantity and frequency of Kratom use over time. In Thailand, traditional users often chew fresh or powdered Kratom leaves (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B44" ref-type="bibr">44</xref>). In Malaysia, Kratom users commonly ingest brewed Kratom tea/juice (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B49" ref-type="bibr">49</xref>). In the US and in Europe, Kratom is primarily used as a natural alternative to self-medicate for chronic pain and as an opioid withdrawal treatment (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). Kratom is marketed as a “legal high” and can be easily obtained in different forms, such as powder extracts, tablets, capsule, or liquids, through the Internet (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B52" ref-type="bibr">52</xref>). As a consequence of the rise in Kratom mortality and toxicity cases in the West, regulatory agencies have begun to view Kratom negatively (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). The US Drug Enforcement Administration intends to regulate Kratom use in the US (<xref rid="B51" ref-type="bibr">51</xref>). However, it appears that most, if not all of the Kratom-induced medical complications in the West were triggered by the use of adulterated Kratom products (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p><p>About 40 alkaloids have been identified in <italic>M. speciosa</italic> leaves. The alkaloid content in the leaves varies, depending on geographical location and season of harvest (<xref rid="B55" ref-type="bibr">55</xref>). Mitragynine and 7-hydroxymitragynine are the principal psychoactive constituents of <italic>M. speciosa</italic> and were shown to induce morphine-like effects in animal models (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). The synthesis of the mitragynine was reported by Takayama et al. (<xref rid="B57" ref-type="bibr">57</xref>) and later by Ma and colleagues (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). However, a synthesis of mitragynine is with 18–23 steps rather laborious, time-consuming, not economical, and has only a low yield of 3–13% (<xref rid="B60" ref-type="bibr">60</xref>). Thus, direct isolation of mitragynine from the leaves is much more efficient and cost-effective.</p><p>A comprehensive pharmacokinetic description of mitragynine in rats was provided by Parthasarathy et al. (<xref rid="B61" ref-type="bibr">61</xref>) after intravenous (i.v.) and oral administration. The blood concentration peaked at 1.2 h with 2.3 µg/mL followed by biphasic elimination with a half-life of 2.9 h and a clearance of 0.09 L/h/kg after administration of 1.5 mg/kg mitragynine (i.v.). The volume of distribution was rather small with 0.79 L/kg, suggesting that mitragynine is not widely distributed into tissue compartments (<xref rid="B62" ref-type="bibr">62</xref>). The oral absorption of mitragynine was shown to be lengthy and incomplete, with an absolute oral bioavailability of around 3%. Several studies revealed that after oral application of 20–50 mg/kg mitragynine, a volume distribution of 37–89 L/kg and clearance of 1.6–7 L/h (per kg) was reached (<xref rid="B61" ref-type="bibr">61</xref>–<xref rid="B63" ref-type="bibr">63</xref>), which supports the low bioavailability and poor absorption of mitragynine.</p><p>Mitragynine is a lipophilic alkaloid with poor water solubility (<xref rid="B64" ref-type="bibr">64</xref>). Mitragynine has a biphasic metabolism. The first phase produces seven identified metabolites, thereby mitragynine is processed through hydrolysis of methyl ester in position 16 and O-demethylation of the 9-methoxy- and of the 17-methoxy groups (<xref rid="B65" ref-type="bibr">65</xref>). The second phase involves further oxidation to carboxylic acids or reduction to alcohols and the combinations of some steps <italic>via</italic> the intermediate aldehydes. Four metabolites were additionally conjugated to glucuronides and to sulfates in rats and humans (<xref rid="B65" ref-type="bibr">65</xref>). Abuse of mitragynine and related compounds can be detected through gas chromatography or liquid chromatography with mass spectrometry, respectively (<xref rid="B65" ref-type="bibr">65</xref>–<xref rid="B67" ref-type="bibr">67</xref>).</p><p>Mitragynine shows the highest affinity to κ-opioid receptors followed by μ- and δ-opioid receptors (<xref rid="B68" ref-type="bibr">68</xref>). It acts as a receptor agonist at μ-opioid receptors and possibly as an antagonist at κ-opioid receptors (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B69" ref-type="bibr">69</xref>–<xref rid="B71" ref-type="bibr">71</xref>). At cellular level, mitragynine blocks neuronal Ca<sup>2+</sup> channels (<xref rid="B72" ref-type="bibr">72</xref>). It was also found to inhibit forskolin-stimulated cyclic adenosine monophosphate (cAMP) formation <italic>in vitro</italic> in an opiate receptor-dependent way (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>). A study by Fakurazi et al. (<xref rid="B75" ref-type="bibr">75</xref>) showed that repeated exposure to mitragynine attenuated the expression of cAMP and cAMP response element-binding protein.</p><p>Mitragynine was extensively investigated for its antinociceptive effects. A study by Reanmongkol et al. (<xref rid="B76" ref-type="bibr">76</xref>) found prolonged antinociceptive effects in the hot plate test, but not in the tail flick test. Another study showed prolonged antinociceptive effect in both tests (<xref rid="B77" ref-type="bibr">77</xref>). Intraperitoneal administration also yielded positive antinociceptive results in the hot plate, formalin-, and acetic-acid tests (<xref rid="B78" ref-type="bibr">78</xref>). Mitragynine’s antinociceptive effects were comparable to those of oxycodone suggesting an abuse potential (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>).</p><p>In animal models, mitragynine induces anxiolytic effects after acute treatment in several test paradigms (<xref rid="B81" ref-type="bibr">81</xref>). This may be mediated by its effects on Fos expression in dorsal raphe nucleus (<xref rid="B82" ref-type="bibr">82</xref>), and the activation of δ-opioid receptors (<xref rid="B83" ref-type="bibr">83</xref>). Withdrawal from chronic mitragynine induces anxiety-related behavior in rats (<xref rid="B84" ref-type="bibr">84</xref>). There have been conflicting reports of mitragynine affecting cognitive function. Apryani et al. (<xref rid="B85" ref-type="bibr">85</xref>) found that mitragynine i.p. administration can impair object location memory in mice. Another study, however, showed no impairment of short-term memory in the Y-maze task. The mice, however, were given <italic>M. speciosa</italic> extract through oral administration (<xref rid="B86" ref-type="bibr">86</xref>). In rats, a study showed an increase in learning ability when given <italic>M. speciosa</italic> extract in a passive- and an active avoidance task. However, mitragynine alone did not have significant effects on long-term memory consolidation in both tasks (<xref rid="B87" ref-type="bibr">87</xref>). A recent study using a passive avoidance task showed independent impairments of learning, memory consolidation, as well as memory retrieval after acute mitragynine administration at a dose ≥10 mg/kg (i.p.) in rats. In parallel, mitragynine-treated rats showed a disrupted low frequency rhythm (delta and theta) in the electroencephalogram (EEG), which may account for the learning and memory impairments (<xref rid="B84" ref-type="bibr">84</xref>).</p><p>Chronic administration of mitragynine at a dose of ≥10 mg/kg (i.p.) may cause addiction-like behaviors in animal models (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B88" ref-type="bibr">88</xref>). Mitragynine (15 mg/kg, i.p.) shows discriminative stimulus properties in rats. It fully substituted for a morphine (5 mg/kg) stimulus, and partially for a cocaine cue (10 mg/kg, i.p.) (<xref rid="B89" ref-type="bibr">89</xref>). Thus, mitragynine likely possess both opioid and psychostimulant effects. Mitragynine at doses ≥10 mg/kg (i.p.) shows rewarding properties in rodents as measured by conditioned place preference. These effects are opiate receptor dependent and can be blocked by the opiate receptor antagonist naloxone (<xref rid="B56" ref-type="bibr">56</xref>). Subchronic administration of mitragynine increased the expression of dopamine transporter- and dopamine (DA) receptor-regulating factor mRNA in the limbic system of the brain (<xref rid="B84" ref-type="bibr">84</xref>) indicating a critical role of DA in the rewarding effects of mitragynine, thereby the dose of mitragynine may be crucial, given that addiction-like behaviors were only observed at doses ≥10 mg/kg (i.p.) in rodents. Those are considerably higher than reported maximum doses of mitragynine consumed by humans, which are usually in the range of <3 mg/kg (p.o.) per day.</p><p>Altogether, Kratom and its main psychoactive ingredient mitragynine are drugs that are widely used in Southeast Asia with an increasing appearance in Western countries. Experimental studies in animals have now shown that mitragynine has an addictive potential, however, only at higher doses. Human users in countries of frequent use with a traditional context report a rather low daily consumption with only mild side effects. Kratom and mitragynine can be instrumentalized to enhance physical work power and endurance. A major reason for Kratom consumption is its reported efficacy to replace opiates in chronic users. This makes the Kratom plant preparation and also the isolated compound mitragynine interesting options to treat opiate addiction.</p></sec><sec id="S3"><title>Synthetic Cannabinoids</title><p>The abuse of herbal preparations spiked with synthetic cannabinoids is still increasing. A hallmark of this consumption is the use of an inhomogeneous group of substances that occur on the market with different names, such as Spice, Spice gold, diamond-spice, chill X, abyss, Pandora’s box, exodus, annihilation, fire, smoke, sence, chillX, chillys, highdi’s, earth impact, and many more (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>). Synthetic cannabinoid preparations are frequently mislabeled as research chemicals, herbal incenses, or as legal highs, including the explicit warning that it is not for human consumption (<xref rid="B92" ref-type="bibr">92</xref>–<xref rid="B97" ref-type="bibr">97</xref>). The first evidence of synthetic cannabinoid use as a recreational drug appeared in 2004 (<xref rid="B98" ref-type="bibr">98</xref>). However, a wide spread use of synthetic cannabinoids did not emerge until 2008. In 2012, the lifetime prevalence for “Spice” consumption was already at 7% among the 15- to 18-year olds (<xref rid="B99" ref-type="bibr">99</xref>–<xref rid="B101" ref-type="bibr">101</xref>), thereby the coabuse of synthetic- and natural cannabinoids is common (<xref rid="B102" ref-type="bibr">102</xref>–<xref rid="B109" ref-type="bibr">109</xref>).</p><p>Research in the active ingredients of synthetic cannabinoids such as Spice and their neuropharmacological action has revealed several hundred compounds that are artificially added to a carrier medium of herbal origin (<xref rid="B110" ref-type="bibr">110</xref>). The synthetic compounds usually display a high affinity for cannabinoid receptors (CB-R), which reaches far beyond that of natural cannabinoids (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B111" ref-type="bibr">111</xref>). Compared to the partial agonist, Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids can act as agonists, neutral antagonists, or inverse agonists at the CB-R1 (<xref rid="B110" ref-type="bibr">110</xref>–<xref rid="B112" ref-type="bibr">112</xref>). Synthetic cannabinoid preparations also lack the naturally occurring cannabidiol, which is present in cannabis preparations and which is supposed to antagonize some of the psychotogenic effects of THC (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>).</p><p>A gram of herbal preparation can contain up to 200 mg of a synthetic cannabinoid. However, the variability in substance composition and amount between one package and another is high and largely unpredictable. Additional ingredients have been found and may include, e.g., clenbuterol, which may be responsible for the frequently observed sympathomimetic manifestations of an intoxication with synthetic cannabinoids, or tocopherol. The latter is usually added to blur chemical detection (<xref rid="B113" ref-type="bibr">113</xref>–<xref rid="B115" ref-type="bibr">115</xref>). Occasionally, some investigated herbal preparations did not contain any pharmacologically active synthetic cannabinoids, but only psychoactive compounds from plant-derived carrier material, such as mitragynine (<xref rid="B116" ref-type="bibr">116</xref>–<xref rid="B120" ref-type="bibr">120</xref>).</p><p>Users report that synthetic cannabinoids can cause psychotropic effects that are qualitatively similar, but much more intense, than those of cannabis. As such, synthetic cannabinoids may cause THC-like effects including alterations of mood, sleep, perception/wakefulness, body temperature, and cardiovascular function (<xref rid="B121" ref-type="bibr">121</xref>–<xref rid="B123" ref-type="bibr">123</xref>). Additional diffuse effects, which are different from cannabis, include palpitations, tachycardia, and unspecific effects in the electrocardiogram (<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>). Harmful somatic effects comprise gastrointestinal and renal defects (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B126" ref-type="bibr">126</xref>–<xref rid="B128" ref-type="bibr">128</xref>). Neuropsychiatric symptoms were reported, such as psychosis, panic and anxiety attacks, agitation, and aggressive behavior (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>). A psychosis induced by synthetic cannabinoids manifests by delusions, acoustic and visual hallucinations, and paranoia. Neurological symptoms may include seizures, dystonia, and tremors. Other frequently reported side effects are nausea, vomiting, diaphoresis, and respiratory depression (<xref rid="B131" ref-type="bibr">131</xref>–<xref rid="B141" ref-type="bibr">141</xref>). Use of synthetic cannabinoids may have fatal consequences. Reported single cases mention coronary ischemic events and suicide caused by an extreme anxiety attack (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>).</p><p>The active compound of the preparation “Spice” was first described in 2009, following the detection of formerly non-declared, synthetic CB-R1 agonists (<xref rid="B141" ref-type="bibr">141</xref>, <xref rid="B142" ref-type="bibr">142</xref>). Synthetic cannabinoids were originally developed for research purposes in the 1970s with the goal of better understanding the endogenous cannabinoid pathways and to develop pharmacotherapies for conditions such as cancer-associated pain (<xref rid="B108" ref-type="bibr">108</xref>). Synthetic cannabinoids may contain aminoalkyl-indoles of the JWH series, which was first synthesized by the chemist J. W. Huffmann. Major ingredients of herbal preparations in the past included the aminoalkyl-indoles, JWH-018, JWH-073, JWH-019, JWH-250, and the cyclohexylphenols, CP-47,497-C6, CP-47,497, and CP-47,497-C8. These compounds are lipid-soluble, non-polar, and typically contain 20–26 carbon atoms. However, there are at least 100 chemically related compounds currently known (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B143" ref-type="bibr">143</xref>–<xref rid="B146" ref-type="bibr">146</xref>). While some of them have been legally controlled on individual level, recent legislation in Germany now considers the lead structures and attempts to control whole drug classes. It is expected that this will make it more difficult to simply replace single banned compounds by their substituted analogs in the synthetic cannabinoid preparations (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B147" ref-type="bibr">147</xref>–<xref rid="B153" ref-type="bibr">153</xref>).</p><p>At the current stage, one may conclude that synthetic cannabinoids constitute dangerous psychoactive drug preparations with a rather chimeric nature (<xref rid="B154" ref-type="bibr">154</xref>). It is not a single compound, but draws from a plethora of already available synthetic cannabinoids that are unsystematically mixed and brought on a plant carrier material, that may even by itself have psychoactive effects. This strategy of drug preparation paved the way into the perception as a natural and perfectly “legal high” by consumers. The natural claim is now clearly rejected by the understanding that most psychoactive effects are brought about by purely synthetic compounds added to a natural carrier. Given the strong cannabinoid-like effects of synthetic cannabinoids, which are now increasingly understood, single substances have been legally banned. But this has done little damage to the unique drug design of synthetic cannabinoid preparations in that single disallowed compounds were almost immediately replaced by substituted analogs that had not been banned yet. The now emerging control of whole substance classes will most likely put an end to this strategy and help to reduce harm that is clearly associated with synthetic cannabinoid consumption.</p></sec><sec id="S4"><title>Dimethyltryptamine</title><p><italic>N</italic>-<italic>N</italic>-dimethyltryptamine (DMT) is an indole alkaloid found in plants and animals. It has been proposed that the endogenous DMT may act as a neurotransmitter. DMT is a natural psychedelic substance and has similar effects as other serotonergic hallucinogens such as lysergic acid diethylamide (LSD), psilocybin, and mescaline. DMT is one of the ingredients used in various shamanic preparations, such as ayahuasca, hoasca, or yagé in South America and is used as a recreational drug in Europe and North America (<xref rid="B155" ref-type="bibr">155</xref>). DMT rich plants belong to genera such as <italic>Phalaris, Delosperma, Acacia, Desmodium, Mimosa, Virola</italic>, and <italic>Psychotria</italic>. When DMT is ingested at high concentrations, the user experiences episodic visual hallucinations (<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>). The recreational use of DMT has been rising for its acclaimed self-perceived benefits. Capsules, known as pharmahuasca, became available containing DMT as a free base together with some monoamine oxidase inhibitors (MAOIs), such as synthetic harmaline, or plant-based MAOIs such as Harmala alkaloids (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>). The MAOIs inhibit the otherwise rapid metabolization of DMT and, thus, allow for the hallucinogenic effects when the drug is taken orally.</p><p>Endogenous DMT can be found in the human brain and other tissues of the body such as blood, urine, cerebral spinal fluid (<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B159" ref-type="bibr">159</xref>), and the pineal gland (<xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B160" ref-type="bibr">160</xref>). Synthesis of endogenous DMT begins with the decarboxylation of tryptophan to tryptamine. <italic>N</italic>-methyltryptamine (NMT) and DMT are the products of methyl group additions to tryptamine by the enzyme indolethylamine-<italic>N</italic>-methyltransferase (<xref rid="B160" ref-type="bibr">160</xref>). DMT levels were found to increase under stress in the rodent brain and adrenal gland (<xref rid="B161" ref-type="bibr">161</xref>). This can activate trace amine-associated receptors and serotonin receptors (5-HT-Rs), such as the 5-HT<sub>1A</sub>-Rs, 5-HT<sub>2A</sub>-Rs, and the 5-HT<sub>2C</sub>-Rs (<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B162" ref-type="bibr">162</xref>). It was suggested that endogenous DMT has a role in cellular protective mechanisms (<xref rid="B155" ref-type="bibr">155</xref>).</p><p>Exogenous DMT is metabolized by MAO and peroxidases leading to the metabolites NMT, 6-hydroxy-DMT, 6-OH-DMT-<italic>N</italic>-oxide, DMT-<italic>N</italic>-oxide, and indole-3-acetic acid (<xref rid="B160" ref-type="bibr">160</xref>). The pharmacokinetics of DMT shows a rapid onset of action within 5–30 min. This is followed by an intense modification of the mental state lasting for approximately 4 h (<xref rid="B163" ref-type="bibr">163</xref>). The routes of DMT administration are <italic>via</italic> smoking or snorting. For the hallucinogenic or psychedelic effects to occur, an oral formulation must contain MAOIs to prolong the half-life of DMT in the body. MAOIs block the enzyme in the stomach after which DMT is able to be absorbed through the stomach lining into the blood stream. An oral dosing of DMT, e.g., <italic>via</italic> ayahuasca, produces both behavioral and neuroendocrinological effects, such as a decrease in locomotor activity, cognitive impairments, sympathomimetic effects, increased prolactin, and cortisol levels (<xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>). DMT also interacts with various ionotropic and metabotropic receptors in the glutamate, DA, and acetylcholine systems. The subjective effects of exogenous DMT are primarily mediated by 5-HT<sub>2A</sub>-Rs. 5-HT<sub>2C</sub>-Rs play little or no role (<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B167" ref-type="bibr">167</xref>). Glutamatergic mGluR2 receptors might have modulatory effects in DMT action (<xref rid="B167" ref-type="bibr">167</xref>). DMT does not affect DA receptors but may alter DA levels in the brain with subsequent neurochemical and behavioral effects.</p><p>Chronic DMT induces tolerance for some behavioral and subjective effects. However, it failed to elicit tolerance to the disruption of responding maintained on a fixed-ratio schedule of food reinforcement (<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>). DMT yields similar discriminative stimulus effects as the serotonergic hallucinogens 2,5-dimethoxy-4-methylamphetamine (DOM) and LSD. Furthermore, DMT fully substituted in DOM-trained rats and for LSD in rats and pigeons (<xref rid="B170" ref-type="bibr">170</xref>, <xref rid="B171" ref-type="bibr">171</xref>).</p><p>Beside its sought-after acute effects, DMT can cause considerable side effects. The ingestion of DMT may induce intense fear, paranoia, anxiety, grief, and depression, which may result in physical harm to the user or others (<xref rid="B157" ref-type="bibr">157</xref>). There have been no serious adverse events reported on long-term use of DMT apart from the acute cardiovascular effects. Single and repeated administrations of DMT produce marked changes in the cardiovascular system (<xref rid="B172" ref-type="bibr">172</xref>). In fact, DMT has been reported to act as neuroprotective agent, working <italic>via</italic> Sigma-1 receptor (Sig-1R) activation (<xref rid="B173" ref-type="bibr">173</xref>–<xref rid="B177" ref-type="bibr">177</xref>). Sig-1Rs activate the antioxidant response elements (<xref rid="B176" ref-type="bibr">176</xref>). Hence, DMT may function as an indirect antioxidant. Frecska et al. (<xref rid="B177" ref-type="bibr">177</xref>) have suggested that peripheral synthesis of DMT, consumptions of DMT-containing plant material, or systemic administration of DMT can trigger endogenous central nervous system pathways that produce psychedelic experiences. At the same time, it may serve mechanisms such as neuroprotection and neuroregeneration. Interestingly, ayahuasca and DMT mixtures have been proposed as a treatment for psychiatric disorders. Symptoms of schizophrenia, such as delusions and hallucinations, have been assumed to involve activation of 5-HT<sub>2A</sub>-Rs along with changes in the DA system (<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B178" ref-type="bibr">178</xref>). Endogenous DMT has been reported to be increased in schizophrenic patients during psychotic episodes (<xref rid="B179" ref-type="bibr">179</xref>) indicating that the endogenous DMT signaling pathway might be a treatment target for schizophrenia. Based on animal models and on clinical studies in humans, DMT has potential antidepressant and anxiolytic effects (<xref rid="B180" ref-type="bibr">180</xref>), possibly mediated by a 5-HT<sub>1A</sub>-R agonistic action (<xref rid="B181" ref-type="bibr">181</xref>). Further therapeutic applications include the treatment of cancer and inflammations. DMT has been shown to increase immune system activity (<xref rid="B165" ref-type="bibr">165</xref>, <xref rid="B182" ref-type="bibr">182</xref>). Sig-1R activation can reduce pro-inflammatory cytokines and enhance the production of the anti-inflammatory cytokine IL-10 (<xref rid="B183" ref-type="bibr">183</xref>).</p><p>In conclusion, DMT is a naturally occurring psychoactive compound found in various plants. It is now understood that its main psychoactive effects are mediated by 5-HT<sub>2A</sub>-R activation. Endogenous DMT may play a role in the immunoregulation in peripheral and brain tissues. Preliminary evidence now suggests a possible therapeutic use of DMT.</p></sec><sec id="S5"><title>Novel Serotonergic Hallucinogens</title><p>Since thousands of years, indigene cultures in North and South America have used plants and mushrooms containing serotonergic hallucinogens for shamanic rituals and religious ceremonies (<xref rid="B184" ref-type="bibr">184</xref>). The most famous examples are (1) <italic>Psilocybe</italic> mushrooms containing psilocybin, which were used as Teonanacatl (“god’s flesh”) by the Aztecs, (2) the cactus <italic>Lophophora williamsii</italic> enclosing mescaline and applied as Peyote or Peyotl by Mexican and North American indigene cultures, and (3) a brew of <italic>Banisteriopsis caapi</italic> and <italic>Psychotria viridis</italic> called Ayahuasca utilized by Amazonian indigene cultures containing the psychedelic ingredient DMT together with harmala alkaloids acting as MAOIs inhibitors and preventing the metabolism of DMT (<xref rid="B185" ref-type="bibr">185</xref>).</p><p>Classical serotonergic hallucinogens usually have either a tryptamine or phenylethylamine basic structure (<xref rid="B186" ref-type="bibr">186</xref>). Typical tryptamines, such as psilocybin and its psychoactive metabolite psilocin, 5-methoxy-<italic>N</italic>,<italic>N</italic>-dimethyltryptamine (5-MeO-DMT), and bufotenine, resemble in their structure the neurotransmitter 5-HT, while the phenylethylamine mescaline has a similar basic structure as the neurotransmitter DA and as amphetamines. In addition, ergoline alkaloids such as the naturally occurring <sc>d</sc>-lysergic acid amide, also called ergine—the psychoactive compound of <italic>Turbina corymbosa, Argyreia nervosa</italic>, and <italic>Ipomea tricolor</italic>—and the semi-synthetic LSD (Delysid<sup>®</sup>), have a tryptamine backbone as well (<xref rid="B186" ref-type="bibr">186</xref>).</p><p>It was suggested that the term “hallucinogens” may be a misnomer as these drugs not necessarily produce real hallucinations, at least when applied at typical doses, but many other emotional, perceptual, cognitive, and behavioral effects. It was suggested that “psychotomimetics” might be the more appropriate term for them (<xref rid="B186" ref-type="bibr">186</xref>). However, all 5-HT hallucinogens have in common that they induce altered states of consciousness (<xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B187" ref-type="bibr">187</xref>). According to Hollister (<xref rid="B188" ref-type="bibr">188</xref>), the psychoactive effects of classical serotonergic hallucinogens usually include (1) somatic symptoms: dizziness, weakness, tremors, nausea, drowsiness, paresthesia, and blurred vision; (2) perceptual symptoms: altered shapes and colors, difficulty in focusing on objects, sharpened sense of hearing, and rarely synesthesia; and (3) psychic symptoms: alterations in mood (happy, sad, or irritable at varying times), tension, distorted time sense, difficulty in expressing thoughts, depersonalization, dream-like feelings, and visual hallucinations.</p><p>All tryptamine- and phenylethylamine-based hallucinogens share the agonistic mechanism of action at postsynaptic 5-HT<sub>2A</sub>-Rs and 5-HT<sub>2C</sub>-Rs, where they act as partial, mixed-partial, or full agonists (<xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B189" ref-type="bibr">189</xref>). In animals and humans, 5-HT<sub>2A</sub>-R antagonists such as ketanserin are able to block most of the behavioral and psychotropic effects of psilocybin, mescaline, DOI, and LSD, indicating that the 5-HT<sub>2A</sub>-R agonism is necessary for the induction of psychedelic effects (<xref rid="B189" ref-type="bibr">189</xref>–<xref rid="B194" ref-type="bibr">194</xref>). However, some of these drugs show a strong affinity to 5-HT<sub>1A</sub>-Rs and other 5-HT receptor subtypes as well as to DA D2-Rs. These additional mechanisms are likely to contribute to the specific psychotropic effects of each compound (<xref rid="B189" ref-type="bibr">189</xref>, <xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B195" ref-type="bibr">195</xref>). A decade ago, it has been proposed that only 5-HT<sub>2A</sub>-Rs coupled to metabotropic mGluR2 mediate the psychotogenic effects of 5-HT hallucinogens (<xref rid="B196" ref-type="bibr">196</xref>)—a position that has been questioned recently (<xref rid="B197" ref-type="bibr">197</xref>). At the neuronal level, 5-HT hallucinogens, such as psilocin, LSD, and DMT, directly activate 5-HT<sub>2A</sub>-Rs located on cortical pyramidal neurons. In addition, they increase extracellular glutamate levels in the prefrontal cortex through stimulation of postsynaptic 5-HT<sub>2A</sub>-Rs located on large glutamatergic pyramidal cells in deep cortical layers V and VI. This glutamate release leads to an activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and <italic>N</italic>-methyl-<sc>d</sc>-aspartic acid (NMDA) receptors on cortical pyramidal neurons (<xref rid="B187" ref-type="bibr">187</xref>).</p><p>Historically, LSD was probably one of the first NPS of the hallucinogen class as it was a semi-synthetic compound whose psychedelic effects have only accidentally been discovered by its inventor Albert Hofmann in 1943 (<xref rid="B198" ref-type="bibr">198</xref>). The next, even though less accidental, producer of NPS hallucinogens was Alexander T. Shulgin, who synthesized hundreds of novel hallucinogenic tryptamines and phenylethylamines in his home laboratory. He described the synthesis of these compounds and also their psychotomimetic effects experienced in self-experiments in detail in his books PIHKAL and TIHKAL (<xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B200" ref-type="bibr">200</xref>). He created several dimethoxy-substituted phenylethylamines, such as DOM, 2,5-dimethoxy-4-bromoamphetamine (DOB), 2,5-dimethoxy-4-iodoamphetamine (DOI), and 2,5-dimethoxy-4-ethylamphetamine (DOET), which all display strong hallucinogenic properties. These drugs usually have much longer durations of action (12–30 h) and are much more potent agonists at 5-HT<sub>2A</sub>-Rs (50- to 175-fold) compared to their related phenylethylamine derivative mescaline (duration of action: 4–8 h) (<xref rid="B189" ref-type="bibr">189</xref>, <xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B200" ref-type="bibr">200</xref>). Also, another novel class of substituted dimethoxyphenethylamines—the “2C psychedelics”—was invented by Shulgin, which mostly contains methoxy groups at positions 2 and 5 of a benzene ring together with lipophilic substituents (often halogens) at position 4. The most famous exponent of this class is 2,5-dimethoxy-4-bromophenethylamine (2C-B, “nexus,” “bromo”), which was initially marketed as a legal surrogate of MDMA (“ecstasy”) in the late 80s before it was finally scheduled by the UN Commission on Narcotic Drugs in March 2001 (<xref rid="B201" ref-type="bibr">201</xref>). Dozens of 2C-B analogs, such as 2C-I, 2C-C, 2C-F, 2C-E, and 2C-N, have later been sold as “research chemical” or “legal highs” <italic>via</italic> the Internet. Because their structure can be easily changed without losing their psychoactive properties, 2C drugs have, thus, often been referred as a typical class of designer drugs (<xref rid="B201" ref-type="bibr">201</xref>). 2C drugs commonly do not only act as 5-HT<sub>2A</sub>-R and 5-HT<sub>1A</sub>-R agonists but also as monoamine transporter inhibitors (<xref rid="B195" ref-type="bibr">195</xref>). Consequently, these compounds have not only hallucinogenic properties but also slight stimulating and empathogenic/entactogenic effects sometimes mimicking the effects of the prototypical empathogen MDMA (<xref rid="B199" ref-type="bibr">199</xref>). Shulgin also described novel ergolines such as <italic>N</italic>-allyl-nor-lysergic acid diethylamide (AL-LAD), <italic>N</italic>-ethyl-nor-lysergic acid diethylamide (ETH-LAD), and <italic>N</italic>-propyl-nor-lysergic acid diethylamide (PRO-LAD) (<xref rid="B200" ref-type="bibr">200</xref>). These LSD-analogs are as potent as LSD (potency relative to LSD in human: AL-LAD: 110%, ETH-LAD: 140%, PRO-LAD: 90%), but AL-LAD and PRO-LAD have shorter duration of action (6–8 h) as ETH-LAD and LSD (both: 8–12 h) (<xref rid="B189" ref-type="bibr">189</xref>, <xref rid="B200" ref-type="bibr">200</xref>). Finally, Shulgin synthesized a large number of novel tryptamines, such as 4-hydroxy-<italic>N</italic>-methyl-<italic>N</italic>-ethyltryptamine (4-HO-MET), 5-methoxy-diisopropyltryptamine (5-MeO-DIPT), and alpha-ethyltryptamine (alpha-ET), which are mostly hallucinogenic, but with some exceptions (e.g., alpha-ET has pronounced empathogenic effects) (<xref rid="B200" ref-type="bibr">200</xref>). Shulgins books PIHKAL and TIHKAL served as cook books for a generation of illegal drug laboratories. His dimethoxyphenethylamines, 2C drugs, and novel ergolines and tryptamines are still circulating as NPS, although they have been created at least 20 years ago. However, their human toxicology and their consequences are still unknown as they are neither used frequently nor purely enough in order to systematically investigate their chronic effects in recreational users.</p><p>In the last decade, a substantial amount of new serotonergic hallucinogens appeared on the drug markets. As their number grows each day, it is simply not possible to list them exhaustively here. Thus, only some prototypical exponents of each class will be discussed. Again the main classes are either tryptamines and related ergolines or substituted phenethylamines but also some new classes such as benzodifurans and aminoindanes occurred (<xref rid="B202" ref-type="bibr">202</xref>–<xref rid="B205" ref-type="bibr">205</xref>). Novel tryptamines such as alpha-methyltryptamine (AMT), <italic>N</italic>,<italic>N</italic>-diallyl-5-methoxytryptamine (5-MeO-DALT) have multiple serotonergic actions including strong affinity for the 5-HT<sub>2A</sub>-R, but can also act as monoamine transporter substrates. They combine hallucinogenic effects with stimulant and empathogenic features (<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B205" ref-type="bibr">205</xref>). Novel ergolines such as 1-propionyl-lysergic acid diethylamide (1P-LSD) and lysergic acid 2,4-dimethylazetidide (LSZ) are LSD-analogs mainly interacting with 5-HT<sub>2A</sub>-R and 5-HT<sub>1A</sub>-R subtypes. They are slightly more potent as LSD and have a comparable duration of action. They are also mostly marketed as blotters (<xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B205" ref-type="bibr">205</xref>). <italic>N</italic>-2-methoxybenzyl derivatives of 2,5-dimethoxy-substituted phenethylamines also called NBOMe drugs, such as 25B-NBOMe, 25C-NBOMe, 25I-NBOMe, 25T2-NBOMe, and mescaline-NBOMe, are highly potent 5-HT<sub>2A</sub>-R full agonists. In addition, they show a high-binding affinity to the 5-HT<sub>1A</sub>-R, to adrenergic α1A and α2A, and histamine H1 receptors. Some derivatives also possess low-to-moderate affinity to DA D2- and D3-Rs. Several NBOMe drugs show higher affinity, higher activation potency, and higher activation efficacy at 5-HT<sub>2A</sub>-Rs than LSD. Anecdotal user reports consider them as very strong hallucinogens (<xref rid="B195" ref-type="bibr">195</xref>, <xref rid="B205" ref-type="bibr">205</xref>, <xref rid="B206" ref-type="bibr">206</xref>). Benzodifurans, the so-called “fly drugs,” such as 2C-B-FLY, 3C-Bromo-Dragonfly, and TFMFly, are a group of ring-substituted phenethylamines that are structurally related to MDMA. Unlike MDMA, benzodifurans commonly display a high affinity for 5-HT<sub>1A</sub>-Rs, 5-HT<sub>2A</sub>-Rs, 5-HT<sub>2B</sub>-Rs, and 5-HT<sub>2C</sub>-Rs, but show only little action at monoamine transporters (<xref rid="B195" ref-type="bibr">195</xref>, <xref rid="B205" ref-type="bibr">205</xref>). Aminoindanes, such as 5-iodo-2-aminoindane (5-IAI), are usually 5-HT and noradrenaline (NA) releasers that have been sold as a legal surrogate for MDMA (<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B205" ref-type="bibr">205</xref>). At least 5-IAI was recently demonstrated to show a strong affinity for 5-HT<sub>1A</sub>-Rs and 5-HT<sub>2A</sub>-Rs, thus, indicating that aminoindanes can not only be empathogens, but they can also display hallucinogenic properties (<xref rid="B207" ref-type="bibr">207</xref>).</p><p>At the moment, systematic investigations on the prevalence of novel serotonergic hallucinogens are rare. In the global drug survey of 2012, 11.3% of the respondents, mainly regular drug users, reported to have used a 2C drug at least once during their lifetime and that 2C-B was the most common one (8.4%). Moreover, 2.6% of respondents reported to have used 25B-NBOMe, 25C-NBOMe, or 25I-NBOMe at least once, while 25I-NBOMe (2.0%) was the most popular derivate. The most common drug source for NBOMes was the Internet (41.7%). For comparison, 39.4% of the respondents in this survey had used LSD and 43.1% “magic mushrooms” at least once during lifetime (<xref rid="B206" ref-type="bibr">206</xref>). A recent representative survey in the US (<italic>N</italic> = 213.076) revealed that the lifetime prevalence of novel hallucinogenic drugs was generally low: NBOMes, 0.015%; 2C drugs, 0.195%; dimethoxyphenethylamines, 0.019%; novel tryptamines, 1.060% (primarily DMT) (<xref rid="B208" ref-type="bibr">208</xref>). It should be noted that DMT was the only hallucinogenic NPS that was systematically asked for but that participants were given the opportunity to type in the names of NPS they used, indicating that these numbers are likely underestimated (<xref rid="B208" ref-type="bibr">208</xref>).</p><p>Data from the European Drug Emergencies Network have recently shown that, compared to all other investigated drugs, novel tryptamine users have the highest risk [odds ratio (OR) = 12.4] to be treated for psychosis-like symptoms in an emergency care unit, while also LSD use was significantly associated with an increased psychosis risk (OR = 3.1) (<xref rid="B209" ref-type="bibr">209</xref>). Overall frequencies for the development of acute psychosis following experimentally administered LSD range between 0.08 and 4.6%, while patients having a psychiatric disorder before LSD intake displayed the highest risk (<xref rid="B185" ref-type="bibr">185</xref>). However, if 5-HT hallucinogens can also induce long-lasting psychotic disorders is still controversially discussed (<xref rid="B185" ref-type="bibr">185</xref>). Beyond acute psychotic reactions including hallucinations, ego impairment, and paranoia, also “bad trips,” panic attacks, confusion, agitation, aggression, and disorientation are common acute psychiatric side effects of classical and novel serotonergic hallucinogens (<xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B205" ref-type="bibr">205</xref>, <xref rid="B210" ref-type="bibr">210</xref>). Moreover, also nausea and vomiting, serotonin syndrome including hyperthermia, liver and kidney failures, and cardiovascular complications have been reported for serotonergic hallucinogens. The acute toxicity of high potency dimethoxyphenylethylamines, NBOMEs, and 2C drugs seems to be considerably increased compared to classical hallucinogens. High potency compounds have been associated with a number of life-threatening conditions, such as rhabdomyolysis, seizures, vasoconstriction/hypertension, tachycardia, pulmonary edema, and serotonin syndrome with hyperthermia and organ failures, sometimes with fatal outcome (<xref rid="B210" ref-type="bibr">210</xref>–<xref rid="B214" ref-type="bibr">214</xref>).</p><p>Chronic side effects of hallucinogens can include panic disorder and a hallucinogen persisting perception disorder (HPPD, “flashback”) (<xref rid="B185" ref-type="bibr">185</xref>). In fact, 60% of LSD users know “flashbacks” and 4% of users report sustained HPPD of putative clinical significance (<xref rid="B215" ref-type="bibr">215</xref>). Also, MDMA users are at risk to develop HPPD (<xref rid="B216" ref-type="bibr">216</xref>). It is highly likely that potent novel serotonergic hallucinogens bear a strong risk to induce HPPD too. Changes of 5-HT<sub>2A</sub>-R function in the visual cortex were claimed to be responsible for HPPD (<xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B216" ref-type="bibr">216</xref>). In general, 5-HT-Rs show considerable plasticity after exposure to serotonergic drugs. Accordingly, due to post-transcriptional mechanisms, 5-HT<sub>2A</sub>-Rs show a rapid and long-lasting downregulation in response to 5-HT agonists (<xref rid="B217" ref-type="bibr">217</xref>–<xref rid="B219" ref-type="bibr">219</xref>). Specifically, LSD, 2-bromo-LSD, and DOI selectively reduce 5-HT<sub>2A</sub>-R density without affecting 5-HT<sub>2C</sub>-Rs (<xref rid="B220" ref-type="bibr">220</xref>). Furthermore, hallucinogens acting at 5-HT<sub>2A</sub>-Rs show strong behavioral tolerance coinciding with a robust decrease in 5-HT<sub>2A</sub>-Rs. This might explain the strong tolerance effect of 5-HT hallucinogens (<xref rid="B221" ref-type="bibr">221</xref>). Recently, it was shown that 5-HT hallucinogens can also reduce either 5-HT<sub>2A</sub>-R binding sites or glutamate-binding sites and that tolerance effects were correlated with changes in both binding sites (<xref rid="B222" ref-type="bibr">222</xref>).</p><p>High potency 5-HT hallucinogens—specifically if they have a long duration of action—are probably neurotoxic due to their sustained activation of 5-HT<sub>2A</sub>-Rs that can induce apoptosis in neurons (<xref rid="B223" ref-type="bibr">223</xref>). Neurotoxic effects have been shown not only for DOI (<xref rid="B224" ref-type="bibr">224</xref>, <xref rid="B225" ref-type="bibr">225</xref>) and 5-MeO-DIPT (<xref rid="B226" ref-type="bibr">226</xref>) but also for chronic low doses of LSD (<xref rid="B227" ref-type="bibr">227</xref>) and repeated high doses of MDMA (<xref rid="B223" ref-type="bibr">223</xref>–<xref rid="B225" ref-type="bibr">225</xref>). Thus, it is likely that all long-acting dimethoxyphenylethylamines, 2C drugs, NBOMes, tryptamines, and ergolines with strong agonistic actions at 5-HT<sub>2A</sub>-Rs have a neurotoxic potential.</p><p>In conclusion, beyond LSD, mescaline, and psilocybin, a vast amount of new serotonergic hallucinogens appeared on the drug market during the last decades. Their distribution has strongly increased and will likely further increase in the future due to their easy availability on the Internet. Alarmingly, little is known about the acute and chronic effects of novel 5-HT hallucinogenic drugs in human users. The neuropsychiatric long-term consequences of regular intake of such compounds are completely unclear. However, it is becoming increasingly apparent that high potency drugs with very strong affinities to 5-HT<sub>2A</sub>-Rs and long durations of action bear a considerable risk for negative health effects and fatalities.</p></sec><sec id="S6"><title>Mephedrone and Methylone</title><p>Dozens of research chemicals with a cathinone basic structure appeared as “legal highs” on the drug marked. However, an exhaustive discussion of all of them is not possible here due to space restrictions (<xref rid="B228" ref-type="bibr">228</xref>). Thus, in this section, the two generic compounds, mephedrone and methylone, are discussed as important examples.</p><p>Mephedrone (4-methylmethcathinone) is a substituted cathinone homolog of ephedrine first described in 1929 (<xref rid="B229" ref-type="bibr">229</xref>, <xref rid="B230" ref-type="bibr">230</xref>). Mephedrone has a ring-substituted cathinone structure which is related to the phenethylamine family, to which also drugs such as amphetamine, MDMA, and methamphetamine belong to (<xref rid="B231" ref-type="bibr">231</xref>). As a hydrochloride salt, mephedrone is a water soluble white, yellow, beige, or brown powder. In the European market, it is sold under different names such as Meow Meow, Bubbles, Mef, MMC Hammer, and many more (<xref rid="B231" ref-type="bibr">231</xref>). Mephedrone is available on the Internet, or from street dealers. On Internet sources, mephedrone is often marketed as bath salt, plant fertilizer, or research chemical (<xref rid="B232" ref-type="bibr">232</xref>, <xref rid="B233" ref-type="bibr">233</xref>).</p><p>Mephedrone was first identified as an abused drug by European authorities in 2007 (<xref rid="B234" ref-type="bibr">234</xref>, <xref rid="B235" ref-type="bibr">235</xref>). By 2010, mephedrone use spread, and the drug was found in many European countries (<xref rid="B236" ref-type="bibr">236</xref>). The use of mephedrone increased rapidly in the club scene and soon reached the level MDMA and cocaine use, reaching a life-time use in Europe among the 15- to 24-year olds of 6% by 2010 (<xref rid="B236" ref-type="bibr">236</xref>, <xref rid="B237" ref-type="bibr">237</xref>). Mephedrone is frequently used together with other synthetic cathinones, such as methylone, butylone, or ethylcathinone (<xref rid="B236" ref-type="bibr">236</xref>). The predominant user populations are teenagers and young adults (<xref rid="B238" ref-type="bibr">238</xref>), thereby use of new psychoactive cathinones is highly correlated with binge-drinking habits in young adults (<xref rid="B239" ref-type="bibr">239</xref>).</p><p>Mephedrone can be consumed by different routes. In an oral preparation, mephedrone powder is rolled up in cigarette paper (bombing). Furthermore, intranasal, intramuscular, intravenous (slamming), and rectal routes of administration have been reported (<xref rid="B240" ref-type="bibr">240</xref>). Mephedrone is also mixed with other drugs, such as heroin, alcohol, cocaine, MDMA, or cannabis (<xref rid="B235" ref-type="bibr">235</xref>, <xref rid="B241" ref-type="bibr">241</xref>). Consumption usually takes place in a social context at home, at rave parties, clubs, or music festivals. Mephedrone binge consumption has been reported to last for up to 9 h with a new dose all 0.5–2 h (<xref rid="B231" ref-type="bibr">231</xref>). Intranasal mephedrone elicits rapid effects within minutes. They reach a peak level in less than 30 min and last for up to 1 h. Orally applied mephedrone powder or tablets induce psychoactive effects in 45–120 min which may last for 2–4 h, thereby a sequence of first intranasal snorting followed by repeated oral ingestion has been reported, in order to achieve both, fast and long-lasting effects (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B240" ref-type="bibr">240</xref>, <xref rid="B242" ref-type="bibr">242</xref>, <xref rid="B243" ref-type="bibr">243</xref>). The sought-after psychoactive effects of mephedrone comprise an elevated mood, the feeling of an intense euphoria, a sense of well-being, increased self-esteem, motor excitation, reduced tiredness, increased alertness and concentration, talkativeness, empathy, disinhibition, and a mild sexual stimulation (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B244" ref-type="bibr">244</xref>, <xref rid="B245" ref-type="bibr">245</xref>).</p><p>A high dose and/or chronic consumption of mephedrone have been associated with significant adverse effects. Those include cardiovascular, gastrointestinal, and neurological side effects (<xref rid="B233" ref-type="bibr">233</xref>, <xref rid="B246" ref-type="bibr">246</xref>). Well-described effects are also jaw clenching, reduced appetite, increased body temperature, increased sweating, abnormal vision, dilated pupils, headaches, tachycardia, palpitations, hypertension, arrhythmias, chest pain, nausea, bruxism, teeth grinding (bruxism), rhabdomyolysis, and renal failure (<xref rid="B247" ref-type="bibr">247</xref>). An important dangerous side effect is the significant hyponatremia. This is similar to that shown after acute MDMA consumption. It is supposed to be induced by a combination of sweating, electrolyte loss, and antidiuretic hormone secretion (<xref rid="B247" ref-type="bibr">247</xref>). The intranasal application of mephedrone is associated with a significant nasal irritation. Mephedrone addiction is often associated with intravenous drug use that is also found to be linked to an increased risk of using other addictive drugs (<xref rid="B248" ref-type="bibr">248</xref>). Intravenous mephedrone injections often result in vein blockages, leading to localized infections, blisters, abscesses, scabs, lumps, gangrenous tissue, blood clots, and large necroses at the injection site (<xref rid="B249" ref-type="bibr">249</xref>). Major adverse psychiatric effects associated with mephedrone use include agitation, anxiety, dysphoria, depression, insomnia, hallucinations, paranoia, delusions, aggressive behavior, as well as suicidal ideation and suicidal action. Cognitive impairments affect short-term memory and attention span (<xref rid="B250" ref-type="bibr">250</xref>). Psychotic effects predominantly occur after a high mephedrone dose, after binge consumption in one session, and in users with an individual vulnerability for psychiatric disorders (<xref rid="B251" ref-type="bibr">251</xref>–<xref rid="B253" ref-type="bibr">253</xref>). Fatalities resulting from mephedrone use have been reported worldwide now (<xref rid="B254" ref-type="bibr">254</xref>). They are related to hyponatremia and brain edema (<xref rid="B255" ref-type="bibr">255</xref>–<xref rid="B257" ref-type="bibr">257</xref>). However, the lethal dose (LD<sub>50</sub>) is not known yet (<xref rid="B258" ref-type="bibr">258</xref>).</p><p>Accumulating evidence suggests that mephedrone has a clear addiction potential (<xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B259" ref-type="bibr">259</xref>, <xref rid="B260" ref-type="bibr">260</xref>). The abuse potential for intranasally consumed mephedrone was suggested to be comparable with that of cocaine or methamphetamine (<xref rid="B246" ref-type="bibr">246</xref>). Among regular users, about 50% reported an addiction to the drug (<xref rid="B261" ref-type="bibr">261</xref>) and about 25% admitted mephedrone-related craving (<xref rid="B262" ref-type="bibr">262</xref>). Mephedrone withdrawal effects include tiredness, insomnia, impaired concentration, irritability, tremor, temperature dysregulation, palpitations, headaches, depression, anxiety, and paranoia (<xref rid="B235" ref-type="bibr">235</xref>, <xref rid="B244" ref-type="bibr">244</xref>, <xref rid="B260" ref-type="bibr">260</xref>).</p><p>Virtually all synthetic cathinones are considered to inhibit the monoamine uptake in the brain, thereby mephedrone acts as a substrate for the transporter proteins and evokes a reverse neurotransmitter transport and, thus, neurotransmitters release (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B244" ref-type="bibr">244</xref>, <xref rid="B263" ref-type="bibr">263</xref>).</p><p>Synthetic cathinones including mephedrone are now classified as illicit substances in many countries (<xref rid="B231" ref-type="bibr">231</xref>). However, since the legal ban of single substances came in place, various second-generation analogs have appeared, including 4-methyl-<italic>N</italic>-ethylcathinone (4-MEC). The consumption may in the long term only effectively be limited when whole substance classes, i.e., with a cathinone lead structure, are legally controlled (<xref rid="B231" ref-type="bibr">231</xref>).</p><p>Methylone (3,4-methylenedioxymethcathinone) is a substituted cathinone methylated on the amine group of the keto-phenethylamine backbone. It has a chemical structure similar to that of MDMA by a methylenedioxy ring attached to the aromatic ring (<xref rid="B264" ref-type="bibr">264</xref>). Methylone was first synthesized in 1996 as a potential antidepressant and anti-Parkinson agent (<xref rid="B265" ref-type="bibr">265</xref>), which, however, never made it into pharmacotherapy. Instead, it emerged on the street market under different names, such as Ease, Explosion, M1, MDMC, and bk-MDMA (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B246" ref-type="bibr">246</xref>). Methylone was marketed initially in a liquid solution as a vanilla-scented room odorizer. Following its introduction in 2004, methylone could be purchased in the Internet and in headshops (<xref rid="B266" ref-type="bibr">266</xref>), where it was sold in powder form and as tablets (<xref rid="B267" ref-type="bibr">267</xref>). Methylone use has been reported to be high in the club scene (<xref rid="B261" ref-type="bibr">261</xref>) and in addicts on substitution therapy (<xref rid="B267" ref-type="bibr">267</xref>).</p><p>Similar to other cathinones, methylone can be administered by different routes, such as orally, intranasally, intravenously, sublingually, or rectally. The most popular route is the oral administration. A common application pattern is to start with a large “boosting” dose and then maintain effects by smaller “bumping” doses (<xref rid="B268" ref-type="bibr">268</xref>, <xref rid="B269" ref-type="bibr">269</xref>). The onset of the desired psychoactive effects of methylone is usually 15–60 min after oral administration. These effects last approximately 30–45 min (<xref rid="B268" ref-type="bibr">268</xref>). They have been described as an amphetamine-like stimulation with calm euphoria, happiness, thought acceleration, alertness, restlessness, reduced fatigue, and increased locomotor activity. They might also involve MDMA-like entactogenic effects with a strong sense of emotional openness, enhanced empathy, and reduced fear (<xref rid="B270" ref-type="bibr">270</xref>). A methylone high can be from moderate to extreme euphoria with tingling sensation (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B268" ref-type="bibr">268</xref>).</p><p>The adverse effects of methylone include anxiety and psychosis with derealization, depersonalization, hallucinations, and suicidal ideation. Cognitive impairments affect the short-term memory (<xref rid="B258" ref-type="bibr">258</xref>). Furthermore, methylone may induce seizures and hyponatremia, similar to that induced by MDMA. Methylone may also induce a hyperthermia (<xref rid="B271" ref-type="bibr">271</xref>). This is believed to be a major cause for the fatal consequences of a methylone overdose (<xref rid="B272" ref-type="bibr">272</xref>). Other factors in fatal overdose can be cardiac events, metabolic acidosis, rhabdomyolysis, acute renal failure, intravascular coagulation, and a serotonin syndrome (<xref rid="B273" ref-type="bibr">273</xref>–<xref rid="B276" ref-type="bibr">276</xref>).</p><p>Accumulating evidence suggests a considerable addictive potential of methylone (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B277" ref-type="bibr">277</xref>). Much like mephedrone, methylone acts as a monoamine reuptake blocker that leads to a profound hyperactivity of DA, 5-HT, and NA in the brain and periphery (<xref rid="B263" ref-type="bibr">263</xref>). In particular, dopaminergic and serotonergic adaptations in the brain may drive the addiction potential of psychostimulant drugs (<xref rid="B278" ref-type="bibr">278</xref>, <xref rid="B279" ref-type="bibr">279</xref>). The use and abuse of the substance emerged with considerable side effects around the world (<xref rid="B268" ref-type="bibr">268</xref>). The legal ban of methylone started in 2007 with now an increasing number of countries controlling it (<xref rid="B231" ref-type="bibr">231</xref>).</p></sec><sec id="S7"><title>Ketamine and Novel Dissociative Drugs</title><p>(±)Ketamine (±2-chlorophenyl-2-methylamino-cyclohexanone) is a non-competitive antagonist of the NMDA receptor (<xref rid="B27" ref-type="bibr">27</xref>). It has been widely used in clinical settings as an anesthetic agent and in veterinary medicine. However, ketamine is also recreationally consumed in entertainment settings for its hallucinogenic, mood enhancing, and reinforcing properties by young club goers (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B280" ref-type="bibr">280</xref>–<xref rid="B282" ref-type="bibr">282</xref>). Ketamine is a derivative of phencyclidine (PCP), which was discovered as anesthetic in 1956 and became a popular street drug during 1960s (<xref rid="B280" ref-type="bibr">280</xref>). Ketamine is regulated in many countries due to its abuse potential as a psychotropic substance (<xref rid="B282" ref-type="bibr">282</xref>). A significant number of studies have demonstrated that ketamine has a short-acting antidepressant effect and is increasingly used to treat therapy-refractory major depression and pain (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B283" ref-type="bibr">283</xref>–<xref rid="B285" ref-type="bibr">285</xref>). Although ketamine is viewed as a safe substance in medical settings, its recreational use is reported to impose adverse effects on users by producing neurological and peripheral toxicity (<xref rid="B286" ref-type="bibr">286</xref>, <xref rid="B287" ref-type="bibr">287</xref>).</p><p>Ketamine can be administered through intravenous, intramuscular, smoking, and snorting routes (<xref rid="B288" ref-type="bibr">288</xref>). Apparently, snorting or intranasal use is the main route of ketamine consumption among recreational users (<xref rid="B289" ref-type="bibr">289</xref>). Ketamine produces dose-dependent effects. Lower doses are associated with a feeling of relaxation. At higher doses, ketamine induces a dream-like state called a “<italic>k-hole</italic>.” This experience is akin to dissociative anesthetic characteristics (<xref rid="B290" ref-type="bibr">290</xref>, <xref rid="B291" ref-type="bibr">291</xref>). Chronic ketamine use is reported to induce schizophrenia-like positive and negative symptoms, including hallucinations, detachment, delusion, auditory, and verbal hallucinations (<xref rid="B292" ref-type="bibr">292</xref>). A major concern of ketamine use is that people drive under the influence of the drug (<xref rid="B293" ref-type="bibr">293</xref>). Ketamine can impair cognitive functioning, such as executive and memory function, as well as attentional control (<xref rid="B294" ref-type="bibr">294</xref>, <xref rid="B295" ref-type="bibr">295</xref>). Ketamine users are also more vulnerable to HIV infections. The use of the drug is reported to enhance sexual experience and predispose users to engage in unprotected sex (<xref rid="B296" ref-type="bibr">296</xref>, <xref rid="B297" ref-type="bibr">297</xref>). Ketamine-related mortality has increased 10-fold in the UK from 1999 to 2008 (<xref rid="B287" ref-type="bibr">287</xref>), while in Australia 40% of party drug users were tested positive for ketamine use (<xref rid="B281" ref-type="bibr">281</xref>).</p><p>Some of the most common complaints of ketamine use include chest pain, palpitations, and tachycardia (<xref rid="B298" ref-type="bibr">298</xref>). However, these symptoms are often transient (<xref rid="B286" ref-type="bibr">286</xref>). Abdominal pain and urinary tract symptoms, such as suprapubic pain, dysuria, and hematuria, are common symptoms of chronic regular ketamine use (<xref rid="B299" ref-type="bibr">299</xref>–<xref rid="B301" ref-type="bibr">301</xref>). Findings from clinical case studies have shown that ketamine use can decrease bladder volume, bladder wall thickening, mucosal enhancement, dilation of ureter, and cause perivesical inflammation (<xref rid="B302" ref-type="bibr">302</xref>, <xref rid="B303" ref-type="bibr">303</xref>). The renal toxicity of ketamine is due to the direct toxic action of ketamine and its metabolites (<xref rid="B288" ref-type="bibr">288</xref>).</p><p>Fatigue, poor appetite, drowsiness, craving, anxiety, sleeping problems, and dysphoria are common physical and psychological side effects of ketamine use (<xref rid="B304" ref-type="bibr">304</xref>, <xref rid="B305" ref-type="bibr">305</xref>). Currently, there is no specific treatment for ketamine users presenting with peripheral toxicity. However, it was reported that cessation from ketamine abuse may lead to a recovery from organ damage (<xref rid="B28" ref-type="bibr">28</xref>). Despite its abuse potential and reported side effects, ketamine has promising medicinal properties. Currently, it is used to treat therapy-refractory depression (<xref rid="B306" ref-type="bibr">306</xref>), although the antidepressant effect of a single infusion only last for some days. Despite that development, which moved the drug increasingly out of the drug abuse focus, proper prevention strategies for young club goers engaged in recreational ketamine use are still warranted. Moreover, addiction experts warned recently that psychiatrist should not underestimate the addictive potential of ketamine when treating depressive patients with the drug (<xref rid="B307" ref-type="bibr">307</xref>).</p><p>Dissociative anesthetics such as PCP and ketamine are non-medically used since more than 60 years (<xref rid="B280" ref-type="bibr">280</xref>). Importantly, “dissociative anesthetics” are originally defined as substances inducing a general form of anesthesia characterized by analgesia, amnesia, and cataplexy, but with minimal effect on respiratory function (<xref rid="B308" ref-type="bibr">308</xref>). Today, the term “dissociative drugs” includes the family of dissociative anesthetics but is not restricted to them. It more generally denotes hallucinogenic drugs inducing dissociative states, including sensory alterations and hallucinations as well as dream-like states or trance (<xref rid="B280" ref-type="bibr">280</xref>). More than 14 known derivatives of PCP have been marketed for non-medical but also illicit use already between the late 1960s and the 1990s. However, with the advent of online drug shops selling “legal highs,” novel dissociative drugs appeared too. Starting with the first dissociative, 4-MeO-PCP in 2008, thenceforth at least 12 novel dissociative drugs appeared on the drug marked, which were unknown in the scientific literature prior to their introduction to the drug market (<xref rid="B280" ref-type="bibr">280</xref>). In the meantime, the most common agents, methoxetamine (MXE), diphenidine, methoxphenidine (MXP), 3-MeO-PCP, and 4-MeO-PCP, have reached widespread use in Europe and North America.</p><p>PCP, ketamine, and its novel derivatives belong to the chemical class of arylcyclohexylamines, which have in common that they act as non-competitive antagonists at the PCP-binding site of the NMDA receptor (<xref rid="B280" ref-type="bibr">280</xref>). Beyond their high affinity for NMDA receptors, some of the arylcyclohexylamines have shown agonistic actions at DA receptors (e.g., D2 receptors) and inhibitory effects at DA transporters, agonistic effects at μ-opioid and σ-1 receptors, as well as antagonistic actions at both nicotinic and muscarinic acetylcholine receptors. It is plausible that the specific receptor profile of each compound mediates its characteristic psychotropic effects (<xref rid="B280" ref-type="bibr">280</xref>). Beyond the desired dissociative acute effects, these drugs exert a number of severe and sometimes fatal side effects. Following MXE ingestion, users were confused, agitated, hallucinating, and unresponsive. The somatic and neurological adverse effects included tachycardia, hypertension, ataxia, mydriasis, nystagmus, seizures, leukocytosis, massive rhabdomyolysis, hepatic failure, onset of acute renal failure, sinus bradycardia, elevated creatinine kinase, and hyponatremia (<xref rid="B210" ref-type="bibr">210</xref>). Several fatalities have been reported each for MXE, MXP, 3-MeO-PCP, and 4-MeO-PCP (<xref rid="B210" ref-type="bibr">210</xref>, <xref rid="B240" ref-type="bibr">240</xref>). According to anecdotal reports, MXE and MXP seem to have stronger empathogenic and euphorigenic properties than PCP and ketamine (<xref rid="B210" ref-type="bibr">210</xref>).</p><p>Novel dissociative drugs from the arylcyclohexylamine class, such as MXE, have been sold as a “legal” and “bladder friendly” alternative to ketamine. However, animal studies have shown that MXE and likely all arylcyclohexylamines are in fact equally toxic for the bladder and the kidneys as ketamine when applied chronically (<xref rid="B240" ref-type="bibr">240</xref>). Further chronic side effects of novel arylcyclohexylamines have not been investigated yet, but it is likely that the total class might have an addictive potential similar to that of ketamine and PCP (<xref rid="B309" ref-type="bibr">309</xref>, <xref rid="B310" ref-type="bibr">310</xref>). This seems to be specifically high in adolescents and young adults (<xref rid="B311" ref-type="bibr">311</xref>). Moreover, like PCP and ketamine, all arylcyclohexylamines with a strong action at the NMDA receptor may impair memory function (<xref rid="B310" ref-type="bibr">310</xref>) and induce psychotic symptoms after acute and chronic consumption (<xref rid="B312" ref-type="bibr">312</xref>, <xref rid="B313" ref-type="bibr">313</xref>).</p></sec><sec id="S8"><title>γ-Hydroxybutyrate, γ-Butyrolactone, and 1,4-Butanediol</title><p>γ-Hydroxybutyrate (GHB, or sodium oxybate), γ-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) are potent central depressant agents with a broad spectrum of subjective, behavioral, and neuropharmacological effects in humans. These drugs are used clinically for the treatment of neuropsychiatric disorders such as narcolepsy, alcohol withdrawal, and fibromyalgia but also instrumentalized illicitly for hedonic purposes (<xref rid="B314" ref-type="bibr">314</xref>).</p><p>GBL and 1,4-BD are rapidly metabolized endogenously to GHB. The psychoactive effects of the drug result from this conversion (<xref rid="B315" ref-type="bibr">315</xref>, <xref rid="B316" ref-type="bibr">316</xref>). GHB is an endogenous short-chain fatty acid. It is biosynthetically derived from γ-aminobutyric acid (GABA) which occurs naturally in the mammalian brain, mainly in the hypothalamus and the basal ganglia (<xref rid="B317" ref-type="bibr">317</xref>, <xref rid="B318" ref-type="bibr">318</xref>). The molecule binds to GABA-B receptors (<xref rid="B319" ref-type="bibr">319</xref>) and to specific GHB receptors (<xref rid="B320" ref-type="bibr">320</xref>). Due to the presence of endogenous GHB in the brain, specific G-protein-coupled GHB receptors, and the specificity of the GHB antagonist NCS-382, GHB is considered to be a neurotransmitter (<xref rid="B321" ref-type="bibr">321</xref>). While physiological concentrations of GHB seem to be insufficient to stimulate GABA-B receptors, the subjective and behavioral effects of the exogenously applied drug, and thus GBL and 1,4-BD, result from direct stimulation of these receptors (<xref rid="B322" ref-type="bibr">322</xref>). Moreover, GHB has extensive downstream effects on DA, 5-HT, NA, glutamate, and acetylcholine transmission (<xref rid="B323" ref-type="bibr">323</xref>). GHB, GBL, and 1,4-BD are well absorbed orally in humans. Peak plasma concentrations are reached within 25–60 min, with a half-life of 20–60 min (<xref rid="B324" ref-type="bibr">324</xref>, <xref rid="B325" ref-type="bibr">325</xref>). All compounds are metabolized to water and carbon dioxide through the citric acid cycle (<xref rid="B326" ref-type="bibr">326</xref>).</p><p>In humans, the spectrum of the subjective effects of these compounds ranges from euphoria, stimulation, and disinhibition in oral doses of 10–25 mg/kg (<xref rid="B327" ref-type="bibr">327</xref>–<xref rid="B329" ref-type="bibr">329</xref>), toward heavy sedation and loss of consciousness at oral doses of 35–70 mg/kg (<xref rid="B324" ref-type="bibr">324</xref>, <xref rid="B330" ref-type="bibr">330</xref>). A seemingly paradoxical pattern of concomitant sedation and stimulation was described in several reports (<xref rid="B327" ref-type="bibr">327</xref>, <xref rid="B328" ref-type="bibr">328</xref>).</p><p>GHB, GBL, and 1,4-BD strongly influence behaviors related to core autonomic functions, such as the control of food intake, sexual behavior, and sleep–wake regulation (<xref rid="B314" ref-type="bibr">314</xref>). GHB was reported to normalize dysfunctional food intake behavior and body weight in preclinical and in clinical studies (<xref rid="B331" ref-type="bibr">331</xref>–<xref rid="B334" ref-type="bibr">334</xref>). It was effective in the treatment of binge-eating disorder (<xref rid="B335" ref-type="bibr">335</xref>). Confirming subjective reports from illicit GHB users (<xref rid="B336" ref-type="bibr">336</xref>–<xref rid="B338" ref-type="bibr">338</xref>), the drug was experimentally shown to have prosocial (<xref rid="B328" ref-type="bibr">328</xref>), and prosexual effects in healthy male subjects (<xref rid="B339" ref-type="bibr">339</xref>). Moreover, GHB and its precursors have a unique effect on sleep–wake regulation (<xref rid="B340" ref-type="bibr">340</xref>). Since GHB improves sleep and daytime vigilance, it is used as standard treatment for disorders of the sleep–wake cycle, such as narcolepsy and fibromyalgia (<xref rid="B341" ref-type="bibr">341</xref>–<xref rid="B343" ref-type="bibr">343</xref>).</p><p>Neuropharmacological studies with GHB, GBL, and 1,4-BD are scarce and were until recently limited to early EEG investigations. Resting state EEG studies showed a paradoxical EEG-behavioral dissociation with the occurrence of increased delta and theta oscillations, during wake states, which usually occur during sleep (<xref rid="B344" ref-type="bibr">344</xref>, <xref rid="B345" ref-type="bibr">345</xref>). Moreover, increased nocturnal slow wave sleep under the influence of GHB was demonstrated (<xref rid="B346" ref-type="bibr">346</xref>). A recent EEG study showed increased current source density of theta oscillations in the posterior cingulate cortex and alpha oscillations in the anterior cingulate cortex (ACC) under 20 and 35 mg/kg GHB in healthy male subjects (<xref rid="B347" ref-type="bibr">347</xref>). In the first functional neuroimaging study with GHB, 35 mg/kg of the drug increased regional cerebral blood perfusion in the ACC and the insula, both of which correlated with increased subjective ratings of emotion and body awareness (<xref rid="B348" ref-type="bibr">348</xref>). Moreover, the drug increased the susceptibility of the mesolimbic reward system, resulting in an increased sexual arousal after the presentation of erotic but also neutral pictures of persons. This effect correlated with an increased activity in the nucleus accumbens and the ACC (<xref rid="B349" ref-type="bibr">349</xref>).</p><p>The euphoric, prosocial, and prosexual effects of GHB, GBL, and 1,4-BD are instrumentalized illicitly, mostly by members of urban subcultures (<xref rid="B314" ref-type="bibr">314</xref>). Internationally, GHB, GBL, and 1,4-BD are mainly used as recreational drugs by young adults aged 20–29 years (<xref rid="B349" ref-type="bibr">349</xref>, <xref rid="B350" ref-type="bibr">350</xref>). Reliable prevalence data are difficult to obtain (<xref rid="B351" ref-type="bibr">351</xref>). However, the prevalence of GHB, GBL, and 1,4-BD seem low compared to other drugs of abuse and are estimated at about 4.3% in Europe (<xref rid="B349" ref-type="bibr">349</xref>). After GHB was used in a deadly case of drug-facilitated sexual assault in the USA in the year 2000, the drug was internationally banned (<xref rid="B352" ref-type="bibr">352</xref>). However, a recent meta-analysis showed that GHB is very infrequently used as a date rape drug (<xref rid="B353" ref-type="bibr">353</xref>).</p><p>The development of addiction after illicit use of these drugs was estimated for about 4–21% of illicit users (<xref rid="B351" ref-type="bibr">351</xref>). Both addiction and withdrawal can be severe and in extreme cases lead to psychosis, delirium, and death (<xref rid="B314" ref-type="bibr">314</xref>). Interestingly, the development of addiction after medical use of GHB is at a very low rate with an estimated risk of about 0.015% (<xref rid="B351" ref-type="bibr">351</xref>).</p><p>Internationally, GHB is approved for the treatment of narcolepsy with cataplexy. In a recent meta-analysis, it was confirmed to be effective in treating major, clinically relevant narcolepsy symptoms and sleep architecture impairments in patients (<xref rid="B354" ref-type="bibr">354</xref>). Another clinical indication is the treatment of alcohol withdrawal, for which GHB is used since two decades in Italy and Austria (<xref rid="B355" ref-type="bibr">355</xref>). Moreover, several randomized controlled trials showed a therapeutic effect of GHB on clinical course and life quality in patients suffering from fibromyalgia (<xref rid="B343" ref-type="bibr">343</xref>, <xref rid="B356" ref-type="bibr">356</xref>–<xref rid="B358" ref-type="bibr">358</xref>). Other neuropsychiatric disorders in which GHB showed therapeutic effects are binge-eating disorders (<xref rid="B335" ref-type="bibr">335</xref>), schizophrenia (<xref rid="B359" ref-type="bibr">359</xref>), Parkinson’s disease (<xref rid="B360" ref-type="bibr">360</xref>), and cluster headache (<xref rid="B361" ref-type="bibr">361</xref>, <xref rid="B362" ref-type="bibr">362</xref>), mostly by regulating homeostatic dysbalances, as well as improving sleep and pain symptoms. Because disrupted homeostatic processes including food intake, sexual behavior, and the sleep–wake cycle frequently occur in major depressive disorder, GHB was proposed as an experimental therapeutic in this condition (<xref rid="B363" ref-type="bibr">363</xref>, <xref rid="B364" ref-type="bibr">364</xref>). However, therapeutic use of the drug is limited by side effects, such as nausea, vomiting, altered consciousness, and nocturnal O<sub>2</sub> desaturations (<xref rid="B357" ref-type="bibr">357</xref>, <xref rid="B365" ref-type="bibr">365</xref>–<xref rid="B367" ref-type="bibr">367</xref>).</p><p>In conclusion, GHB and partially its precursors GBL and 1,4-BD have undeniable caveats such as limiting side effects and abuse liability. These, however, seem to be outweighed by a unique spectrum of clinically relevant psychopharmacological effects, which warrant further studies in neuropsychiatric conditions such as major depressive disorder following a personalized treatment paradigm (<xref rid="B368" ref-type="bibr">368</xref>).</p></sec><sec id="S9"><title>Conclusion</title><p>The amount of evidence on the psychoactive drugs discussed shows that many of them are not really novel anymore. For most of them a classification in terms of their use and harm potential has been made. In fact, most of them are already legally controlled or banned in certain countries. An important feature of this process is that it appears socio-geographically biased. Even in a globalized world, new psychoactive drugs emerge and spread in a regionally bound way. This brings about that evidence on their use, instrumentalization, and abuse accumulates often only regionally. Also, the drug may for a long time not spread beyond the socio-geographic boundaries. However, this does not mean that it is not eventually “discovered” by other societies making use of the drug for a new and essentially different purpose. The scientific challenge is then to use locally gathered knowledge to be prepared for a drug that is novel in a certain culture and establish a judgment on its harm potential and/or medical use on a rather global scale. It also means to delineate future research needs for those drugs that are brand new as a psychoactive drug. This review shows that despite accumulating evidence, for many of those NPSs, a final classification is still in progress and gathering of more evidence is pivotal.</p></sec><sec id="S10"><title>Author Contributions</title><p>CM and ZH planned the review article and contributed to several chapters. CM prepared the final version of the manuscript. CM, ZH, OB, DS, SN, BK, ES, JK, and BQ wrote single chapters of the manuscript.</p></sec><sec id="S11"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The work of the authors was funded by the Interdisciplinary Center for Clinical Research (IZKF) Erlangen, Project E22 (CM), by the Deutsche Forschungsgemeinschaft grant MU 2789/8-1 (CM) and KO 947/15-1 (JK), by the Higher Education Centre of Excellence, Malaysia (HiCoE) special funding 304/CDADAH/4401009 and the Fundamental Research Grant Scheme 203/CDADAH/6711469.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jay</surname><given-names>M</given-names></name></person-group><source>High Society. Mind-Altering Drugs in History and Culture</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Thames & Hudson</publisher-name> (<year>2010</year>).</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadley</surname><given-names>G</given-names></name></person-group>. <article-title>How psychoactive drugs shape human culture: a multi-disciplinary perspective</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>(<issue>Pt 1</issue>):<fpage>138</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.04.008</pub-id><pub-id pub-id-type="pmid">27083300</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagen</surname><given-names>EH</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>G</given-names></name><name><surname>Kempter</surname><given-names>R</given-names></name><name><surname>Hammerstein</surname><given-names>P</given-names></name></person-group>. <article-title>Ecology and neurobiology of toxin avoidance and the paradox of drug reward</article-title>. <source>Neuroscience</source> (<year>2009</year>) <volume>160</volume>:<fpage>69</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.01.077</pub-id><pub-id pub-id-type="pmid">19233250</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellu</surname><given-names>F</given-names></name><name><surname>Piazza</surname><given-names>PV</given-names></name><name><surname>Mayo</surname><given-names>W</given-names></name><name><surname>Le Moal</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name></person-group><article-title>Novelty-seeking in rats – biobehavioral characteristics and possible relationship with the sensation-seeking trait in man</article-title>. <source>Neuropsychobiology</source> (<year>1996</year>) <volume>34</volume>:<fpage>136</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1159/000119305</pub-id><pub-id pub-id-type="pmid">8916071</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidwell</surname><given-names>LC</given-names></name><name><surname>Knopik</surname><given-names>VS</given-names></name><name><surname>Audrain-McGovern</surname><given-names>J</given-names></name><name><surname>Glynn</surname><given-names>TR</given-names></name><name><surname>Spillane</surname><given-names>NS</given-names></name><name><surname>Ray</surname><given-names>LA</given-names></name><etal></etal></person-group><article-title>Novelty seeking as a phenotypic marker of adolescent substance use</article-title>. <source>Subst Abuse</source> (<year>2015</year>) <volume>9</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.4137/SART.S22440</pub-id><pub-id pub-id-type="pmid">26106262</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Schumann</surname><given-names>G</given-names></name></person-group><article-title>Drugs as an instrument: a new framework for non-addictive psychoactive drug use</article-title>. <source>Behav Brain Sci</source> (<year>2011</year>) <volume>34</volume>(<issue>6</issue>):<fpage>293</fpage>–<lpage>310</lpage>.<pub-id pub-id-type="doi">10.1017/S0140525X11000057</pub-id><pub-id pub-id-type="pmid">22074962</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Schumann</surname><given-names>G</given-names></name></person-group>. <article-title>To use or not to use: expanding the view on non-addictive psychoactive drug consumption and its implications</article-title>. <source>Behav Brain Sci</source> (<year>2011</year>) <volume>34</volume>(<issue>6</issue>):<fpage>328</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1017/S0140525X1100135X</pub-id><pub-id pub-id-type="pmid">22379623</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name></person-group><article-title>Non addictive drug use: the way forward</article-title>. In: <person-group person-group-type="editor"><name><surname>Wolff</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Karch</surname><given-names>S</given-names></name></person-group>, editors. <source>The SAGE Handbook of Drugs & Alcohol Studies – Biological Approaches</source>. (Vol. <volume>2</volume>, Chap. 42), <publisher-loc>London</publisher-loc>: <publisher-name>SAGE</publisher-name> (<year>2017</year>). p. <fpage>411</fpage>–<lpage>34</lpage>.</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Wolff</surname><given-names>W</given-names></name><name><surname>Ziegler</surname><given-names>M</given-names></name></person-group>. <article-title>Drugs as instruments: describing and testing a behavioral approach to the study of neuroenhancement</article-title>. <source>Front Psychol</source> (<year>2016</year>) <volume>7</volume>:<fpage>1226</fpage>.<pub-id pub-id-type="doi">10.3389/fpsyg.2016.01226</pub-id><pub-id pub-id-type="pmid">27582720</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCreary</surname><given-names>AC</given-names></name><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Filip</surname><given-names>M</given-names></name></person-group><article-title>Psychostimulants: basic and clinical pharmacology</article-title>. <source>Int Rev Neurobiol</source> (<year>2015</year>) <volume>120</volume>:<fpage>41</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/bs.irn.2015.02.008</pub-id><pub-id pub-id-type="pmid">26070753</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name></person-group>. <article-title>Episodic memories and their relevance for psychoactive drug use and addiction</article-title>. <source>Front Behav Neurosci</source> (<year>2013</year>) <volume>7</volume>:<fpage>34</fpage>.<pub-id pub-id-type="doi">10.3389/fnbeh.2013.00034</pub-id><pub-id pub-id-type="pmid">23734106</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>SH</given-names></name></person-group>. <article-title>Toward an evolutionary basis for resilience to drug addiction</article-title>. <source>Behav Brain Sci</source> (<year>2011</year>) <volume>34</volume>:<fpage>310</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="doi">10.1017/S0140525X11000677</pub-id><pub-id pub-id-type="pmid">22074963</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chick</surname><given-names>J</given-names></name></person-group>. <article-title>Can light or moderate drinking benefit mental health?</article-title><source>Eur Addict Res</source> (<year>1999</year>) <volume>5</volume>:<fpage>74</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1159/000018969</pub-id><pub-id pub-id-type="pmid">10394037</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Heath</surname><given-names>DB</given-names></name></person-group><source>Drinking Occasions: Comparative Perspectives on Alcohol and Culture</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Brunner/Mazel</publisher-name> (<year>2000</year>).</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peele</surname><given-names>S</given-names></name><name><surname>Brodsky</surname><given-names>A</given-names></name></person-group>. <article-title>Exploring psychological benefits associated with moderate alcohol use: a necessary corrective to assessments of drinking outcomes?</article-title><source>Drug Alcohol Depend</source> (<year>2000</year>) <volume>60</volume>:<fpage>221</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1016/S0376-8716(00)00112-5</pub-id><pub-id pub-id-type="pmid">11053757</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lende</surname><given-names>DH</given-names></name><name><surname>Leonard</surname><given-names>T</given-names></name><name><surname>Sterk</surname><given-names>CE</given-names></name><name><surname>Elifson</surname><given-names>K</given-names></name></person-group><article-title>Functional methamphetamine use: the insider’s perspective</article-title>. <source>Addict Res Ther</source> (<year>2007</year>) <volume>15</volume>(<issue>5</issue>):<fpage>465</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1080/16066350701284552</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spear</surname><given-names>LP</given-names></name></person-group>. <article-title>The adolescent brain and age-related behavioral manifestations</article-title>. <source>Neurosci Biobehav Rev</source> (<year>2000</year>) <volume>24</volume>:<fpage>417</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/S0149-7634(00)00014-2</pub-id><pub-id pub-id-type="pmid">10817843</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuntsche</surname><given-names>E</given-names></name><name><surname>Knibbe</surname><given-names>R</given-names></name><name><surname>Gmel</surname><given-names>G</given-names></name><name><surname>Engels</surname><given-names>R</given-names></name></person-group>. <article-title>Who drinks and why? A review of socio-demographic, personality, and contextual issues behind the drinking motives in young people</article-title>. <source>Addict Behav</source> (<year>2006</year>) <volume>31</volume>:<fpage>1844</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/j.addbeh.2005.12.028</pub-id><pub-id pub-id-type="pmid">16460883</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Kalinichenko</surname><given-names>LS</given-names></name><name><surname>Tiesel</surname><given-names>J</given-names></name><name><surname>Witt</surname><given-names>M</given-names></name><name><surname>Stöckl</surname><given-names>T</given-names></name><name><surname>Sprenger</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Paradoxical antidepressant effects of alcohol are related to acid sphingomyelinase and its control of sphingolipid homeostasis</article-title>. <source>Acta Neuropathol</source> (<year>2017</year>) <volume>133</volume>(<issue>3</issue>):<fpage>463</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1007/s00401-016-1658-6</pub-id><pub-id pub-id-type="pmid">28000031</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonn-Miller</surname><given-names>MO</given-names></name><name><surname>Zvolensky</surname><given-names>MJ</given-names></name><name><surname>Bernstein</surname><given-names>A</given-names></name></person-group><article-title>Marihuana use motives: concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marihuana smokers</article-title>. <source>Addict Behav</source> (<year>2007</year>) <volume>32</volume>:<fpage>49</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.addbeh.2006.03.018</pub-id><pub-id pub-id-type="pmid">16647822</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattore</surname><given-names>L</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name></person-group>. <article-title>Beyond THC: the new generation of cannabinoid designer drugs</article-title>. <source>Front Behav Neurosci</source> (<year>2011</year>) <volume>5</volume>:<fpage>60</fpage>.<pub-id pub-id-type="doi">10.3389/fnbeh.2011.00060</pub-id><pub-id pub-id-type="pmid">22007163</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="webpage"><collab>United Nations Office on Drugs and Crime</collab>. <source>Single Convention on Narcotic Drugs</source>. (<year>1961</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.unodc.org/unodc/en/treaties/single-convention.html">http://www.unodc.org/unodc/en/treaties/single-convention.html</uri></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="webpage"><collab>United Nations Office on Drugs and Crime</collab>. <source>Convention on Psychotropic Substances</source>. (<year>1971</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.unodc.org/unodc/en/treaties/psychotropics.html">http://www.unodc.org/unodc/en/treaties/psychotropics.html</uri></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schifano</surname><given-names>F</given-names></name><name><surname>Orsolini</surname><given-names>L</given-names></name><name><surname>Duccio Papanti</surname><given-names>G</given-names></name><name><surname>Corkery</surname><given-names>JM</given-names></name></person-group><article-title>Novel psychoactive substances of interest for psychiatry</article-title>. <source>World Psychiatry</source> (<year>2015</year>) <volume>14</volume>:<fpage>15</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1002/wps.20174</pub-id><pub-id pub-id-type="pmid">25655145</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Vicknasingam</surname><given-names>BK</given-names></name></person-group>. <article-title>Kratom (<italic>Mitragyna speciosa</italic>) dependence, withdrawal symptoms and craving in regular users</article-title>. <source>Drug Alcohol Depend</source> (<year>2014</year>) <volume>139</volume>:<fpage>132</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.03.017</pub-id><pub-id pub-id-type="pmid">24698080</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frederiksen</surname><given-names>NJ</given-names></name><name><surname>Bakke</surname><given-names>SL</given-names></name><name><surname>Dalum</surname><given-names>P</given-names></name></person-group><article-title>“No alcohol, no party”: an explorative study of young Danish moderate drinkers</article-title>. <source>Scand J Public Health</source> (<year>2012</year>) <volume>40</volume>:<fpage>585</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1177/1403494812458988</pub-id><pub-id pub-id-type="pmid">23027894</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name></person-group><article-title>Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists</article-title>. In: <person-group person-group-type="editor"><name><surname>Fog</surname><given-names>R</given-names></name><name><surname>Gerlach</surname><given-names>J</given-names></name><name><surname>Hemmingsen</surname><given-names>R</given-names></name><name><surname>Krogsgaard-Larsen</surname><given-names>P</given-names></name><name><surname>Thaysen Schizophrenia</surname><given-names>JH</given-names></name></person-group>, editors. <source>Schizophrenia – An Integrated View. Alfred Benzon Symposium 38</source>. <publisher-loc>Copenhagen</publisher-loc>: <publisher-name>Munksgaard</publisher-name> (<year>1995</year>). p. <fpage>314</fpage>–<lpage>25</lpage>.</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name></person-group>. <article-title>Ketamine abuse potential and use disorder</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>:<fpage>68</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.05.016</pub-id><pub-id pub-id-type="pmid">27261367</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>B</given-names></name><name><surname>Choucha</surname><given-names>W</given-names></name><name><surname>Fossati</surname><given-names>P</given-names></name><name><surname>Rotge</surname><given-names>JY</given-names></name></person-group>. <article-title>Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression</article-title>. <source>Psychiatry Res</source> (<year>2015</year>) <volume>230</volume>:<fpage>682</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2015.10.032</pub-id><pub-id pub-id-type="pmid">26548981</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Hassan</surname><given-names>Z</given-names></name></person-group><article-title>The evaluation of new psychoactive drugs</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>:<fpage>1</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.05.013</pub-id><pub-id pub-id-type="pmid">27235862</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>Z</given-names></name><name><surname>Muzaimi</surname><given-names>M</given-names></name><name><surname>Navaratnam</surname><given-names>V</given-names></name><name><surname>Yusoff</surname><given-names>NHM</given-names></name><name><surname>Suhaimi</surname><given-names>FW</given-names></name><name><surname>Vadivelu</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction</article-title>. <source>Neurosci Biobehav Rev</source> (<year>2013</year>) <volume>37</volume>:<fpage>138</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.11.012</pub-id><pub-id pub-id-type="pmid">23206666</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Vicknasingam</surname><given-names>B</given-names></name></person-group>. <article-title>Traditional and non-traditional uses of mitragynine (Kratom): a survey of the literature</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>(<issue>Pt 1</issue>):<fpage>41</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.05.004</pub-id><pub-id pub-id-type="pmid">27178014</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>PN</given-names></name><name><surname>Lund</surname><given-names>JA</given-names></name><name><surname>Murch</surname><given-names>SJ</given-names></name></person-group>. <article-title>A botanical, phytochemical and ethnomedicinal review of the genus <italic>Mitragyna korth</italic>: implications for products sold as Kratom</article-title>. <source>J Ethnopharmacol</source> (<year>2017</year>) <volume>202</volume>:<fpage>302</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1016/j.jep.2017.03.020</pub-id><pub-id pub-id-type="pmid">28330725</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saingam</surname><given-names>D</given-names></name><name><surname>Assanangkornchai</surname><given-names>S</given-names></name><name><surname>Geater</surname><given-names>AF</given-names></name><name><surname>Lerkiatbundit</surname><given-names>S</given-names></name></person-group><article-title>Validation of Krathom (<italic>Mitragyna speciosa Korth</italic>.) dependence scale (KDS): a dependence screen for internationally emerging psychoactive substance</article-title>. <source>Subst Abuse</source> (<year>2014</year>) <volume>35</volume>:<fpage>276</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1080/08897077.2014.924464</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicknasingam</surname><given-names>B</given-names></name><name><surname>Narayanan</surname><given-names>S</given-names></name><name><surname>Beng</surname><given-names>GT</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name></person-group>. <article-title>The informal use of ketum (<italic>Mitragyna speciosa</italic>) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy</article-title>. <source>Int J Drug Policy</source> (<year>2010</year>) <volume>21</volume>:<fpage>283</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugpo.2009.12.003</pub-id><pub-id pub-id-type="pmid">20092998</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>EW</given-names></name><name><surname>Babu</surname><given-names>KM</given-names></name><name><surname>Adkins</surname><given-names>JE</given-names></name><name><surname>McCurdy</surname><given-names>CR</given-names></name><name><surname>Halpern</surname><given-names>JH</given-names></name></person-group><article-title>Self-treatment of opioid withdrawal using Kratom (<italic>Mitragyna speciosa Korth</italic>)</article-title>. <source>Addiction</source> (<year>2008</year>) <volume>103</volume>:<fpage>1048</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1111/j.1360-0443.2008.02209.x</pub-id><pub-id pub-id-type="pmid">18482427</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prozialeck</surname><given-names>WC</given-names></name><name><surname>Jivan</surname><given-names>JK</given-names></name><name><surname>Andurkar</surname><given-names>SV</given-names></name></person-group>. <article-title>Pharmacology of Kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects</article-title>. <source>J Am Osteopath Assoc</source> (<year>2012</year>) <volume>112</volume>(<issue>12</issue>):<fpage>792</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23212430</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinosi</surname><given-names>E</given-names></name><name><surname>Martinotti</surname><given-names>G</given-names></name><name><surname>Simonato</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Demetrovics</surname><given-names>Z</given-names></name><name><surname>Roman-Urrestarazu</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Following “the roots” of Kratom (<italic>Mitragyna speciosa</italic>): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries</article-title>. <source>Biomed Res Int</source> (<year>2015</year>) <volume>2015</volume>:<fpage>968786</fpage><pub-id pub-id-type="doi">10.1155/2015/968786</pub-id><pub-id pub-id-type="pmid">26640804</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>ML</given-names></name><name><surname>Kaufman</surname><given-names>NC</given-names></name><name><surname>Grundmann</surname><given-names>O</given-names></name></person-group>. <article-title>The pharmacology and toxicology of Kratom: from traditional herb to drug of abuse</article-title>. <source>Int J Legal Med</source> (<year>2016</year>) <volume>130</volume>:<fpage>127</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1007/s00414-015-1279-y</pub-id><pub-id pub-id-type="pmid">26511390</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swogger</surname><given-names>MT</given-names></name><name><surname>Hart</surname><given-names>E</given-names></name><name><surname>Erowid</surname><given-names>F</given-names></name><name><surname>Erowid</surname><given-names>E</given-names></name><name><surname>Trabold</surname><given-names>N</given-names></name><name><surname>Yee</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Experiences of Kratom users: a qualitative analysis</article-title>. <source>J Psychoactive Drugs</source> (<year>2015</year>) <volume>47</volume>(<issue>5</issue>):<fpage>360</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.2015.1096434</pub-id><pub-id pub-id-type="pmid">26595229</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suhaimi</surname><given-names>FW</given-names></name><name><surname>Yusoff</surname><given-names>NHM</given-names></name><name><surname>Hassan</surname><given-names>R</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name><name><surname>Navaratnam</surname><given-names>V</given-names></name><name><surname>Müller</surname><given-names>CP</given-names></name><etal></etal></person-group><article-title>Neurobiology of Kratom and its main alkaloid mitragynine</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>:<fpage>29</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.03.015</pub-id><pub-id pub-id-type="pmid">27018165</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>K</given-names></name><name><surname>Aziz</surname><given-names>Z</given-names></name></person-group><article-title><italic>Mitragyna speciosa</italic> use in the northern states of Malaysia: cross-sectional study</article-title>. <source>J Ethnopharmacol</source> (<year>2012</year>) <volume>141</volume>:<fpage>446</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.jep.2012.03.009</pub-id><pub-id pub-id-type="pmid">22440259</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saingam</surname><given-names>D</given-names></name><name><surname>Assanangkornchai</surname><given-names>S</given-names></name><name><surname>Geater</surname><given-names>AF</given-names></name><name><surname>Balthip</surname><given-names>Q</given-names></name></person-group><article-title>Pattern and consequences of Krathom (<italic>Mitragyna speciosa Korth</italic>.) use among male villagers in southern Thailand: a qualitative study</article-title>. <source>Int J Drug Policy</source> (<year>2012</year>) <volume>24</volume>(<issue>4</issue>):<fpage>351</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugpo.2012.09.004</pub-id><pub-id pub-id-type="pmid">23083922</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tanguay</surname><given-names>P</given-names></name></person-group><article-title>Kratom in Thailand: decriminalisation and community control?</article-title><source>Legislative Reform of Drug Policies</source>. (Vol. <volume>13</volume>) <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Transnational Institute</publisher-name> (<year>2011</year>). p. <fpage>1</fpage>–<lpage>16</lpage>.</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assanangkornchai</surname><given-names>S</given-names></name><name><surname>Muekthong</surname><given-names>A</given-names></name><name><surname>Sam-Angsri</surname><given-names>N</given-names></name><name><surname>Pattanasattayawong</surname><given-names>U</given-names></name></person-group><article-title>The use of mitragynine species (“Krathom”), an addictive plant, in Thailand</article-title>. <source>Subst Use Misuse</source> (<year>2007</year>) <volume>42</volume>:<fpage>2145</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1080/10826080701205869</pub-id><pub-id pub-id-type="pmid">18097996</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Vicknasingam</surname><given-names>BK</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name></person-group>. <article-title>Social functioning of Kratom (<italic>Mitragyna speciosa</italic>) users in Malaysia</article-title>. <source>J Psychoactive Drugs</source> (<year>2015</year>) <volume>47</volume>(<issue>2</issue>):<fpage>125</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.2015.1012610</pub-id><pub-id pub-id-type="pmid">25950592</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trakulsrichai</surname><given-names>S</given-names></name><name><surname>Tongpo</surname><given-names>A</given-names></name><name><surname>Sriapha</surname><given-names>C</given-names></name><name><surname>Wongvisawakorn</surname><given-names>S</given-names></name><name><surname>Rittilert</surname><given-names>P</given-names></name><name><surname>Kaojarern</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Kratom abuse in Ramathibodi Poison Center, Thailand. A five-year experience</article-title>. <source>J Psychoactive Drugs</source> (<year>2013</year>) <volume>45</volume>(<issue>5</issue>):<fpage>404</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.2013.844532</pub-id><pub-id pub-id-type="pmid">24592666</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Rosenbaum</surname><given-names>C</given-names></name><name><surname>Hernon</surname><given-names>C</given-names></name><name><surname>McCurdy</surname><given-names>CR</given-names></name><name><surname>Boyer</surname><given-names>EW</given-names></name></person-group><article-title>Herbal medicines for the management of opioid addiction</article-title>. <source>CNS Drugs</source> (<year>2011</year>) <volume>25</volume>(<issue>12</issue>):<fpage>999</fpage>–<lpage>1007</lpage>.<pub-id pub-id-type="doi">10.2165/11596830-000000000-00000</pub-id><pub-id pub-id-type="pmid">22133323</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suwanlert</surname><given-names>S</given-names></name></person-group><article-title>A study of Kratom eaters in Thailand</article-title>. <source>Bull Narc</source> (<year>1975</year>) <volume>27</volume>(<issue>3</issue>):<fpage>21</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">1041694</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prozialeck</surname><given-names>WC</given-names></name></person-group>. <article-title>Update on the pharmacology and legal status of Kratom</article-title>. <source>J Am Osteopath Assoc</source> (<year>2016</year>) <volume>116</volume>(<issue>12</issue>):<fpage>802</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.7556/jaoa.2016.156</pub-id><pub-id pub-id-type="pmid">27893147</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MM</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Schifano</surname><given-names>F</given-names></name><name><surname>Feinmann</surname><given-names>C</given-names></name></person-group><article-title>“Legal highs” on the net – evaluation of UK-based websites, products and product information</article-title>. <source>Forensic Sci Int</source> (<year>2011</year>) <volume>206</volume>:<fpage>92</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.forsciint.2010.06.030</pub-id><pub-id pub-id-type="pmid">20650576</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronstrand</surname><given-names>R</given-names></name><name><surname>Roman</surname><given-names>M</given-names></name><name><surname>Thelander</surname><given-names>G</given-names></name><name><surname>Eriksson</surname><given-names>A</given-names></name></person-group>. <article-title>Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend krypton</article-title>. <source>J Anal Toxicol</source> (<year>2011</year>) <volume>35</volume>:<fpage>242</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/anatox/35.4.242</pub-id><pub-id pub-id-type="pmid">21513619</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anwar</surname><given-names>M</given-names></name><name><surname>Law</surname><given-names>R</given-names></name><name><surname>Schier</surname><given-names>J</given-names></name></person-group><article-title>Notes from the field: Kratom (<italic>Mitragyna speciosa</italic>) exposures reported to poison centers – United States, 2010-2015</article-title>. <source>MMWR Morb Mortal Wkly Rep</source> (<year>2016</year>) <volume>65</volume>(<issue>29</issue>):<fpage>748</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.15585/mmwr.mm6529a4</pub-id><pub-id pub-id-type="pmid">27466822</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lydecker</surname><given-names>AG</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>McCurdy</surname><given-names>CR</given-names></name><name><surname>Avery</surname><given-names>BA</given-names></name><name><surname>Babu</surname><given-names>KM</given-names></name><name><surname>Boyer</surname><given-names>EW</given-names></name></person-group>. <article-title>Suspected adulteration of commercial Kratom products with 7-hydroxymitragynine</article-title>. <source>J Med Toxicol</source> (<year>2016</year>) <volume>12</volume>(<issue>4</issue>):<fpage>341</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s13181-016-0588-y</pub-id><pub-id pub-id-type="pmid">27752985</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shellard</surname><given-names>EJ</given-names></name></person-group><article-title>The alkaloids of <italic>Mitragyna</italic> with special reference to those of <italic>M. speciosa korth</italic></article-title>. <source>Bull Narc</source> (<year>1974</year>) <volume>26</volume>(<issue>2</issue>):<fpage>41</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">4607551</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusoff</surname><given-names>NHM</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Hassan</surname><given-names>Z</given-names></name></person-group><article-title>Opioid receptors mediate the acquisition, but not the expression of mitragynine-induced conditioned place preference in rats</article-title>. <source>Behav Brain Res</source> (<year>2017</year>) <volume>332</volume>:<fpage>1</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbr.2017.05.059</pub-id><pub-id pub-id-type="pmid">28559179</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Ohbayashi</surname><given-names>S</given-names></name><name><surname>Kitajima</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>SI</given-names></name><name><surname>Aimi</surname><given-names>N</given-names></name></person-group><article-title>The first total synthesis of (−)-mitragynine, an analgesic indole alkaloid in <italic>Mitragyna speciosa</italic></article-title>. <source>Tetrahed Lett</source> (<year>1995</year>) <volume>36</volume>:<fpage>9337</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1016/0040-4039(95)02022-H</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Cook</surname><given-names>JM</given-names></name></person-group><article-title>Total synthesis of the opioid agonistic indole alkaloid mitragynine and the first total syntheses of 9-methoxygeissoschizol and 9-methoxy-Nb-methylgeissoschizol</article-title>. <source>Organic Lett</source> (<year>2007</year>) <volume>9</volume>:<fpage>3491</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1021/ol071220l</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>WY</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Liao</surname><given-names>XB</given-names></name><name><surname>Cook</surname><given-names>JM</given-names></name></person-group><article-title>General approach to the total synthesis of 9-methoxy-substituted indole alkaloids: synthesis of mitragynine, as well as 9-methoxygeissoschizol and 9-methoxy-N-b-methylgeissoschizol</article-title>. <source>J Org Chem</source> (<year>2009</year>) <volume>74</volume>:<fpage>264</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1021/jo801839t</pub-id><pub-id pub-id-type="pmid">19046119</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Isabel</surname><given-names>K</given-names></name></person-group><source>Total Synthesis of (−)-Mitragynine and Analogues</source>. Master Thesis, <publisher-name>Universiteit van Amsterdam</publisher-name>, <publisher-loc>Amsterdam</publisher-loc> (<year>2012</year>).</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Ramanathan</surname><given-names>S</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name><name><surname>Adenan</surname><given-names>MI</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name><name><surname>Murugaiyah</surname><given-names>V</given-names></name></person-group>. <article-title>Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat</article-title>. <source>Anal Bioanal Chem</source> (<year>2010</year>) <volume>397</volume>:<fpage>2023</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1007/s00216-010-3707-7</pub-id><pub-id pub-id-type="pmid">20454783</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janchawee</surname><given-names>B</given-names></name><name><surname>Keawpradub</surname><given-names>N</given-names></name><name><surname>Chittrakarn</surname><given-names>S</given-names></name><name><surname>Prasettho</surname><given-names>S</given-names></name><name><surname>Wararatananurak</surname><given-names>P</given-names></name><name><surname>Sawangjareon</surname><given-names>K</given-names></name></person-group>. <article-title>A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats</article-title>. <source>Biomed Chromatogr</source> (<year>2007</year>) <volume>21</volume>:<fpage>176</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1002/bmc.731</pub-id><pub-id pub-id-type="pmid">17221920</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Moraes</surname><given-names>NV</given-names></name><name><surname>Moretti</surname><given-names>RA</given-names></name><name><surname>Furr</surname><given-names>EB</given-names><suffix>III</suffix></name><name><surname>McCurdy</surname><given-names>CR</given-names></name><name><surname>Lanchote</surname><given-names>VL</given-names></name></person-group>. <article-title>Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source> (<year>2009</year>) <volume>877</volume>:<fpage>2593</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.jchromb.2009.06.023</pub-id><pub-id pub-id-type="pmid">19589735</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanathan</surname><given-names>S</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Murugaiyah</surname><given-names>V</given-names></name><name><surname>Magosso</surname><given-names>E</given-names></name><name><surname>Tan</surname><given-names>SC</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name></person-group>. <article-title>Understanding the physicochemical properties of mitragynine, a principal alkaloid of <italic>Mitragyna speciosa</italic>, for preclinical evaluation</article-title>. <source>Molecules</source> (<year>2015</year>) <volume>20</volume>:<fpage>4915</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.3390/molecules20034915</pub-id><pub-id pub-id-type="pmid">25793541</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipp</surname><given-names>AA</given-names></name><name><surname>Wissenbach</surname><given-names>DK</given-names></name><name><surname>Zoerntlein</surname><given-names>SW</given-names></name><name><surname>Klein</surname><given-names>ON</given-names></name><name><surname>Kanogsunthornrat</surname><given-names>J</given-names></name><name><surname>Maurer</surname><given-names>HH</given-names></name></person-group>. <article-title>Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry</article-title>. <source>J Mass Spectrom</source> (<year>2009</year>) <volume>44</volume>:<fpage>1249</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1002/jms.1607</pub-id><pub-id pub-id-type="pmid">19536806</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipp</surname><given-names>AA</given-names></name><name><surname>Wissenbach</surname><given-names>DK</given-names></name><name><surname>Weber</surname><given-names>AA</given-names></name><name><surname>Zapp</surname><given-names>J</given-names></name><name><surname>Maurer</surname><given-names>HH</given-names></name></person-group><article-title>Phase I and II metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry</article-title>. <source>J Mass Spectrom</source> (<year>2010</year>) <volume>45</volume>:<fpage>1344</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1002/jms.1848</pub-id><pub-id pub-id-type="pmid">20967737</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philipp</surname><given-names>AA</given-names></name><name><surname>Wissenbach</surname><given-names>DK</given-names></name><name><surname>Weber</surname><given-names>AA</given-names></name><name><surname>Zapp</surname><given-names>J</given-names></name><name><surname>Zoerntlein</surname><given-names>SW</given-names></name><name><surname>Kanogsunthornrat</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Use of liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine</article-title>. <source>Anal Bioanal Chem</source> (<year>2010</year>) <volume>396</volume>:<fpage>2379</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1007/s00216-009-3239-1</pub-id><pub-id pub-id-type="pmid">19902190</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taufik Hidayat</surname><given-names>M</given-names></name><name><surname>Apryani</surname><given-names>E</given-names></name><name><surname>Nabishah</surname><given-names>BM</given-names></name><name><surname>Moklas</surname><given-names>MAA</given-names></name><name><surname>Sharida</surname><given-names>F</given-names></name><name><surname>Farhan</surname><given-names>MA</given-names></name></person-group><article-title>Determination of mitragynine bound opioid receptors</article-title>. <source>Adv Med Dent Sci</source> (<year>2010</year>) <volume>3</volume>:<fpage>65</fpage>–<lpage>70</lpage>.</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>LT</given-names></name><name><surname>Horie</surname><given-names>S</given-names></name><name><surname>Takayama</surname><given-names>H</given-names></name><name><surname>Aimi</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant <italic>Mitragyna speciosa</italic></article-title>. <source>Gen Pharmacol</source> (<year>1999</year>) <volume>33</volume>:<fpage>73</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/S0306-3623(98)00265-1</pub-id><pub-id pub-id-type="pmid">10428019</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Horie</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>LT</given-names></name></person-group>. <article-title>Inhibitory effect of mitragynine, an alkaloid with analgesic effect from Thai medicinal plant <italic>Mitragyna speciosa</italic>, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor</article-title>. <source>Life Sci</source> (<year>1997</year>) <volume>60</volume>:<fpage>933</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/S0024-3205(97)00023-4</pub-id><pub-id pub-id-type="pmid">9061050</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamima</surname><given-names>AR</given-names></name><name><surname>Fakurazi</surname><given-names>S</given-names></name><name><surname>Hidayat</surname><given-names>MT</given-names></name><name><surname>Hairuszah</surname><given-names>I</given-names></name><name><surname>Moklas</surname><given-names>MA</given-names></name><name><surname>Arulselvan</surname><given-names>P</given-names></name></person-group>. <article-title>Antinociceptive action of isolated mitragynine from <italic>Mitragyna speciosa</italic> through activation of opioid receptor system</article-title>. <source>Int J Mol Sci</source> (<year>2012</year>) <volume>13</volume>:<fpage>11427</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.3390/ijms130911427</pub-id><pub-id pub-id-type="pmid">23109863</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>LT</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>PK</given-names></name><etal></etal></person-group><article-title>Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens</article-title>. <source>Life Sci</source> (<year>2005</year>) <volume>78</volume>:<fpage>187</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/j.lfs.2005.04.042</pub-id><pub-id pub-id-type="pmid">16107269</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohda</surname><given-names>M</given-names></name><name><surname>Thongpraditchote</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><name><surname>Aimi</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Effects of mitragynine on cAMP formation mediated by delta-opiate receptors in NG108-15 cells</article-title>. <source>Biol Pharm Bull</source> (<year>1997</year>) <volume>20</volume>:<fpage>338</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1248/bpb.20.338</pub-id><pub-id pub-id-type="pmid">9145205</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamil</surname><given-names>MF</given-names></name><name><surname>Subki</surname><given-names>MF</given-names></name><name><surname>Lan</surname><given-names>TM</given-names></name><name><surname>Majid</surname><given-names>MI</given-names></name><name><surname>Adenan</surname><given-names>MI</given-names></name></person-group>. <article-title>The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell</article-title>. <source>J Ethnopharmacol</source> (<year>2013</year>) <volume>148</volume>:<fpage>135</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.jep.2013.03.078</pub-id><pub-id pub-id-type="pmid">23608241</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakurazi</surname><given-names>S</given-names></name><name><surname>Rahman</surname><given-names>SA</given-names></name><name><surname>Hidayat</surname><given-names>MT</given-names></name><name><surname>Ithnin</surname><given-names>H</given-names></name><name><surname>Moklas</surname><given-names>MA</given-names></name><name><surname>Arulselvan</surname><given-names>P</given-names></name></person-group>. <article-title>The combination of mitragynine and morphine prevents the development of morphine tolerance in mice</article-title>. <source>Molecules</source> (<year>2013</year>) <volume>18</volume>:<fpage>666</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.3390/molecules18010666</pub-id><pub-id pub-id-type="pmid">23292329</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reanmongkol</surname><given-names>W</given-names></name><name><surname>Keawpradub</surname><given-names>N</given-names></name><name><surname>Sawangjaroen</surname><given-names>K</given-names></name></person-group><article-title>Effects of the extracts from <italic>Mitragyna speciosa Korth</italic>. Leaves on analgesic and behavioral activities in experimental animals</article-title>. <source>Songkl J Sci Technol</source> (<year>2007</year>) <volume>29</volume>:<fpage>39</fpage>–<lpage>48</lpage>.</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabetghadam</surname><given-names>A</given-names></name><name><surname>Ramanathan</surname><given-names>S</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name></person-group>. <article-title>The evaluation of antinociceptive activity of alkaloid, methanolic, and aqueous extracts of Malaysian <italic>Mitragyna speciosa Korth</italic> leaves in rats</article-title>. <source>Pharmacognosy Res</source> (<year>2010</year>) <volume>2</volume>:<fpage>181</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.4103/0974-8490.65514</pub-id><pub-id pub-id-type="pmid">21808563</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaik Mossadeq</surname><given-names>WM</given-names></name><name><surname>Sulaiman</surname><given-names>MR</given-names></name><name><surname>Tengku Mohamad</surname><given-names>TA</given-names></name><name><surname>Chiong</surname><given-names>HS</given-names></name><name><surname>Zakaria</surname><given-names>ZA</given-names></name><name><surname>Jabit</surname><given-names>ML</given-names></name><etal></etal></person-group><article-title>Anti-inflammatory and antinociceptive effects of <italic>Mitragyna speciosa Korth</italic> methanolic extract</article-title>. <source>Med Princ Pract</source> (<year>2009</year>) <volume>18</volume>:<fpage>378</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1159/000226292</pub-id><pub-id pub-id-type="pmid">19648761</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Criddle</surname><given-names>CA</given-names></name></person-group><source>A Comparison of Mitragyna speciosa and Mitragynine against Opioids on Thermal Nociception in Rats</source>. (<year>2015</year>). Available from: <uri xlink:type="simple" xlink:href="http://thesis.honors.olemiss.edu">http://thesis.honors.olemiss.edu</uri></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>JM</given-names></name><name><surname>Criddle</surname><given-names>CA</given-names></name><name><surname>Craig</surname><given-names>HK</given-names></name><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Khan</surname><given-names>IA</given-names></name><etal></etal></person-group><article-title>Comparative effects of <italic>Mitragyna speciosa</italic> extract, mitragynine, and opioid agonists on thermal nociception in rats</article-title>. <source>Fitoterapia</source> (<year>2016</year>) <volume>109</volume>:<fpage>87</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.fitote.2015.12.001</pub-id><pub-id pub-id-type="pmid">26688378</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farah Idayu</surname><given-names>N</given-names></name><name><surname>Hidayat</surname><given-names>MT</given-names></name><name><surname>Moklas</surname><given-names>MA</given-names></name><name><surname>Sharida</surname><given-names>F</given-names></name><name><surname>Raudzah</surname><given-names>AR</given-names></name><name><surname>Shamima</surname><given-names>AR</given-names></name><etal></etal></person-group><article-title>Antidepressant-like effect of mitragynine isolated from <italic>Mitragyna speciosa Korth</italic> in mice model of depression</article-title>. <source>Phytomedicine</source> (<year>2011</year>) <volume>18</volume>:<fpage>402</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.phymed.2010.08.011</pub-id><pub-id pub-id-type="pmid">20869223</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarnsit</surname><given-names>E</given-names></name><name><surname>Vongvatcharanon</surname><given-names>U</given-names></name><name><surname>Keawpradub</surname><given-names>N</given-names></name><name><surname>Intasaro</surname><given-names>P</given-names></name></person-group>. <article-title>Fos-like immunoreactivity in rat dorsal raphe nuclei induced by alkaloid extract of <italic>Mitragyna speciosa</italic></article-title>. <source>Neurosci Lett</source> (<year>2007</year>) <volume>416</volume>:<fpage>128</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/j.neulet.2007.01.061</pub-id><pub-id pub-id-type="pmid">17316993</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitoh</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name></person-group>. <article-title>Antidepressant-like effects of δ opioid receptor agonists in animal models</article-title>. <source>Curr Neuropharmacol</source> (<year>2012</year>) <volume>10</volume>:<fpage>231</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.2174/157015912803217314</pub-id><pub-id pub-id-type="pmid">23449756</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusoff</surname><given-names>NHM</given-names></name><name><surname>Suhaimi</surname><given-names>FW</given-names></name><name><surname>Vadivelu</surname><given-names>RK</given-names></name><name><surname>Hassan</surname><given-names>Z</given-names></name><name><surname>Rümler</surname><given-names>A</given-names></name><name><surname>Rotter</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Abuse potential and adverse cognitive effects of mitragynine (Kratom)</article-title>. <source>Addict Biol</source> (<year>2016</year>) <volume>21</volume>:<fpage>98</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="doi">10.1111/adb.12185</pub-id><pub-id pub-id-type="pmid">25262913</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apryani</surname><given-names>E</given-names></name><name><surname>Hidayat</surname><given-names>MT</given-names></name><name><surname>Moklas</surname><given-names>MA</given-names></name><name><surname>Fakurazi</surname><given-names>S</given-names></name><name><surname>Idayu</surname><given-names>NF</given-names></name></person-group>. <article-title>Effects of mitragynine from <italic>Mitragyna speciosa Korth</italic> leaves on working memory</article-title>. <source>J Ethnopharmacol</source> (<year>2010</year>) <volume>129</volume>:<fpage>357</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1016/j.jep.2010.03.036</pub-id><pub-id pub-id-type="pmid">20371280</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazim</surname><given-names>AI</given-names></name><name><surname>Mustapha</surname><given-names>M</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name></person-group><article-title>The effects on motor behaviour and short-term memory tasks in mice following an acute administration of <italic>Mitragyna speciosa</italic> alkaloid extract and mitragynine</article-title>. <source>J Med Plants Res</source> (<year>2011</year>) <volume>5</volume>:<fpage>5810</fpage>–<lpage>7</lpage>.</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senik</surname><given-names>MH</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name><name><surname>John Tharakan</surname><given-names>KJ</given-names></name><name><surname>Abdullah</surname><given-names>JM</given-names></name></person-group><article-title>Effect of acute administration of <italic>Mitragyna speciosa Korth</italic>. Standardized methanol extract in animal model of learning and memory</article-title>. <source>J Med Plants Res</source> (<year>2012</year>) <volume>6</volume>:<fpage>1007</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="doi">10.5897/JMPR11.601</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>NIW</given-names></name><name><surname>Jayabalan</surname><given-names>N</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Muzaimi</surname><given-names>M</given-names></name></person-group>. <article-title>Chronic mitragynine (Kratom) enhances punishment resistance in natural reward seeking and impairs place learning in mice</article-title>. <source>Addict Biol</source> (<year>2017</year>) <volume>22</volume>:<fpage>967</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1111/adb.12385</pub-id><pub-id pub-id-type="pmid">26990882</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harun</surname><given-names>N</given-names></name><name><surname>Hassan</surname><given-names>Z</given-names></name><name><surname>Navaratnam</surname><given-names>V</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name><name><surname>Shoaib</surname><given-names>M</given-names></name></person-group>. <article-title>Discriminative stimulus properties of mitragynine (Kratom) in rats</article-title>. <source>Psychopharmacology</source> (<year>2015</year>) <volume>232</volume>:<fpage>2227</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-015-3866-5</pub-id><pub-id pub-id-type="pmid">25616583</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>DM</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Button</surname><given-names>J</given-names></name><name><surname>Ramsey</surname><given-names>J</given-names></name><name><surname>Archer</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Purchasing ‘legal highs’ on the Internet—is there consistency in what you get?</article-title><source>QJM</source> (<year>2010</year>) <volume>103</volume>(<issue>7</issue>):<fpage>489</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1093/qjmed/hcq056</pub-id><pub-id pub-id-type="pmid">20413562</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemp</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>M</given-names></name><name><surname>Dobbs</surname><given-names>T</given-names></name><name><surname>Galli</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>R</given-names></name></person-group><article-title>Top 10 facts you should know. Synthetic cannabinoids: not so nice spice</article-title>. <source>Am J Med</source> (<year>2016</year>) <volume>129</volume>(<issue>3</issue>):<fpage>240</fpage>–<lpage>4.e1</lpage>.<pub-id pub-id-type="doi">10.1016/j.amjmed.2015.10.008</pub-id><pub-id pub-id-type="pmid">26522795</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><collab>WHO</collab>. <article-title>Expert committee on drug dependence. Thirty-sixth report</article-title>. <source>World Health Organ Tech Rep Ser</source> (<year>2015</year>) <volume>991</volume>:<fpage>1</fpage>–<lpage>50</lpage>.</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>W</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name></person-group><article-title>High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis</article-title>. <source>Br Med J</source> (<year>2015</year>) <volume>350</volume>:<fpage>h1205</fpage><pub-id pub-id-type="doi">10.1136/bmj.h1205</pub-id><pub-id pub-id-type="pmid">25739398</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torjesen</surname><given-names>I</given-names></name></person-group><article-title>High potency cannabis is associated with tripled risk of psychosis, study indicates</article-title>. <source>Br Med J</source> (<year>2015</year>) <volume>350</volume>:<fpage>h939</fpage><pub-id pub-id-type="doi">10.1136/bmj.h939</pub-id><pub-id pub-id-type="pmid">25694180</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Forti</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><name><surname>Dazzan</surname><given-names>P</given-names></name><name><surname>Pariante</surname><given-names>C</given-names></name><name><surname>Mondelli</surname><given-names>V</given-names></name><name><surname>Marques</surname><given-names>TR</given-names></name><etal></etal></person-group><article-title>High-potency cannabis and the risk of psychosis</article-title>. <source>Br J Psychiatry</source> (<year>2009</year>) <volume>195</volume>(<issue>6</issue>):<fpage>488</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.bp.109.064220</pub-id><pub-id pub-id-type="pmid">19949195</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Forti</surname><given-names>M</given-names></name><name><surname>Sallis</surname><given-names>H</given-names></name><name><surname>Allegri</surname><given-names>F</given-names></name><name><surname>Trotta</surname><given-names>A</given-names></name><name><surname>Ferraro</surname><given-names>L</given-names></name><name><surname>Stilo</surname><given-names>SA</given-names></name><etal></etal></person-group><article-title>Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users</article-title>. <source>Schizophr Bull</source> (<year>2014</year>) <volume>40</volume>(<issue>6</issue>):<fpage>1509</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbt181</pub-id><pub-id pub-id-type="pmid">24345517</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>MB</given-names></name><name><surname>Kleinschmidt</surname><given-names>K</given-names></name><name><surname>Schwarz</surname><given-names>E</given-names></name><name><surname>Young</surname><given-names>A</given-names></name></person-group>. <article-title>Synthetic cannabinoid and marijuana exposures reported to poison centers</article-title>. <source>Hum Exp Toxicol</source> (<year>2012</year>) <volume>31</volume>(<issue>10</issue>):<fpage>1006</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1177/0960327111421945</pub-id><pub-id pub-id-type="pmid">22859662</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debruyne</surname><given-names>D</given-names></name><name><surname>Le Boisselier</surname><given-names>R</given-names></name></person-group>. <article-title>Emerging drugs of abuse: current perspectives on synthetic cannabinoids</article-title>. <source>Subst Abuse Rehabil</source> (<year>2015</year>) <volume>6</volume>:<fpage>113</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="doi">10.2147/SAR.S73586</pub-id><pub-id pub-id-type="pmid">26543389</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barratt</surname><given-names>MJ</given-names></name><name><surname>Potter</surname><given-names>GR</given-names></name><name><surname>Wouters</surname><given-names>M</given-names></name><name><surname>Wilkins</surname><given-names>C</given-names></name><name><surname>Werse</surname><given-names>B</given-names></name><name><surname>Perälä</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Lessons from conducting trans-national Internet-mediated participatory research with hidden populations of cannabis cultivators</article-title>. <source>Int J Drug Policy</source> (<year>2015</year>) <volume>26</volume>(<issue>3</issue>):<fpage>238</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugpo.2014.12.004</pub-id><pub-id pub-id-type="pmid">25576247</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurdal</surname><given-names>F</given-names></name><name><surname>Asirdizer</surname><given-names>M</given-names></name><name><surname>Aker</surname><given-names>RG</given-names></name><name><surname>Korkut</surname><given-names>S</given-names></name><name><surname>Gocer</surname><given-names>Y</given-names></name><name><surname>Kucukibrahimoglu</surname><given-names>EE</given-names></name><etal></etal></person-group><article-title>Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey</article-title>. <source>J Forensic Leg Med</source> (<year>2013</year>) <volume>20</volume>(<issue>6</issue>):<fpage>667</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/j.jflm.2013.03.041</pub-id><pub-id pub-id-type="pmid">23910858</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>B</given-names></name><name><surname>Yepes</surname><given-names>A</given-names></name><name><surname>Nugent</surname><given-names>K</given-names></name></person-group>. <article-title>Synthetic cannabinoids</article-title>. <source>Am J Med Sci</source> (<year>2015</year>) <volume>350</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1097/MAJ.0000000000000466</pub-id><pub-id pub-id-type="pmid">26132518</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadaria</surname><given-names>D</given-names></name><name><surname>Sinclair</surname><given-names>SE</given-names></name></person-group><article-title>A case of acute agitation with a negative urine drug screen: a new wave of legal drugs of abuse</article-title>. <source>Tenn Med</source> (<year>2012</year>) <volume>105</volume>(<issue>9</issue>):<fpage>31</fpage>–<lpage>2</lpage>.</mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>MF</given-names></name><name><surname>Hopper</surname><given-names>JA</given-names></name><name><surname>Gunderson</surname><given-names>EW</given-names></name></person-group>. <article-title>Designer drugs 2015: assessment and management</article-title>. <source>Addict Sci Clin Pract</source> (<year>2015</year>) <volume>10</volume>:<fpage>8</fpage>.<pub-id pub-id-type="doi">10.1186/s13722-015-0024-7</pub-id><pub-id pub-id-type="pmid">25928069</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khullar</surname><given-names>V</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Sattari</surname><given-names>M</given-names></name></person-group>. <article-title>Emergence of new classes of recreational drugs – synthetic cannabinoids and cathinones</article-title>. <source>J Gen Intern Med</source> (<year>2014</year>) <volume>29</volume>(<issue>8</issue>):<fpage>1200</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s11606-014-2802-4</pub-id><pub-id pub-id-type="pmid">24553958</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>MB</given-names></name><name><surname>Kleinschmidt</surname><given-names>K</given-names></name><name><surname>Schwarz</surname><given-names>E</given-names></name><name><surname>Young</surname><given-names>A</given-names></name></person-group>. <article-title>Synthetic cannabinoid exposures reported to Texas poison centers</article-title>. <source>J Addict Dis</source> (<year>2011</year>) <volume>30</volume>(<issue>4</issue>):<fpage>351</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1080/10550887.2011.609807</pub-id><pub-id pub-id-type="pmid">22026527</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>H</given-names></name><name><surname>Huttner</surname><given-names>HB</given-names></name><name><surname>Köhrmann</surname><given-names>M</given-names></name><name><surname>Wielopolski</surname><given-names>JE</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Sperling</surname><given-names>W</given-names></name></person-group><article-title>Panic attack after spice abuse in a patient with ADHD</article-title>. <source>Pharmacopsychiatry</source> (<year>2010</year>) <volume>43</volume>(<issue>4</issue>):<fpage>152</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1055/s-0029-1243252</pub-id><pub-id pub-id-type="pmid">20127596</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>H</given-names></name><name><surname>Sperling</surname><given-names>W</given-names></name><name><surname>Köhrmann</surname><given-names>M</given-names></name><name><surname>Huttner</surname><given-names>HB</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Maler</surname><given-names>JM</given-names></name></person-group><article-title>The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes</article-title>. <source>Schizophr Res</source> (<year>2010</year>) <volume>118</volume>(<issue>1–3</issue>):<fpage>309</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2009.12.001</pub-id><pub-id pub-id-type="pmid">20056392</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeffler</surname><given-names>G</given-names></name><name><surname>Delaney</surname><given-names>E</given-names></name><name><surname>Hann</surname><given-names>M</given-names></name></person-group>. <article-title>International trends in spice use: prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>(<issue>Pt 1</issue>):<fpage>8</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.04.013</pub-id><pub-id pub-id-type="pmid">27108542</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castaneto</surname><given-names>MS</given-names></name><name><surname>Gorelick</surname><given-names>DA</given-names></name><name><surname>Desrosiers</surname><given-names>NA</given-names></name><name><surname>Hartman</surname><given-names>RL</given-names></name><name><surname>Pirard</surname><given-names>S</given-names></name><name><surname>Huestis</surname><given-names>MA</given-names></name></person-group>. <article-title>Synthetic cannabinoids: epidemiology pharmacodynamics, and clinical implications</article-title>. <source>Drug Alcohol Depend</source> (<year>2014</year>) <volume>144</volume>:<fpage>12</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.08.005</pub-id><pub-id pub-id-type="pmid">25220897</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seely</surname><given-names>KA</given-names></name><name><surname>Lapoint</surname><given-names>J</given-names></name><name><surname>Moran</surname><given-names>JH</given-names></name><name><surname>Fattore</surname><given-names>L</given-names></name></person-group>. <article-title>Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2012</year>) <volume>39</volume>(<issue>2</issue>):<fpage>234</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.04.017</pub-id><pub-id pub-id-type="pmid">22561602</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trecki</surname><given-names>J</given-names></name><name><surname>Gerona</surname><given-names>RR</given-names></name><name><surname>Schwartz</surname><given-names>MD</given-names></name></person-group><article-title>Synthetic cannabinoid-related illnesses and deaths</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>373</volume>:<fpage>103</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMp1505328</pub-id><pub-id pub-id-type="pmid">26154784</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>JL</given-names></name><name><surname>Marusich</surname><given-names>JA</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Huffman</surname><given-names>JW</given-names></name></person-group>. <article-title>1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice</article-title>. <source>Drug Alcohol Depend</source> (<year>2012</year>) <volume>123</volume>(<issue>1–3</issue>):<fpage>148</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.11.001</pub-id><pub-id pub-id-type="pmid">22127210</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>L</given-names></name><name><surname>Schiebel</surname><given-names>HM</given-names></name><name><surname>Theuring</surname><given-names>C</given-names></name><name><surname>Lindigkeit</surname><given-names>R</given-names></name><name><surname>Beuerle</surname><given-names>T</given-names></name></person-group><article-title>Identification and characterization of JWH-122 used as new ingredient in spice-like herbal incenses</article-title>. <source>Forensic Sci Int</source> (<year>2011</year>) <volume>208</volume>(<issue>1–3</issue>):<fpage>e31</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.forsciint.2011.03.020</pub-id><pub-id pub-id-type="pmid">21482054</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musshoff</surname><given-names>F</given-names></name><name><surname>Hottmann</surname><given-names>L</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Madea</surname><given-names>B</given-names></name></person-group><article-title>Legal highs from the German Internet—bath salt drugs on the rise</article-title>. <source>Arch Kriminol</source> (<year>2013</year>) <volume>232</volume>(<issue>3–4</issue>):<fpage>91</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">24358620</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillebrand</surname><given-names>J</given-names></name><name><surname>Olszewski</surname><given-names>D</given-names></name><name><surname>Sedefov</surname><given-names>R</given-names></name></person-group>. <article-title>Legal highs on the Internet</article-title>. <source>Subst Use Misuse</source> (<year>2010</year>) <volume>45</volume>(<issue>3</issue>):<fpage>330</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.3109/10826080903443628</pub-id><pub-id pub-id-type="pmid">20141450</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Möller</surname><given-names>I</given-names></name><name><surname>Wintermeyer</surname><given-names>A</given-names></name><name><surname>Bender</surname><given-names>K</given-names></name><name><surname>Jübner</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Krug</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls</article-title>. <source>Drug Test Anal</source> (<year>2011</year>) <volume>3</volume>(<issue>9</issue>):<fpage>609</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1002/dta.158</pub-id><pub-id pub-id-type="pmid">20872894</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strano-Rossi</surname><given-names>S</given-names></name><name><surname>Anzillotti</surname><given-names>L</given-names></name><name><surname>Castrignanò</surname><given-names>E</given-names></name><name><surname>Romolo</surname><given-names>FS</given-names></name><name><surname>Chiarotti</surname><given-names>M</given-names></name></person-group><article-title>Ultra high performance liquid chromatography–electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, spice and stimulants in oral fluid</article-title>. <source>J Chromatogr A</source> (<year>2012</year>) <volume>1258</volume>:<fpage>37</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.chroma.2012.07.098</pub-id><pub-id pub-id-type="pmid">22939380</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>S</given-names></name><name><surname>Ramsey</surname><given-names>J</given-names></name></person-group>. <article-title>The emergence and analysis of synthetic cannabinoids</article-title>. <source>Drug Test Anal</source> (<year>2011</year>) <volume>3</volume>(<issue>7–8</issue>):<fpage>466</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="doi">10.1002/dta.268</pub-id><pub-id pub-id-type="pmid">21337724</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundström</surname><given-names>M</given-names></name><name><surname>Pelander</surname><given-names>A</given-names></name><name><surname>Angerer</surname><given-names>V</given-names></name><name><surname>Hutter</surname><given-names>M</given-names></name><name><surname>Kneisel</surname><given-names>S</given-names></name><name><surname>Ojanperä</surname><given-names>I</given-names></name></person-group><article-title>A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC–HR–TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine</article-title>. <source>Anal Bioanal Chem</source> (<year>2013</year>) <volume>405</volume>(<issue>26</issue>):<fpage>8463</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1007/s00216-013-7272-8</pub-id><pub-id pub-id-type="pmid">23954996</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabenauer</surname><given-names>M</given-names></name><name><surname>Krol</surname><given-names>WL</given-names></name><name><surname>Wiley</surname><given-names>JL</given-names></name><name><surname>Thomas</surname><given-names>BF</given-names></name></person-group>. <article-title>Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for non targeted screening of designer drugs</article-title>. <source>Anal Chem</source> (<year>2012</year>) <volume>84</volume>(<issue>13</issue>):<fpage>5574</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1021/ac300509h</pub-id><pub-id pub-id-type="pmid">22724537</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller-Vahl</surname><given-names>K</given-names></name><name><surname>Grotenhermen</surname><given-names>F</given-names></name></person-group><article-title>Cannabis therapy</article-title>. <source>Dtsch Arztebl Int</source> (<year>2013</year>) <volume>110</volume>(<issue>9</issue>):<fpage>144</fpage><pub-id pub-id-type="doi">10.3238/arztebl.2013.0144a</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotenhermen</surname><given-names>F</given-names></name></person-group>. <article-title>Pharmacology of cannabinoids</article-title>. <source>Neuro Endocrinol Lett</source> (<year>2004</year>) <volume>25</volume>(<issue>1–2</issue>):<fpage>14</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">15159677</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotenhermen</surname><given-names>F</given-names></name></person-group>. <article-title>Cannabinoids</article-title>. <source>Curr Drug Targets CNS Neurol Disord</source> (<year>2005</year>) <volume>4</volume>(<issue>5</issue>):<fpage>507</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.2174/156800705774322111</pub-id><pub-id pub-id-type="pmid">16266285</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunderson</surname><given-names>EW</given-names></name></person-group><article-title>Synthetic cannabinoids: a new frontier of designer drugs</article-title>. <source>Ann Intern Med</source> (<year>2013</year>) <volume>159</volume>(<issue>8</issue>):<fpage>563</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.7326/0003-4819-159-8-201310150-00707</pub-id><pub-id pub-id-type="pmid">24018791</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>CD</given-names></name><name><surname>Carreiro</surname><given-names>SP</given-names></name><name><surname>Babu</surname><given-names>KM</given-names></name></person-group><article-title>Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), Kratom, <italic>Salvia divinorum</italic>, methoxetamine, and piperazines</article-title>. <source>J Med Toxicol</source> (<year>2012</year>) <volume>8</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1007/s13181-011-0202-2</pub-id><pub-id pub-id-type="pmid">22271566</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penders</surname><given-names>T</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name></person-group><article-title>Synthetic cannabinoids and bath salts should be considered drugs of abuse</article-title>. <source>Am Fam Physician</source> (<year>2012</year>) <volume>85</volume>(<issue>9</issue>):<fpage>852</fpage>.<pub-id pub-id-type="pmid">22612177</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuinness</surname><given-names>TM</given-names></name><name><surname>Newell</surname><given-names>D</given-names></name></person-group>. <article-title>Risky recreation: synthetic cannabinoids have dangerous effects</article-title>. <source>J Psychosoc Nurs Ment Health Serv</source> (<year>2012</year>) <volume>50</volume>(<issue>8</issue>):<fpage>16</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.3928/02793695-20120703-04</pub-id><pub-id pub-id-type="pmid">22801822</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhanushali</surname><given-names>GK</given-names></name><name><surname>Jain</surname><given-names>G</given-names></name><name><surname>Fatima</surname><given-names>H</given-names></name><name><surname>Leisch</surname><given-names>LJ</given-names></name><name><surname>Thornley-Brown</surname><given-names>D</given-names></name></person-group><article-title>AKI associated with synthetic cannabinoids: a case series</article-title>. <source>Clin J Am Soc Nephrol</source> (<year>2013</year>) <volume>8</volume>(<issue>4</issue>):<fpage>523</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.2215/CJN.05690612</pub-id><pub-id pub-id-type="pmid">23243266</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Veer</surname><given-names>N</given-names></name><name><surname>Friday</surname><given-names>J</given-names></name></person-group><article-title>Persistent psychosis following the use of spice</article-title>. <source>Schizophr Res</source> (<year>2011</year>) <volume>130</volume>(<issue>1–3</issue>):<fpage>285</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2011.04.022</pub-id><pub-id pub-id-type="pmid">21602030</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brakoulias</surname><given-names>V</given-names></name></person-group><article-title>Products containing synthetic cannabinoids and psychosis</article-title>. <source>Aust N Z J Psychiatry</source> (<year>2012</year>) <volume>46</volume>(<issue>3</issue>):<fpage>281</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1177/0004867411433974</pub-id><pub-id pub-id-type="pmid">22391292</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinwala</surname><given-names>FN</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name></person-group>. <article-title>Synthetic cannabis and respiratory depression</article-title>. <source>J Child Adolesc Psychopharmacol</source> (<year>2012</year>) <volume>22</volume>(<issue>6</issue>):<fpage>459</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1089/cap.2011.0122</pub-id><pub-id pub-id-type="pmid">23234589</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>CR</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name></person-group>. <article-title>Synthetic cannabinoid intoxication: a case series and review</article-title>. <source>J Emerg Med</source> (<year>2013</year>) <volume>44</volume>(<issue>2</issue>):<fpage>360</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.jemermed.2012.07.061</pub-id><pub-id pub-id-type="pmid">22989695</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oluwabusi</surname><given-names>OO</given-names></name><name><surname>Lobach</surname><given-names>L</given-names></name><name><surname>Akhtar</surname><given-names>U</given-names></name><name><surname>Youngman</surname><given-names>B</given-names></name><name><surname>Ambrosini</surname><given-names>PJ</given-names></name></person-group><article-title>Synthetic cannabinoid-induced psychosis: two adolescent cases</article-title>. <source>J Child Adolesc Psychopharmacol</source> (<year>2012</year>) <volume>22</volume>(<issue>5</issue>):<fpage>393</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1089/cap.2012.0004</pub-id><pub-id pub-id-type="pmid">23083027</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goshgarian</surname><given-names>AM</given-names></name><name><surname>Benford</surname><given-names>DM</given-names></name><name><surname>Caplan</surname><given-names>JP</given-names></name></person-group><article-title>Bath salt abuse: neuropsychiatric effects of cathinone derivatives</article-title>. <source>Psychosomatics</source> (<year>2011</year>) <volume>52</volume>(<issue>6</issue>):<fpage>593</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.psym.2011.03.003</pub-id><pub-id pub-id-type="pmid">22054633</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benford</surname><given-names>DM</given-names></name><name><surname>Caplan</surname><given-names>JP</given-names></name></person-group><article-title>Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists</article-title>. <source>Psychosomatics</source> (<year>2011</year>) <volume>52</volume>(<issue>3</issue>):<fpage>295</fpage><pub-id pub-id-type="doi">10.1016/j.psym.2011.01.004</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>MB</given-names></name><name><surname>Haywood</surname><given-names>T</given-names></name></person-group>. <article-title>Geographic distribution of synthetic cannabinoid exposures reported to Texas poison centers</article-title>. <source>Am J Drug Alcohol Abuse</source> (<year>2012</year>) <volume>38</volume>(<issue>6</issue>):<fpage>603</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.3109/00952990.2012.670339</pub-id><pub-id pub-id-type="pmid">22571605</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>MB</given-names></name></person-group>. <article-title>Adolescent synthetic cannabinoid exposures reported to Texas poison centers</article-title>. <source>Pediatr Emerg Care</source> (<year>2012</year>) <volume>28</volume>(<issue>10</issue>):<fpage>985</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1097/PEC.0b013e31826c9a97</pub-id><pub-id pub-id-type="pmid">23023462</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>D</given-names></name><name><surname>Delgado</surname><given-names>LL</given-names></name><name><surname>de la Parra-Pellot</surname><given-names>DM</given-names></name><name><surname>Nichols-Vinueza</surname><given-names>D</given-names></name></person-group>. <article-title>Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report</article-title>. <source>Clin Schizophr Relat Psychoses</source> (<year>2015</year>) <volume>8</volume>(<issue>4</issue>):<fpage>205</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.3371/CSRP.DUDE.031513</pub-id><pub-id pub-id-type="pmid">23518784</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>D</given-names></name><name><surname>Loeffler</surname><given-names>G</given-names></name><name><surname>McLay</surname><given-names>R</given-names></name></person-group><article-title>Psychosis associated with synthetic cannabinoid agonists: a case series</article-title>. <source>Am J Psychiatry</source> (<year>2011</year>) <volume>168</volume>(<issue>10</issue>):<fpage>1119</fpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2011.11010176</pub-id><pub-id pub-id-type="pmid">21969050</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshell</surname><given-names>R</given-names></name><name><surname>Kearney-Ramos</surname><given-names>T</given-names></name><name><surname>Brents</surname><given-names>LK</given-names></name><name><surname>Hyatt</surname><given-names>WS</given-names></name><name><surname>Tai</surname><given-names>S</given-names></name><name><surname>Prather</surname><given-names>PL</given-names></name><etal></etal></person-group><article-title>In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid delta9-THC in mice: inhalation versus intraperitoneal injection</article-title>. <source>Pharmacol Biochem Behav</source> (<year>2014</year>) <volume>124</volume>:<fpage>40</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.pbb.2014.05.010</pub-id><pub-id pub-id-type="pmid">24857780</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brents</surname><given-names>LK</given-names></name><name><surname>Prather</surname><given-names>PL</given-names></name></person-group>. <article-title>The K2/spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products</article-title>. <source>Drug Metab Rev</source> (<year>2014</year>) <volume>46</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.3109/03602532.2013.839700</pub-id><pub-id pub-id-type="pmid">24063277</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auwärter</surname><given-names>V</given-names></name><name><surname>Dresen</surname><given-names>S</given-names></name><name><surname>Weinmann</surname><given-names>W</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Pütz</surname><given-names>M</given-names></name><name><surname>Ferreirós</surname><given-names>N</given-names></name></person-group><article-title>‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?</article-title><source>J Mass Spectrom</source> (<year>2009</year>) <volume>44</volume>(<issue>5</issue>):<fpage>832</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1002/jms.1558</pub-id><pub-id pub-id-type="pmid">19189348</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoryev</surname><given-names>A</given-names></name><name><surname>Savchuk</surname><given-names>S</given-names></name><name><surname>Melnik</surname><given-names>A</given-names></name><name><surname>Moskaleva</surname><given-names>N</given-names></name><name><surname>Dzhurko</surname><given-names>J</given-names></name><name><surname>Ershov</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Chromatography–mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source> (<year>2011</year>) <volume>879</volume>(<issue>15–16</issue>):<fpage>1126</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1016/j.jchromb.2011.07.004</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoryev</surname><given-names>A</given-names></name><name><surname>Kavanagh</surname><given-names>P</given-names></name><name><surname>Melnik</surname><given-names>A</given-names></name></person-group><article-title>The detection of the urinary metabolites of 3-[(adamantan-1-yl) carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography–mass spectrometry</article-title>. <source>Drug Test Anal</source> (<year>2012</year>) <volume>4</volume>(<issue>6</issue>):<fpage>519</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1002/dta.350</pub-id><pub-id pub-id-type="pmid">22102533</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoryev</surname><given-names>A</given-names></name><name><surname>Kavanagh</surname><given-names>P</given-names></name><name><surname>Melnik</surname><given-names>A</given-names></name></person-group><article-title>The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl) methanone(AM-694): a high affinity cannabimimetic, by gas chromatography–mass spectrometry</article-title>. <source>Drug Test Anal</source> (<year>2013</year>) <volume>5</volume>(<issue>2</issue>):<fpage>110</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1002/dta.1336</pub-id><pub-id pub-id-type="pmid">22522907</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>A</given-names></name><name><surname>Rangel-López</surname><given-names>E</given-names></name><name><surname>Hidalgo-Miranda</surname><given-names>A</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Ruiz-García</surname><given-names>E</given-names></name><name><surname>Meneses-García</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>On the effects of CP 55-940 and other cannabinoid receptor agonists in C6 and U373 cell lines</article-title>. <source>Toxicol In Vitro</source> (<year>2015</year>) <volume>29</volume>(<issue>7</issue>):<fpage>1941</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1016/j.tiv.2015.08.003</pub-id><pub-id pub-id-type="pmid">26255146</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latorre</surname><given-names>JG</given-names></name><name><surname>Schmidt</surname><given-names>EB</given-names></name></person-group>. <article-title>Cannabis, cannabinoids, and cerebral metabolism: potential applications in stroke and disorders of the central nervous system</article-title>. <source>Curr Cardiol Rep</source> (<year>2015</year>) <volume>17</volume>(<issue>9</issue>):<fpage>627</fpage>.<pub-id pub-id-type="doi">10.1007/s11886-015-0627-3</pub-id><pub-id pub-id-type="pmid">26238742</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soderstrom</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name></person-group><article-title>CB(1) cannabinoid receptor activation dose dependently modulates neuronal activity within caudal but not rostral song control regions of adult Zebra finch telencephalon</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2008</year>) <volume>199</volume>(<issue>2</issue>):<fpage>265</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-008-1190-z</pub-id><pub-id pub-id-type="pmid">18509622</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>YY</given-names></name><name><surname>D’Agostino</surname><given-names>B</given-names></name><name><surname>Risse</surname><given-names>PA</given-names></name><name><surname>Marrocco</surname><given-names>G</given-names></name><name><surname>Naline</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux</article-title>. <source>Eur J Pharmacol</source> (<year>2007</year>) <volume>573</volume>(<issue>1–3</issue>):<fpage>206</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejphar.2007.06.040</pub-id><pub-id pub-id-type="pmid">17643417</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>ML</given-names></name><name><surname>Haller</surname><given-names>VL</given-names></name><name><surname>Welch</surname><given-names>SP</given-names></name></person-group>. <article-title>The antinociceptive effect of delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2)cannabinoid receptor</article-title>. <source>Eur J Pharmacol</source> (<year>2007</year>) <volume>570</volume>(<issue>1–3</issue>):<fpage>50</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejphar.2007.05.024</pub-id><pub-id pub-id-type="pmid">17588560</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darmani</surname><given-names>NA</given-names></name></person-group>. <article-title>Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A</article-title>. <source>Neuropsychopharmacology</source> (<year>2001</year>) <volume>24</volume>(<issue>2</issue>):<fpage>198</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="doi">10.1016/S0893-133X(00)00197-4</pub-id><pub-id pub-id-type="pmid">11120402</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acquas</surname><given-names>E</given-names></name><name><surname>Pisanu</surname><given-names>A</given-names></name><name><surname>Marrocu</surname><given-names>P</given-names></name><name><surname>Di Chiara</surname><given-names>G</given-names></name></person-group>. <article-title>Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo</article-title>. <source>Eur J Pharmacol</source> (<year>2000</year>) <volume>401</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/S0014-2999(00)00403-9</pub-id><pub-id pub-id-type="pmid">10924924</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>NE</given-names></name><name><surname>McCoy</surname><given-names>KL</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name><name><surname>Bonner</surname><given-names>T</given-names></name><name><surname>Zimmer</surname><given-names>A</given-names></name><name><surname>Felder</surname><given-names>CC</given-names></name><etal></etal></person-group><article-title>Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor</article-title>. <source>Eur J Pharmacol</source> (<year>2000</year>) <volume>396</volume>(<issue>2–3</issue>):<fpage>141</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0014-2999(00)00211-9</pub-id><pub-id pub-id-type="pmid">10822068</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>E</given-names></name></person-group><article-title>Alarm over synthetic cannabinoids</article-title>. <source>Science</source> (<year>2015</year>) <volume>347</volume>(<issue>6221</issue>):<fpage>473</fpage><pub-id pub-id-type="doi">10.1126/science.347.6221.473</pub-id><pub-id pub-id-type="pmid">25635070</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonaro</surname><given-names>TM</given-names></name><name><surname>Gatch</surname><given-names>MB</given-names></name></person-group>. <article-title>Neuropharmacology of <italic>N,N</italic>-dimethyltryptamine</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>:<fpage>74</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.04.016</pub-id><pub-id pub-id-type="pmid">27126737</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>R</given-names></name></person-group><source>DMT: The Spirit Molecule. A Doctor’s Revolutionary Research into the Biology of Near Death and Mystical Experiences</source>. <publisher-loc>United States</publisher-loc>: <publisher-name>Park Street Press</publisher-name> (<year>2001</year>).</mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>JC</given-names></name><name><surname>Raymon</surname><given-names>LP</given-names></name><name><surname>Hearn</surname><given-names>WL</given-names></name><name><surname>McKenna</surname><given-names>DJ</given-names></name><name><surname>Grob</surname><given-names>CS</given-names></name><name><surname>Brito</surname><given-names>GS</given-names></name><etal></etal></person-group><article-title>Quantitation of <italic>N,N</italic>-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca</article-title>. <source>J Anal Toxicol</source> (<year>1996</year>) <volume>20</volume>:<fpage>492</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/jat/20.6.492</pub-id><pub-id pub-id-type="pmid">8889686</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>J</given-names></name></person-group>. <article-title>Pharmahuasca: human pharmacology of oral DMT plus harmine</article-title>. <source>J Psychoactive Drugs</source> (<year>1999</year>) <volume>31</volume>(<issue>2</issue>):<fpage>171</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.1999.10471741</pub-id><pub-id pub-id-type="pmid">10438001</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallach</surname><given-names>JV</given-names></name></person-group>. <article-title>Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception</article-title>. <source>Med Hypotheses</source> (<year>2009</year>) <volume>72</volume>:<fpage>91</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.mehy.2008.07.052</pub-id><pub-id pub-id-type="pmid">18805646</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>SA</given-names></name><name><surname>Borjigin</surname><given-names>J</given-names></name><name><surname>Lomnicka</surname><given-names>I</given-names></name><name><surname>Strassman</surname><given-names>R</given-names></name></person-group><article-title>LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors and major metabolites in rat pineal gland microdialysate</article-title>. <source>Biomed Chromatogr</source> (<year>2013</year>) <volume>27</volume>:<fpage>1690</fpage>–<lpage>700</lpage>.<pub-id pub-id-type="doi">10.1002/bmc.2981</pub-id><pub-id pub-id-type="pmid">23881860</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christian</surname><given-names>ST</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Quayle</surname><given-names>E</given-names></name><name><surname>Pagel</surname><given-names>J</given-names></name><name><surname>Monti</surname><given-names>J</given-names></name></person-group><article-title>The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent</article-title>. <source>Biochem Med</source> (<year>1977</year>) <volume>18</volume>:<fpage>164</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1016/0006-2944(77)90088-6</pub-id><pub-id pub-id-type="pmid">20877</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keiser</surname><given-names>MJ</given-names></name><name><surname>Setola</surname><given-names>V</given-names></name><name><surname>Irwin</surname><given-names>JJ</given-names></name><name><surname>Laggner</surname><given-names>C</given-names></name><name><surname>Abbas</surname><given-names>AI</given-names></name><name><surname>Hufeisen</surname><given-names>SJ</given-names></name><etal></etal></person-group><article-title>Predicting new molecular targets for known drugs</article-title>. <source>Nature</source> (<year>2009</year>) <volume>462</volume>:<fpage>175</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1038/nature08506</pub-id><pub-id pub-id-type="pmid">19881490</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>DJ</given-names></name></person-group>. <article-title>Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges</article-title>. <source>Pharmacol Ther</source> (<year>2004</year>) <volume>102</volume>:<fpage>111</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.03.002</pub-id><pub-id pub-id-type="pmid">15163593</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>RG</given-names></name><name><surname>Valle</surname><given-names>M</given-names></name><name><surname>Bouso</surname><given-names>JC</given-names></name><name><surname>Nomdedéu</surname><given-names>JF</given-names></name><name><surname>Rodríguez-Espinosa</surname><given-names>J</given-names></name><name><surname>McIlhenny</surname><given-names>EH</given-names></name><etal></etal></person-group><article-title>Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine</article-title>. <source>J Clin Psychopharmacol</source> (<year>2011</year>) <volume>31</volume>:<fpage>717</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1097/JCP.0b013e31823607f6</pub-id><pub-id pub-id-type="pmid">22005052</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>RG</given-names></name><name><surname>Grasa</surname><given-names>E</given-names></name><name><surname>Valle</surname><given-names>M</given-names></name><name><surname>Ballester</surname><given-names>MR</given-names></name><name><surname>Bouso</surname><given-names>JC</given-names></name><name><surname>Nomdedéu</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Pharmacology of ayahuasca administered in two repeated doses</article-title>. <source>Psychopharmacology</source> (<year>2012</year>) <volume>219</volume>:<fpage>1039</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-011-2434-x</pub-id><pub-id pub-id-type="pmid">21842159</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Halberstadt</surname><given-names>AL</given-names></name><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><article-title>Serotonin and serotonin receptors in hallucinogen action</article-title>. In: <person-group person-group-type="editor"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Jacobs</surname><given-names>BL</given-names></name></person-group>, editors. <source>Handbook of the Behavioral Neurobiology of Serotonin</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2010</year>). p. <fpage>621</fpage>–<lpage>36</lpage>.</mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonaro</surname><given-names>TM</given-names></name><name><surname>Eshleman</surname><given-names>AJ</given-names></name><name><surname>Forster</surname><given-names>MJ</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name><name><surname>Gatch</surname><given-names>MB</given-names></name></person-group>. <article-title>The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens <italic>N,N-</italic>dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice</article-title>. <source>Psychopharmacology</source> (<year>2015</year>) <volume>232</volume>:<fpage>275</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-014-3658-3</pub-id><pub-id pub-id-type="pmid">24985890</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JM</given-names></name><name><surname>Pieper</surname><given-names>WA</given-names></name></person-group><article-title>The effects of <italic>N,N-</italic>dimethyltryptamine on operant behaviour in squirrel monkeys</article-title>. <source>Psychopharmacology</source> (<year>1973</year>) <volume>29</volume>:<fpage>107</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1007/BF00422642</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>RJ</given-names></name><name><surname>Qualls</surname><given-names>CR</given-names></name><name><surname>Berg</surname><given-names>LM</given-names></name></person-group>. <article-title>Differential tolerance to biological and subjective effects of four closely spaced doses of <italic>N,N</italic>-dimethyltryptamine in humans</article-title>. <source>Biol Psychiatry</source> (<year>1996</year>) <volume>39</volume>:<fpage>784</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1016/0006-3223(95)00200-6</pub-id><pub-id pub-id-type="pmid">8731519</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>RA</given-names></name><name><surname>Young</surname><given-names>R</given-names></name><name><surname>Jacyno</surname><given-names>JM</given-names></name><name><surname>Slusher</surname><given-names>M</given-names></name><name><surname>Rosecrans</surname><given-names>JA</given-names></name></person-group>. <article-title>DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines</article-title>. <source>Eur J Pharmacol</source> (<year>1983</year>) <volume>86</volume>:<fpage>453</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/0014-2999(83)90196-6</pub-id><pub-id pub-id-type="pmid">6572591</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>RA</given-names></name></person-group>. <article-title>Discriminative stimulus properties of phenylisopropylamine derivatives</article-title>. <source>Drug Alcohol Depend</source> (<year>1986</year>) <volume>17</volume>:<fpage>119</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/0376-8716(86)90003-7</pub-id><pub-id pub-id-type="pmid">2874967</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riba</surname><given-names>J</given-names></name><name><surname>Rodríguez-Fornells</surname><given-names>A</given-names></name><name><surname>Urbano</surname><given-names>G</given-names></name><name><surname>Morte</surname><given-names>A</given-names></name><name><surname>Antonijoan</surname><given-names>R</given-names></name><name><surname>Montero</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers</article-title>. <source>Psychopharmacology</source> (<year>2001</year>) <volume>154</volume>:<fpage>85</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1007/s002130000606</pub-id><pub-id pub-id-type="pmid">11292011</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frecska</surname><given-names>E</given-names></name></person-group><article-title>Ayahuasca versus violence – a case report</article-title>. <source>Neuropsychopharmacol Hung</source> (<year>2008</year>) <volume>10</volume>(<issue>2</issue>):<fpage>103</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18959142</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frecska</surname><given-names>E</given-names></name><name><surname>Bokor</surname><given-names>P</given-names></name><name><surname>Winkelman</surname><given-names>M</given-names></name></person-group>. <article-title>The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization</article-title>. <source>Front Pharmacol</source> (<year>2016</year>) <volume>7</volume>:<fpage>35</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2016.00035</pub-id><pub-id pub-id-type="pmid">26973523</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Frecska</surname><given-names>E</given-names></name></person-group><article-title>Dimethyltrypt-amine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?</article-title><source>Neural Regen Res</source> (<year>2016</year>) <volume>11</volume>(<issue>3</issue>):<fpage>396</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.4103/1673-5374.179041</pub-id><pub-id pub-id-type="pmid">27127466</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Fontanilla</surname><given-names>D</given-names></name><name><surname>Gopalakrishnan</surname><given-names>A</given-names></name><name><surname>Chae</surname><given-names>YK</given-names></name><name><surname>Markley</surname><given-names>JL</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group>. <article-title>The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements</article-title>. <source>Eur J Pharmacol</source> (<year>2012</year>) <volume>682</volume>:<fpage>12</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejphar.2012.01.030</pub-id><pub-id pub-id-type="pmid">22381068</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frecska</surname><given-names>E</given-names></name><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Winkelman</surname><given-names>MJ</given-names></name><name><surname>Luna</surname><given-names>LE</given-names></name><name><surname>McKenna</surname><given-names>DJ</given-names></name></person-group><article-title>A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity</article-title>. <source>J Neural Transm</source> (<year>2013</year>) <volume>120</volume>:<fpage>1295</fpage>–<lpage>303</lpage>.<pub-id pub-id-type="doi">10.1007/s00702-013-1024-y</pub-id><pub-id pub-id-type="pmid">23619992</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Halberstadt</surname><given-names>AL</given-names></name></person-group><article-title>Serotonin and schizophrenia</article-title>. In: <person-group person-group-type="editor"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Jacobs</surname><given-names>BL</given-names></name></person-group>, editors. <source>Handbook of the Behavioral Neurobiology of Serotonin</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2010</year>). p. <fpage>585</fpage>–<lpage>620</lpage>.</mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Checkley</surname><given-names>SA</given-names></name><name><surname>Murray</surname><given-names>RM</given-names></name><name><surname>Oon</surname><given-names>MC</given-names></name><name><surname>Rodnight</surname><given-names>R</given-names></name><name><surname>Birley</surname><given-names>JL</given-names></name></person-group><article-title>A longitudinal study of urinary excretion of <italic>N, N</italic>-dimethyltryptamine in psychotic patients</article-title>. <source>Br J Psychiatry</source> (<year>1980</year>) <volume>137</volume>:<fpage>236</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.137.3.236</pub-id><pub-id pub-id-type="pmid">6777009</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osório Fde</surname><given-names>L</given-names></name><name><surname>Sanches</surname><given-names>RF</given-names></name><name><surname>Macedo</surname><given-names>LR</given-names></name><name><surname>Santos</surname><given-names>RG</given-names></name><name><surname>Maia-de-Oliveira</surname><given-names>JP</given-names></name><name><surname>Wichert-Ana</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report</article-title>. <source>Rev Bras Psiquiatr</source> (<year>2015</year>) <volume>37</volume>:<fpage>13</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1590/1516-4446-2014-1496</pub-id><pub-id pub-id-type="pmid">25806551</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>MS</given-names></name><name><surname>Presti</surname><given-names>DE</given-names></name></person-group>. <article-title>Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine</article-title>. <source>Med Hypotheses</source> (<year>2005</year>) <volume>64</volume>:<fpage>930</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.mehy.2004.11.005</pub-id><pub-id pub-id-type="pmid">15780487</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenberg</surname><given-names>EE</given-names></name></person-group>. <article-title>Ayahuasca and cancer treatment</article-title>. <source>SAGE Open Med</source> (<year>2013</year>) <volume>1</volume>:<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1177/2050312113508389</pub-id><pub-id pub-id-type="pmid">26770688</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derocq</surname><given-names>JM</given-names></name><name><surname>Bourrié</surname><given-names>B</given-names></name><name><surname>Ségui</surname><given-names>M</given-names></name><name><surname>Le Fur</surname><given-names>G</given-names></name><name><surname>Casellas</surname><given-names>P</given-names></name></person-group><article-title>In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR-31747</article-title>. <source>J Pharmacol Exp Ther</source> (<year>1995</year>) <volume>272</volume>:<fpage>224</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">7815336</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzner</surname><given-names>R</given-names></name></person-group>. <article-title>Hallucinogenic drugs and plants in psychotherapy and shamanism</article-title>. <source>J Psychoactive Drugs</source> (<year>1998</year>) <volume>30</volume>(<issue>4</issue>):<fpage>333</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.1998.10399709</pub-id><pub-id pub-id-type="pmid">9924839</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>El-Mallakh</surname><given-names>RS</given-names></name><name><surname>Halpern</surname><given-names>JH</given-names></name><name><surname>Abraham</surname><given-names>HD</given-names></name></person-group><article-title>Substance abuse: hallucinogen- and MDMA-related disorders</article-title>. <edition>4th ed</edition> In: <person-group person-group-type="editor"><name><surname>Tasman</surname><given-names>A</given-names></name><name><surname>Kay</surname><given-names>J</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Riba</surname><given-names>M</given-names></name></person-group>, editors. <source>Psychiatry</source>. (Chap. 76), <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>Wiley-Blackwell</publisher-name> (<year>2015</year>). p. <fpage>1480</fpage>–<lpage>506</lpage>.</mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group>. <article-title>Hallucinogens</article-title>. <source>Pharmacol Ther</source> (<year>2004</year>) <volume>101</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2003.11.002</pub-id><pub-id pub-id-type="pmid">14761703</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name></person-group>. <article-title>The neurobiology of psychedelic drugs: implications for the treatment of mood disorders</article-title>. <source>Nat Rev Neurosci</source> (<year>2010</year>) <volume>11</volume>(<issue>9</issue>):<fpage>642</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1038/nrn2884</pub-id><pub-id pub-id-type="pmid">20717121</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hollister</surname><given-names>LE</given-names></name></person-group><article-title>Effects of hallucinogens in humans</article-title>. In: <person-group person-group-type="editor"><name><surname>Jacobs</surname><given-names>BL</given-names></name></person-group>, editor. <source>Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Raven Press</publisher-name> (<year>1984</year>). p. <fpage>19</fpage>–<lpage>33</lpage>.</mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group>. <article-title>Psychedelics</article-title>. <source>Pharmacol Rev</source> (<year>2016</year>) <volume>68</volume>(<issue>2</issue>):<fpage>264</fpage>–<lpage>355</lpage>.<pub-id pub-id-type="doi">10.1124/pr.115.011478</pub-id><pub-id pub-id-type="pmid">26841800</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantegrossi</surname><given-names>WE</given-names></name><name><surname>Murnane</surname><given-names>KS</given-names></name><name><surname>Reissig</surname><given-names>CJ</given-names></name></person-group>. <article-title>The behavioral pharmacology of hallucinogens</article-title>. <source>Biochem Pharmacol</source> (<year>2008</year>) <volume>75</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.bcp.2007.07.018</pub-id><pub-id pub-id-type="pmid">17977517</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halberstadt</surname><given-names>AL</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name></person-group>. <article-title>Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens</article-title>. <source>Neuropharmacology</source> (<year>2011</year>) <volume>61</volume>(<issue>3</issue>):<fpage>364</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.017</pub-id><pub-id pub-id-type="pmid">21256140</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Herdener</surname><given-names>M</given-names></name><name><surname>Pokorny</surname><given-names>T</given-names></name><name><surname>Planzer</surname><given-names>A</given-names></name><name><surname>Kraehenmann</surname><given-names>R</given-names></name><name><surname>Stampfli</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation</article-title>. <source>Curr Biol</source> (<year>2017</year>) <volume>27</volume>(<issue>3</issue>):<fpage>451</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.cub.2016.12.030</pub-id><pub-id pub-id-type="pmid">28132813</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group>. <article-title>Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers</article-title>. <source>Neuropsychopharmacology</source> (<year>2012</year>) <volume>37</volume>(<issue>3</issue>):<fpage>630</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1038/npp.2011.228</pub-id><pub-id pub-id-type="pmid">21956447</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Vollenweider-Scherpenhuyzen</surname><given-names>MF</given-names></name><name><surname>Babler</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Hell</surname><given-names>D</given-names></name></person-group>. <article-title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</article-title>. <source>Neuroreport</source> (<year>1998</year>) <volume>9</volume>(<issue>17</issue>):<fpage>3897</fpage>–<lpage>902</lpage>.<pub-id pub-id-type="doi">10.1097/00001756-199812010-00024</pub-id><pub-id pub-id-type="pmid">9875725</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Luethi</surname><given-names>D</given-names></name><name><surname>Reinisch</surname><given-names>J</given-names></name><name><surname>Buchy</surname><given-names>D</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)</article-title>. <source>Neuropharmacology</source> (<year>2015</year>) <volume>99</volume>:<fpage>546</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.034</pub-id><pub-id pub-id-type="pmid">26318099</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Maeso</surname><given-names>J</given-names></name><name><surname>Ang</surname><given-names>RL</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Weisstaub</surname><given-names>NV</given-names></name><name><surname>Lopez-Gimenez</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Identification of a serotonin/glutamate receptor complex implicated in psychosis</article-title>. <source>Nature</source> (<year>2008</year>) <volume>452</volume>(<issue>7183</issue>):<fpage>93</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nature06612</pub-id><pub-id pub-id-type="pmid">18297054</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delille</surname><given-names>HK</given-names></name><name><surname>Mezler</surname><given-names>M</given-names></name><name><surname>Marek</surname><given-names>GJ</given-names></name></person-group><article-title>The two faces of the pharmacological interaction of mGlu2 and 5-HT(2)A – relevance of receptor heterocomplexes and interaction through functional brain pathways</article-title>. <source>Neuropharmacology</source> (<year>2013</year>) <volume>70</volume>:<fpage>296</fpage>–<lpage>305</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.02.005</pub-id><pub-id pub-id-type="pmid">23466331</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>A</given-names></name></person-group><article-title>Psychotomimetic agents</article-title>. In: <person-group person-group-type="editor"><name><surname>Burger</surname><given-names>A</given-names></name></person-group>, editor. <source>Chemical Constitution and Pharmacodynamic Action</source>. (Vol. <volume>2</volume>), <publisher-loc>New York</publisher-loc>: <publisher-name>M. Dekker</publisher-name> (<year>1968</year>). p. <fpage>169</fpage>–<lpage>235</lpage>.</mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shulgin</surname><given-names>AT</given-names></name><name><surname>Shulgin</surname><given-names>A</given-names></name></person-group><source>PIHKAL: A Chemical Love Story</source>. <publisher-loc>Berkeley</publisher-loc>: <publisher-name>Transform Pres</publisher-name> (<year>1991</year>).</mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shulgin</surname><given-names>AT</given-names></name><name><surname>Shulgin</surname><given-names>A</given-names></name></person-group><source>TIHKAL: The Continuation</source>. <publisher-loc>Berkeley</publisher-loc>: <publisher-name>Transform Pres</publisher-name> (<year>1997</year>).</mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>BV</given-names></name><name><surname>Stellpflug</surname><given-names>SJ</given-names></name><name><surname>Burnett</surname><given-names>AM</given-names></name><name><surname>Engebretsen</surname><given-names>KM</given-names></name></person-group>. <article-title>2C or not 2C: phenethylamine designer drug review</article-title>. <source>J Med Toxicol</source> (<year>2013</year>) <volume>9</volume>(<issue>2</issue>):<fpage>172</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s13181-013-0295-x</pub-id><pub-id pub-id-type="pmid">23494844</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beharry</surname><given-names>S</given-names></name><name><surname>Gibbons</surname><given-names>S</given-names></name></person-group>. <article-title>An overview of emerging and new psychoactive substances in the United Kingdom</article-title>. <source>Forensic Sci Int</source> (<year>2016</year>) <volume>267</volume>:<fpage>25</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/j.forsciint.2016.08.013</pub-id><pub-id pub-id-type="pmid">27552699</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>M</given-names></name></person-group>. <article-title>Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling</article-title>. <source>Swiss Med Wkly</source> (<year>2015</year>) <volume>145</volume>:<fpage>w14043</fpage>.<pub-id pub-id-type="doi">10.4414/smw.2015.14043</pub-id><pub-id pub-id-type="pmid">25588018</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zawilska</surname><given-names>JB</given-names></name><name><surname>Andrzejczak</surname><given-names>D</given-names></name></person-group>. <article-title>Next generation of novel psychoactive substances on the horizon – a complex problem to face</article-title>. <source>Drug Alcohol Depend</source> (<year>2015</year>) <volume>157</volume>:<fpage>1</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.09.030</pub-id><pub-id pub-id-type="pmid">26482089</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schifano</surname><given-names>F</given-names></name><name><surname>Papanti</surname><given-names>GD</given-names></name><name><surname>Orsolini</surname><given-names>L</given-names></name><name><surname>Corkery</surname><given-names>JM</given-names></name></person-group>. <article-title>Novel psychoactive substances: the pharmacology of stimulants and hallucinogens</article-title>. <source>Expert Rev Clin Pharmacol</source> (<year>2016</year>) <volume>9</volume>(<issue>7</issue>):<fpage>943</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1586/17512433.2016.1167597</pub-id><pub-id pub-id-type="pmid">26985969</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>W</given-names></name><name><surname>Barratt</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Winstock</surname><given-names>A</given-names></name></person-group>. <article-title>The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample</article-title>. <source>J Psychopharmacol</source> (<year>2014</year>) <volume>28</volume>(<issue>8</issue>):<fpage>780</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1177/0269881114523866</pub-id><pub-id pub-id-type="pmid">24569095</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Schramm</surname><given-names>Y</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group>. <article-title>Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives</article-title>. <source>Biochem Pharmacol</source> (<year>2014</year>) <volume>88</volume>(<issue>2</issue>):<fpage>237</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.bcp.2014.01.024</pub-id><pub-id pub-id-type="pmid">24486525</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palamar</surname><given-names>JJ</given-names></name><name><surname>Martins</surname><given-names>SS</given-names></name><name><surname>Su</surname><given-names>MK</given-names></name><name><surname>Ompad</surname><given-names>DC</given-names></name></person-group><article-title>Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting</article-title>. <source>Drug Alcohol Depend</source> (<year>2015</year>) <volume>156</volume>:<fpage>112</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.08.028</pub-id><pub-id pub-id-type="pmid">26377051</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallersnes</surname><given-names>OM</given-names></name><name><surname>Dines</surname><given-names>AM</given-names></name><name><surname>Wood</surname><given-names>DM</given-names></name><name><surname>Yates</surname><given-names>C</given-names></name><name><surname>Heyerdahl</surname><given-names>F</given-names></name><name><surname>Hovda</surname><given-names>KE</given-names></name><etal></etal></person-group><article-title>Psychosis associated with acute recreational drug toxicity: a European case series</article-title>. <source>BMC Psychiatry</source> (<year>2016</year>) <volume>16</volume>:<fpage>293</fpage>.<pub-id pub-id-type="doi">10.1186/s12888-016-1002-7</pub-id><pub-id pub-id-type="pmid">27538886</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>BK</given-names></name><name><surname>Mohr</surname><given-names>ALA</given-names></name><name><surname>Friscia</surname><given-names>M</given-names></name><name><surname>Krotulski</surname><given-names>AJ</given-names></name><name><surname>Papsun</surname><given-names>DM</given-names></name><name><surname>Kacinko</surname><given-names>SL</given-names></name><etal></etal></person-group><article-title>Reports of adverse events associated with use of novel psychoactive substances, 2013-2016: a review</article-title>. <source>J Anal Toxicol</source> (<year>2017</year>):<fpage>1</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1093/jat/bkx031</pub-id><pub-id pub-id-type="pmid">28459969</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burish</surname><given-names>MJ</given-names></name><name><surname>Thoren</surname><given-names>KL</given-names></name><name><surname>Madou</surname><given-names>M</given-names></name><name><surname>Toossi</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name></person-group>. <article-title>Hallucinogens causing seizures? A case report of the synthetic amphetamine 2,5-dimethoxy-4-chloroamphetamine</article-title>. <source>Neurohospitalist</source> (<year>2015</year>) <volume>5</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1177/1941874414528939</pub-id><pub-id pub-id-type="pmid">25553227</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halberstadt</surname><given-names>AL</given-names></name></person-group><article-title>Pharmacology and toxicology of N-benzylphenethylamine (“NBOMe”) hallucinogens</article-title>. <source>Curr Top Behav Neurosci</source> (<year>2017</year>) <volume>32</volume>:<fpage>283</fpage>–<lpage>311</lpage>.<pub-id pub-id-type="doi">10.1007/7854_2016_64</pub-id><pub-id pub-id-type="pmid">28097528</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hieger</surname><given-names>MA</given-names></name><name><surname>Rose</surname><given-names>SR</given-names></name><name><surname>Cumpston</surname><given-names>KL</given-names></name><name><surname>Stromberg</surname><given-names>PE</given-names></name><name><surname>Miller</surname><given-names>S</given-names></name><name><surname>Wills</surname><given-names>BK</given-names></name></person-group>. <article-title>Severe poisoning after self-reported use of 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, a novel substituted amphetamine: a case series</article-title>. <source>Am J Emerg Med</source> (<year>2015</year>) <volume>33</volume>(<issue>12</issue>):<fpage>1843.e1</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1016/j.ajem.2015.04.065</pub-id><pub-id pub-id-type="pmid">25983267</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srisuma</surname><given-names>S</given-names></name><name><surname>Bronstein</surname><given-names>AC</given-names></name><name><surname>Hoyte</surname><given-names>CO</given-names></name></person-group>. <article-title>NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System</article-title>. <source>Clin Toxicol (Phila)</source> (<year>2015</year>) <volume>53</volume>(<issue>7</issue>):<fpage>624</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.3109/15563650.2015.1054502</pub-id><pub-id pub-id-type="pmid">26065360</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baggott</surname><given-names>MJ</given-names></name><name><surname>Coyle</surname><given-names>JR</given-names></name><name><surname>Erowid</surname><given-names>E</given-names></name><name><surname>Erowid</surname><given-names>F</given-names></name><name><surname>Robertson</surname><given-names>LC</given-names></name></person-group>. <article-title>Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire</article-title>. <source>Drug Alcohol Depend</source> (<year>2011</year>) <volume>114</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2010.09.006</pub-id><pub-id pub-id-type="pmid">21035275</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litjens</surname><given-names>RP</given-names></name><name><surname>Brunt</surname><given-names>TM</given-names></name><name><surname>Alderliefste</surname><given-names>GJ</given-names></name><name><surname>Westerink</surname><given-names>RH</given-names></name></person-group>. <article-title>Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases</article-title>. <source>Eur Neuropsychopharmacol</source> (<year>2014</year>) <volume>24</volume>(<issue>8</issue>):<fpage>1309</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.05.008</pub-id><pub-id pub-id-type="pmid">24933532</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckholtz</surname><given-names>NS</given-names></name><name><surname>Zhou</surname><given-names>DF</given-names></name><name><surname>Freedman</surname><given-names>DX</given-names></name></person-group>. <article-title>Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors</article-title>. <source>Life Sci</source> (<year>1988</year>) <volume>42</volume>(<issue>24</issue>):<fpage>2439</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1016/0024-3205(88)90342-6</pub-id><pub-id pub-id-type="pmid">3374263</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckholtz</surname><given-names>NS</given-names></name><name><surname>Zhou</surname><given-names>DF</given-names></name><name><surname>Freedman</surname><given-names>DX</given-names></name><name><surname>Potter</surname><given-names>WZ</given-names></name></person-group>. <article-title>Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain</article-title>. <source>Neuropsychopharmacology</source> (<year>1990</year>) <volume>3</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">1969270</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Willins</surname><given-names>DL</given-names></name><name><surname>Kroeze</surname><given-names>WK</given-names></name></person-group><article-title>G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse</article-title>. <source>Drug Alcohol Depend</source> (<year>1998</year>) <volume>51</volume>(<issue>1–2</issue>):<fpage>73</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/S0376-8716(98)00067-2</pub-id><pub-id pub-id-type="pmid">9716931</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloyo</surname><given-names>VJ</given-names></name><name><surname>Dave</surname><given-names>KD</given-names></name><name><surname>Rahman</surname><given-names>T</given-names></name><name><surname>Harvey</surname><given-names>JA</given-names></name></person-group>. <article-title>Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit</article-title>. <source>J Pharmacol Exp Ther</source> (<year>2001</year>) <volume>299</volume>(<issue>3</issue>):<fpage>1066</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">11714896</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gresch</surname><given-names>PJ</given-names></name><name><surname>Smith</surname><given-names>RL</given-names></name><name><surname>Barrett</surname><given-names>RJ</given-names></name><name><surname>Sanders-Bush</surname><given-names>E</given-names></name></person-group>. <article-title>Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex</article-title>. <source>Neuropsychopharmacology</source> (<year>2005</year>) <volume>30</volume>(<issue>9</issue>):<fpage>1693</fpage>–<lpage>702</lpage>.<pub-id pub-id-type="doi">10.1038/sj.npp.1300711</pub-id><pub-id pub-id-type="pmid">15756304</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchborn</surname><given-names>T</given-names></name><name><surname>Schroder</surname><given-names>H</given-names></name><name><surname>Dieterich</surname><given-names>DC</given-names></name><name><surname>Grecksch</surname><given-names>G</given-names></name><name><surname>Hollt</surname><given-names>V</given-names></name></person-group>. <article-title>Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites</article-title>. <source>Behav Brain Res</source> (<year>2015</year>) <volume>281</volume>:<fpage>62</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbr.2014.12.014</pub-id><pub-id pub-id-type="pmid">25513973</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capela</surname><given-names>JP</given-names></name><name><surname>Fernandes</surname><given-names>E</given-names></name><name><surname>Remiao</surname><given-names>F</given-names></name><name><surname>Bastos</surname><given-names>ML</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>F</given-names></name></person-group>. <article-title>Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons</article-title>. <source>Neurotoxicology</source> (<year>2007</year>) <volume>28</volume>(<issue>4</issue>):<fpage>868</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuro.2007.04.005</pub-id><pub-id pub-id-type="pmid">17572501</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capela</surname><given-names>JP</given-names></name><name><surname>da Costa Araujo</surname><given-names>S</given-names></name><name><surname>Costa</surname><given-names>VM</given-names></name><name><surname>Ruscher</surname><given-names>K</given-names></name><name><surname>Fernandes</surname><given-names>E</given-names></name><name><surname>Bastos Mde</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>The neurotoxicity of hallucinogenic amphetamines in primary cultures of hippocampal neurons</article-title>. <source>Neurotoxicology</source> (<year>2013</year>) <volume>34</volume>:<fpage>254</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuro.2012.09.005</pub-id><pub-id pub-id-type="pmid">22983118</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capela</surname><given-names>JP</given-names></name><name><surname>Ruscher</surname><given-names>K</given-names></name><name><surname>Lautenschlager</surname><given-names>M</given-names></name><name><surname>Freyer</surname><given-names>D</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Gaio</surname><given-names>AR</given-names></name><etal></etal></person-group><article-title>Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia</article-title>. <source>Neuroscience</source> (<year>2006</year>) <volume>139</volume>(<issue>3</issue>):<fpage>1069</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.01.007</pub-id><pub-id pub-id-type="pmid">16504407</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noworyta-Sokolowska</surname><given-names>K</given-names></name><name><surname>Kaminska</surname><given-names>K</given-names></name><name><surname>Kreiner</surname><given-names>G</given-names></name><name><surname>Rogoz</surname><given-names>Z</given-names></name><name><surname>Golembiowska</surname><given-names>K</given-names></name></person-group>. <article-title>Neurotoxic effects of 5-MeO-DIPT: a psychoactive tryptamine derivative in rats</article-title>. <source>Neurotox Res</source> (<year>2016</year>) <volume>30</volume>(<issue>4</issue>):<fpage>606</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1007/s12640-016-9654-0</pub-id><pub-id pub-id-type="pmid">27461536</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Ellison</surname><given-names>G</given-names></name></person-group>. <article-title>Long-lasting alterations in behavior and brain neurochemistry following continuous low-level LSD administration</article-title>. <source>Pharmacol Biochem Behav</source> (<year>1989</year>) <volume>33</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/0091-3057(89)90431-0</pub-id><pub-id pub-id-type="pmid">2780790</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karila</surname><given-names>L</given-names></name><name><surname>Reynaud</surname><given-names>M</given-names></name></person-group>. <article-title>GHB and synthetic cathinones: clinical effects and potential consequences</article-title>. <source>Drug Test Anal</source> (<year>2011</year>) <volume>3</volume>:<fpage>552</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/dta.210</pub-id><pub-id pub-id-type="pmid">21960540</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>S</given-names></name></person-group><article-title>Sur un homologue de l’ephedrine</article-title>. <source>Bull Soc Chim Fr</source> (<year>1929</year>) <volume>45</volume>:<fpage>284</fpage>–<lpage>6</lpage>.</mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>King</surname><given-names>MV</given-names></name><name><surname>Shortall</surname><given-names>SE</given-names></name><name><surname>Fone</surname><given-names>KC</given-names></name></person-group>. <article-title>The preclinical pharmacology of mephedrone; not just MDMA by another name</article-title>. <source>Br J Pharmacol</source> (<year>2014</year>) <volume>171</volume>:<fpage>2251</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1111/bph.12628</pub-id><pub-id pub-id-type="pmid">24654568</pub-id></mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karila</surname><given-names>L</given-names></name><name><surname>Billieux</surname><given-names>J</given-names></name><name><surname>Benyamina</surname><given-names>A</given-names></name><name><surname>Lancon</surname><given-names>C</given-names></name><name><surname>Cottencin</surname><given-names>O</given-names></name></person-group>. <article-title>The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>:<fpage>61</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.03.005</pub-id><pub-id pub-id-type="pmid">26995278</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunt</surname><given-names>TM</given-names></name><name><surname>Poortman</surname><given-names>A</given-names></name><name><surname>Niesink</surname><given-names>RJ</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name></person-group>. <article-title>Instability of the ecstasy market and a new kid on the block: mephedrone</article-title>. <source>J Psychopharmacol</source> (<year>2011</year>) <volume>25</volume>:<fpage>1543</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1177/0269881110378370</pub-id><pub-id pub-id-type="pmid">20826554</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottencin</surname><given-names>O</given-names></name><name><surname>Rolland</surname><given-names>B</given-names></name><name><surname>Karila</surname><given-names>L</given-names></name></person-group>. <article-title>New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature</article-title>. <source>Curr Pharm Des</source> (<year>2014</year>) <volume>20</volume>:<fpage>4106</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="doi">10.2174/13816128113199990622</pub-id><pub-id pub-id-type="pmid">24001292</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="book"><collab>EMCDDA</collab>. <source>EMCDDA and Europol Step Up Information Collection on Mephedrone</source>. <publisher-loc>Lisbon</publisher-loc>: <publisher-name>Drugnet Europe</publisher-name> (<year>2010</year>).</mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="book"><collab>EMCDDA</collab>. <source>Risk Assessment Report of a New Psychoactive Substance: 4-Methylmethcathinone (Mephedrone). In Accordance with Article 6 of Council Decision 2005/387/JHA on Information Exchange, Risk Assessment and Control of New Psychoactive Substances</source>. <publisher-loc>Lisbon</publisher-loc>: <publisher-name>European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)</publisher-name> (<year>2010</year>).</mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="book"><collab>EMCDDA</collab>. <source>Annual Report 2011: The State of the Drug Problem in Europe</source>. <publisher-loc>Lisbon</publisher-loc>: <publisher-name>European Monitoring Center for Drugs and Drug Abuse</publisher-name> (<year>2012</year>).</mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debruyne</surname><given-names>D</given-names></name><name><surname>Courné</surname><given-names>MA</given-names></name><name><surname>Le Boisselier</surname><given-names>R</given-names></name><name><surname>Djezzar</surname><given-names>S</given-names></name><name><surname>Gérardin</surname><given-names>M</given-names></name><name><surname>Boucher</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Mephedrone: a designer drug of recent use in France</article-title>. <source>Therapie</source> (<year>2010</year>) <volume>65</volume>:<fpage>519</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="doi">10.2515/therapie/2010077</pub-id><pub-id pub-id-type="pmid">21176758</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vardakou</surname><given-names>I</given-names></name><name><surname>Pistos</surname><given-names>C</given-names></name><name><surname>Spiliopoulou</surname><given-names>C</given-names></name></person-group>. <article-title>Drugs for youth via Internet and the example of mephedrone</article-title>. <source>Toxicol Lett</source> (<year>2011</year>) <volume>201</volume>:<fpage>191</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.toxlet.2010.12.014</pub-id><pub-id pub-id-type="pmid">21187132</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinotti</surname><given-names>G</given-names></name><name><surname>Lupi</surname><given-names>M</given-names></name><name><surname>Carlucci</surname><given-names>L</given-names></name><name><surname>Cinosi</surname><given-names>E</given-names></name><name><surname>Santacroce</surname><given-names>R</given-names></name><name><surname>Acciavatti</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas</article-title>. <source>Hum Psychopharmacol</source> (<year>2015</year>) <volume>30</volume>:<fpage>295</fpage>–<lpage>301</lpage>.<pub-id pub-id-type="doi">10.1002/hup.2486</pub-id><pub-id pub-id-type="pmid">26216566</pub-id></mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zawilska</surname><given-names>JB</given-names></name><name><surname>Wojcieszak</surname><given-names>J</given-names></name></person-group><article-title>Designer cathinones—an emerging class of novel recreational drugs</article-title>. <source>Forensic Sci Int</source> (<year>2013</year>) <volume>231</volume>:<fpage>42</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.forsciint.2013.04.015</pub-id><pub-id pub-id-type="pmid">23890615</pub-id></mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glennon</surname><given-names>RA</given-names></name></person-group>. <article-title>Bath salts mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention</article-title>. <source>Adv Pharmacol</source> (<year>2014</year>) <volume>69</volume>:<fpage>581</fpage>–<lpage>620</lpage>.<pub-id pub-id-type="doi">10.1016/B978-0-12-420118-7.00015-9</pub-id><pub-id pub-id-type="pmid">24484988</pub-id></mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schifano</surname><given-names>F</given-names></name><name><surname>Albanese</surname><given-names>A</given-names></name><name><surname>Fergus</surname><given-names>S</given-names></name><name><surname>Stair</surname><given-names>JL</given-names></name><name><surname>Deluca</surname><given-names>P</given-names></name><name><surname>Corazza</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Mephedrone (4-methylmethcathinone; ’meow meow’): chemical, pharmacological and clinical issues</article-title>. <source>Psychopharmacology</source> (<year>2011</year>) <volume>214</volume>:<fpage>593</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-010-2070-x</pub-id><pub-id pub-id-type="pmid">21072502</pub-id></mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>JP</given-names></name></person-group>. <article-title>Cathinone derivatives: a review of their chemistry, pharmacology and toxicology</article-title>. <source>Drug Test Anal</source> (<year>2011</year>) <volume>3</volume>:<fpage>439</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1002/dta.313</pub-id><pub-id pub-id-type="pmid">21755607</pub-id></mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karila</surname><given-names>L</given-names></name><name><surname>Megarbane</surname><given-names>B</given-names></name><name><surname>Cottencin</surname><given-names>O</given-names></name><name><surname>Lejoyeux</surname><given-names>M</given-names></name></person-group>. <article-title>Synthetic cathinones: a new public health problem</article-title>. <source>Curr Neuropharmacol</source> (<year>2015</year>) <volume>13</volume>:<fpage>12</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.2174/1570159X13666141210224137</pub-id><pub-id pub-id-type="pmid">26074740</pub-id></mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>DM</given-names></name><name><surname>Dargan</surname><given-names>PI</given-names></name></person-group>. <article-title>Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2012</year>) <volume>39</volume>:<fpage>227</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.04.020</pub-id><pub-id pub-id-type="pmid">22564711</pub-id></mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>German</surname><given-names>CL</given-names></name><name><surname>Fleckenstein</surname><given-names>AE</given-names></name><name><surname>Hanson</surname><given-names>GR</given-names></name></person-group>. <article-title>Bath salts and synthetic cathinones: an emerging designer drug phenomenon</article-title>. <source>Life Sci</source> (<year>2014</year>) <volume>97</volume>:<fpage>2</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.lfs.2013.07.023</pub-id><pub-id pub-id-type="pmid">23911668</pub-id></mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapitány-Fövény</surname><given-names>M</given-names></name><name><surname>Mervó</surname><given-names>B</given-names></name><name><surname>Kertész</surname><given-names>M</given-names></name><name><surname>Corazza</surname><given-names>O</given-names></name><name><surname>Farkas</surname><given-names>J</given-names></name><name><surname>Kökönyei</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Is there any difference in patterns of use and psychiatric symptom status between injectors and non-injectors of mephedrone?</article-title><source>Hum Psychopharmacol</source> (<year>2015</year>) <volume>30</volume>:<fpage>233</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1002/hup.2490</pub-id><pub-id pub-id-type="pmid">26216556</pub-id></mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hout</surname><given-names>MC</given-names></name><name><surname>Bingham</surname><given-names>T</given-names></name></person-group><article-title>A costly turn on: patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors</article-title>. <source>Int J Drug Policy</source> (<year>2012</year>) <volume>23</volume>:<fpage>188</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugpo.2012.01.008</pub-id><pub-id pub-id-type="pmid">22342322</pub-id></mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>DM</given-names></name><name><surname>Greene</surname><given-names>SL</given-names></name><name><surname>Dargan</surname><given-names>PI</given-names></name></person-group>. <article-title>Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone</article-title>. <source>Emerg Med J</source> (<year>2011</year>) <volume>28</volume>:<fpage>280</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1136/emj.2010.092288</pub-id><pub-id pub-id-type="pmid">20581379</pub-id></mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>ME</given-names></name><name><surname>Thomas-Rozea</surname><given-names>C</given-names></name><name><surname>Hahn</surname><given-names>D</given-names></name></person-group><article-title>Bath salts abuse leading to new onset psychosis and potential for violence</article-title>. <source>Clin Schizophr Relat Psychoses</source> (<year>2017</year>) <volume>11</volume>(<issue>2</issue>):<fpage>120</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.3371/CSRP.JORO.061314</pub-id><pub-id pub-id-type="pmid">24951715</pub-id></mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragogna</surname><given-names>F</given-names></name><name><surname>Oldani</surname><given-names>L</given-names></name><name><surname>Buoli</surname><given-names>M</given-names></name><name><surname>Altamura</surname><given-names>AC</given-names></name></person-group>. <article-title>A case of severe psychosis induced by novel recreational drugs</article-title>. <source>F1000Res</source> (<year>2014</year>) <volume>3</volume>:<fpage>21</fpage>.<pub-id pub-id-type="doi">10.12688/f1000research.3-21.v1</pub-id><pub-id pub-id-type="pmid">25352977</pub-id></mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajaj</surname><given-names>N</given-names></name><name><surname>Mullen</surname><given-names>D</given-names></name><name><surname>Wylie</surname><given-names>S</given-names></name></person-group>. <article-title>Dependence and psychosis with 4-methylmethcathinone (mephedrone) use</article-title>. <source>BMJ Case Rep</source> (<year>2010</year>) <volume>2010</volume>:<fpage>1</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1136/bcr.02.2010.2780</pub-id><pub-id pub-id-type="pmid">22791836</pub-id></mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loi</surname><given-names>B</given-names></name><name><surname>Corkery</surname><given-names>JM</given-names></name><name><surname>Claridge</surname><given-names>H</given-names></name><name><surname>Goodair</surname><given-names>C</given-names></name><name><surname>Chiappini</surname><given-names>S</given-names></name><name><surname>Gimeno Clemente</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Deaths of individuals aged 16–24 years in the UK after using mephedrone</article-title>. <source>Hum Psychopharmacol</source> (<year>2015</year>) <volume>30</volume>:<fpage>225</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1002/hup.2423</pub-id><pub-id pub-id-type="pmid">26216555</pub-id></mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustavsson</surname><given-names>D</given-names></name><name><surname>Escher</surname><given-names>C</given-names></name></person-group><article-title>Mephedrone—Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance</article-title>. <source>Lakartidningen</source> (<year>2009</year>) <volume>106</volume>(<issue>43</issue>):<fpage>2769</fpage>–<lpage>71</lpage>.</mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schifano</surname><given-names>F</given-names></name><name><surname>Corkery</surname><given-names>J</given-names></name><name><surname>Ghodse</surname><given-names>A</given-names></name></person-group><article-title>Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, Meow Meow) in the United Kingdom</article-title>. <source>J Clin Psychopharmacol</source> (<year>2012</year>) <volume>32</volume>:<fpage>710</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1097/JCP.0b013e318266c70c</pub-id><pub-id pub-id-type="pmid">22926609</pub-id></mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busardò</surname><given-names>FP</given-names></name><name><surname>Kyriakou</surname><given-names>C</given-names></name><name><surname>Napoletano</surname><given-names>S</given-names></name><name><surname>Marinelli</surname><given-names>E</given-names></name><name><surname>Zaami</surname><given-names>S</given-names></name></person-group>. <article-title>Mephedrone related fatalities: a review</article-title>. <source>Eur Rev Med Pharmacol Sci</source> (<year>2015</year>) <volume>19</volume>:<fpage>3777</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">26502870</pub-id></mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosser</surname><given-names>JM</given-names></name><name><surname>Nelson</surname><given-names>LS</given-names></name></person-group>. <article-title>The toxicology of bath salts: a review of synthetic cathinones</article-title>. <source>J Med Toxicol</source> (<year>2012</year>) <volume>8</volume>:<fpage>33</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1007/s13181-011-0193-z</pub-id><pub-id pub-id-type="pmid">22108839</pub-id></mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>H</given-names></name></person-group><source>Mephedrone: The Phantom Menace</source>. <publisher-loc>Montreal</publisher-loc>: <publisher-name>Vice</publisher-name> (<year>2010</year>). p. <fpage>98</fpage>–<lpage>100</lpage>.</mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winder</surname><given-names>GS</given-names></name><name><surname>Stern</surname><given-names>N</given-names></name><name><surname>Hosanagar</surname><given-names>A</given-names></name></person-group><article-title>Are bath salts the next generation of stimulant abuse?</article-title><source>J Subst Abuse Treat</source> (<year>2013</year>) <volume>44</volume>:<fpage>42</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.jsat.2012.02.003</pub-id><pub-id pub-id-type="pmid">22445773</pub-id></mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>King</surname><given-names>LA</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group>. <article-title>A web-based survey on mephedrone</article-title>. <source>Drug Alcohol Depend</source> (<year>2011</year>) <volume>118</volume>:<fpage>19</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.02.011</pub-id><pub-id pub-id-type="pmid">21420252</pub-id></mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winstock</surname><given-names>AR</given-names></name><name><surname>Mitcheson</surname><given-names>LR</given-names></name><name><surname>Deluca</surname><given-names>P</given-names></name><name><surname>Davey</surname><given-names>Z</given-names></name><name><surname>Corazza</surname><given-names>O</given-names></name><name><surname>Schifano</surname><given-names>F</given-names></name></person-group>. <article-title>Mephedrone, new kid for the chop?</article-title><source>Addiction</source> (<year>2011</year>) <volume>106</volume>:<fpage>154</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1111/j.1360-0443.2010.03130.x</pub-id><pub-id pub-id-type="pmid">20735367</pub-id></mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Buser</surname><given-names>TA</given-names></name><name><surname>Donzelli</surname><given-names>M</given-names></name><name><surname>Schramm</surname><given-names>Y</given-names></name><name><surname>Dieu</surname><given-names>LH</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Pharmacological characterization of designer cathinones in vitro</article-title>. <source>Br J Pharmacol</source> (<year>2013</year>) <volume>168</volume>:<fpage>458</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02145.x</pub-id><pub-id pub-id-type="pmid">22897747</pub-id></mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>MR</given-names></name><name><surname>Maurer</surname><given-names>HH</given-names></name></person-group>. <article-title>Metabolism of designer drugs of abuse: an updated review</article-title>. <source>Curr Drug Metab</source> (<year>2010</year>) <volume>11</volume>:<fpage>468</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.2174/138920010791526042</pub-id><pub-id pub-id-type="pmid">20540700</pub-id></mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>P</given-names></name><name><surname>Shulgin</surname><given-names>A</given-names></name><collab>Inventors; Neurobiological Technologies, Inc., assignee</collab></person-group><source>Preparation of Novel N-Substituted-2-Amino-3,4-Methylenedioxypropiophenones As Anti-Depressant and Anti-Parkinsonism Agents</source>. (<year>1996</year>). US Patent WO9639133.</mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>MR</given-names></name><name><surname>Wilhelm</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>FT</given-names></name><name><surname>Maurer</surname><given-names>HH</given-names></name></person-group><article-title>Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry</article-title>. <source>Anal Bioanal Chem</source> (<year>2010</year>) <volume>397</volume>:<fpage>1225</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1007/s00216-010-3636-5</pub-id><pub-id pub-id-type="pmid">20333362</pub-id></mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="book"><collab>EMCDDA</collab>. <source>EMCDDA–Europol 2009 Annual Report on the Implementation of Council Decision 2005/387/JHA. In Accordance with Article 10 of Council Decision 2005/387/JHA on the Information Exchange, Risk-Assessment and Control of New Psychoactive Substances</source>. <publisher-loc>Lisbon</publisher-loc>: <publisher-name>EMCDDA–Europol joint publication</publisher-name> (<year>2010</year>).</mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>S</given-names></name><name><surname>Stokes</surname><given-names>S</given-names></name><name><surname>Coleman</surname><given-names>N</given-names></name></person-group>. <article-title>Head shop compound abuse amongst attendees of the Drug Treatment Centre Board</article-title>. <source>Ir Med J</source> (<year>2010</year>) <volume>103</volume>:<fpage>134</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">20666082</pub-id></mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="confproc"><collab>WHO</collab>. <article-title>Methylone (bk-MDMA): critical review report</article-title>. <conf-name>Expert Committee on Drug Dependence Thirty-Sixth Meeting</conf-name><conf-loc>Geneva</conf-loc> (<year>2014</year>).</mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>LJ</given-names></name><name><surname>Glennon</surname><given-names>RA</given-names></name><name><surname>Negus</surname><given-names>SS</given-names></name></person-group>. <article-title>Synthetic cathinones: chemical phylogeny physiology, and neuropharmacology</article-title>. <source>Life Sci</source> (<year>2014</year>) <volume>97</volume>:<fpage>20</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.lfs.2013.10.029</pub-id><pub-id pub-id-type="pmid">24231923</pub-id></mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>E</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Hagiwara</surname><given-names>H</given-names></name><name><surname>Fujisaki</surname><given-names>M</given-names></name><name><surname>Miyatake</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Combined intoxication with methylone and 5-MeO-MIPT</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2007</year>) <volume>31</volume>:<fpage>288</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.06.012</pub-id><pub-id pub-id-type="pmid">16876302</pub-id></mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulanger-Gobeil</surname><given-names>C</given-names></name><name><surname>St-Onge</surname><given-names>M</given-names></name><name><surname>Laliberté</surname><given-names>M</given-names></name><name><surname>Auger</surname><given-names>PL</given-names></name></person-group>. <article-title>Seizures and hyponatremia related to ethcathinone and methylone poisoning</article-title>. <source>J Med Toxicol</source> (<year>2012</year>) <volume>8</volume>:<fpage>59</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1007/s13181-011-0159-1</pub-id><pub-id pub-id-type="pmid">21755421</pub-id></mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname><given-names>YS</given-names></name><name><surname>Hall</surname><given-names>FS</given-names></name><name><surname>Moriya</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Ohara</surname><given-names>A</given-names></name><name><surname>Kikura-Hanajiri</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Methylone-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters</article-title>. <source>Behav Pharmacol</source> (<year>2015</year>) <volume>26</volume>:<fpage>345</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1097/FBP.0000000000000135</pub-id><pub-id pub-id-type="pmid">25794333</pub-id></mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>JM</given-names></name><name><surname>Hargraves</surname><given-names>TL</given-names></name><name><surname>Hair</surname><given-names>LS</given-names></name><name><surname>Massucci</surname><given-names>CJ</given-names></name><name><surname>Frazee</surname><given-names>CC</given-names><suffix>III</suffix></name><name><surname>Garg</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Three fatal intoxications due to methylone</article-title>. <source>J Anal Toxicol</source> (<year>2012</year>) <volume>36</volume>:<fpage>444</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1093/jat/bks043</pub-id><pub-id pub-id-type="pmid">22589523</pub-id></mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warrick</surname><given-names>BJ</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Hedge</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>K</given-names></name><name><surname>Aaron</surname><given-names>C</given-names></name></person-group>. <article-title>Lethal serotonin syndrome after methylone and butylone ingestion</article-title>. <source>J Med Toxicol</source> (<year>2012</year>) <volume>8</volume>:<fpage>65</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s13181-011-0199-6</pub-id><pub-id pub-id-type="pmid">22160789</pub-id></mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbone</surname><given-names>PN</given-names></name><name><surname>Carbone</surname><given-names>DL</given-names></name><name><surname>Carstairs</surname><given-names>SD</given-names></name><name><surname>Luzi</surname><given-names>SA</given-names></name></person-group>. <article-title>Sudden cardiac death associated with methylone use</article-title>. <source>Am J Forensic Med Pathol</source> (<year>2013</year>) <volume>34</volume>:<fpage>26</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/PAF.0b013e31827ab5da</pub-id><pub-id pub-id-type="pmid">23403480</pub-id></mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrios</surname><given-names>L</given-names></name><name><surname>Grison-Hernando</surname><given-names>H</given-names></name><name><surname>Boels</surname><given-names>D</given-names></name><name><surname>Bouquie</surname><given-names>R</given-names></name><name><surname>Monteil-Ganiere</surname><given-names>C</given-names></name><name><surname>Clement</surname><given-names>R</given-names></name></person-group><article-title>Death following ingestion of methylone</article-title>. <source>Int J Legal Med</source> (<year>2015</year>) <volume>130</volume>:<fpage>381</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1007/s00414-015-1212-4</pub-id><pub-id pub-id-type="pmid">26071183</pub-id></mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossong</surname><given-names>MG</given-names></name><name><surname>Van Dijk</surname><given-names>JP</given-names></name><name><surname>Niesink</surname><given-names>RJ</given-names></name></person-group>. <article-title>Methylone and mCPP, two new drugs of abuse?</article-title><source>Addict Biol</source> (<year>2005</year>) <volume>10</volume>:<fpage>321</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1080/13556210500350794</pub-id><pub-id pub-id-type="pmid">16318952</pub-id></mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koob</surname><given-names>GF</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group>. <article-title>Neurobiology of addiction: a neurocircuitry analysis</article-title>. <source>Lancet Psychiatry</source> (<year>2016</year>) <volume>3</volume>:<fpage>760</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/S2215-0366(16)00104-8</pub-id><pub-id pub-id-type="pmid">27475769</pub-id></mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Homberg</surname><given-names>JR</given-names></name></person-group>. <article-title>The role of serotonin in drug use and addiction</article-title>. <source>Behav Brain Res</source> (<year>2015</year>) <volume>277</volume>:<fpage>146</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbr.2014.04.007</pub-id><pub-id pub-id-type="pmid">24769172</pub-id></mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>H</given-names></name><name><surname>Wallach</surname><given-names>J</given-names></name></person-group>. <article-title>From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs</article-title>. <source>Drug Test Anal</source> (<year>2014</year>) <volume>6</volume>(<issue>7–8</issue>):<fpage>614</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1002/dta.1620</pub-id><pub-id pub-id-type="pmid">24678061</pub-id></mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Breen</surname><given-names>C</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>B</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name><name><surname>Chanteloup</surname><given-names>F</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><etal></etal></person-group><source>Australian Party Drugs Trends 2003: Findings from the Party Drug Initiative</source>. <publisher-loc>Sydney</publisher-loc>: <publisher-name>National Drug and Alcohol Research Centre</publisher-name> (<year>2008</year>).</mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurdi</surname><given-names>MS</given-names></name><name><surname>Theerth</surname><given-names>KA</given-names></name><name><surname>Deva</surname><given-names>RS</given-names></name></person-group>. <article-title>Ketamine: current applications in anesthesia, pain, and critical care</article-title>. <source>Anesth Essays Res</source> (<year>2014</year>) <volume>8</volume>:<fpage>283</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.4103/0259-1162.143110</pub-id><pub-id pub-id-type="pmid">25886322</pub-id></mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>CM</given-names></name><name><surname>Laws</surname><given-names>KR</given-names></name></person-group><article-title>The use of ketamine as an antidepressant: a systematic review and meta-analysis</article-title>. <source>Hum Psychopharmacol Clin Exp</source> (<year>2015</year>) <volume>30</volume>:<fpage>233</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1002/hup.2475</pub-id></mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>LM</given-names></name></person-group>. <article-title>Subanesthetic ketamine: how it alters physiology and behavior in humans</article-title>. <source>Aviat Space Environ Med</source> (<year>2005</year>) <volume>76</volume>(<issue>7, Suppl.</issue>):<fpage>C52</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">16018330</pub-id></mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehy</surname><given-names>KA</given-names></name><name><surname>Muller</surname><given-names>EA</given-names></name><name><surname>Lippold</surname><given-names>C</given-names></name><name><surname>Nouraie</surname><given-names>M</given-names></name><name><surname>Finkel</surname><given-names>JC</given-names></name><name><surname>Quezado</surname><given-names>ZM</given-names></name></person-group>. <article-title>Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study</article-title>. <source>BMC Pediatr</source> (<year>2015</year>) <volume>15</volume>:<fpage>198</fpage>.<pub-id pub-id-type="doi">10.1186/s12887-015-0515-4</pub-id><pub-id pub-id-type="pmid">26620833</pub-id></mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gable</surname><given-names>RS</given-names></name></person-group>. <article-title>Acute toxic effects of club drugs</article-title>. <source>J Psychoactive Drugs</source> (<year>2004</year>) <volume>36</volume>:<fpage>303</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.2004.10400031</pub-id><pub-id pub-id-type="pmid">15559678</pub-id></mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>CJ</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name><collab>Independent Scientific Committee on Drugs</collab></person-group><article-title>Ketamine use: a review</article-title>. <source>Addiction</source> (<year>2012</year>) <volume>107</volume>:<fpage>27</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1111/j.1360-0443.2011.03576.x</pub-id><pub-id pub-id-type="pmid">21777321</pub-id></mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokor</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>PD</given-names></name></person-group>. <article-title>Ketamine: an update on its abuse</article-title>. <source>J Pharm Pract</source> (<year>2014</year>) <volume>27</volume>:<fpage>582</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1177/0897190014525754</pub-id><pub-id pub-id-type="pmid">24651639</pub-id></mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynaud-Maurupt</surname><given-names>C</given-names></name><name><surname>Bello</surname><given-names>PY</given-names></name><name><surname>Akoka</surname><given-names>S</given-names></name><name><surname>Toufik</surname><given-names>A</given-names></name></person-group>. <article-title>Characteristics and behaviors of ketamine users in France in 2003</article-title>. <source>J Psychoactive Drugs</source> (<year>2007</year>) <volume>39</volume>:<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.2007.10399859</pub-id><pub-id pub-id-type="pmid">17523580</pub-id></mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britt</surname><given-names>GC</given-names></name><name><surname>McCance-Katz</surname><given-names>EF</given-names></name></person-group><article-title>A brief overview of the clinical pharmacology of club drugs</article-title>. <source>Subst Use Misuse</source> (<year>2005</year>) <volume>40</volume>:<fpage>1189</fpage>–<lpage>201</lpage>.<pub-id pub-id-type="doi">10.1081/JA-200066730</pub-id><pub-id pub-id-type="pmid">16048813</pub-id></mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>CP</given-names></name><name><surname>Pum</surname><given-names>ME</given-names></name><name><surname>Amato</surname><given-names>D</given-names></name><name><surname>Schüttler</surname><given-names>J</given-names></name><name><surname>Huston</surname><given-names>JP</given-names></name><name><surname>de Souza Silva</surname><given-names>MA</given-names></name></person-group><article-title>The in-vivo neurochemistry of the brain during general anesthesia</article-title>. <source>J Neurochem</source> (<year>2011</year>) <volume>119</volume>:<fpage>419</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07445.x</pub-id><pub-id pub-id-type="pmid">21883214</pub-id></mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>AR</given-names><suffix>III</suffix></name><name><surname>Gancsos</surname><given-names>MG</given-names></name><name><surname>Finn</surname><given-names>ES</given-names></name><name><surname>Morgan</surname><given-names>PT</given-names></name><name><surname>Corlett</surname><given-names>PR</given-names></name></person-group>. <article-title>Ketamine-induced hallucinations</article-title>. <source>Psychopathology</source> (<year>2015</year>) <volume>48</volume>:<fpage>376</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1159/000438675</pub-id><pub-id pub-id-type="pmid">26361209</pub-id></mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>X</given-names></name><name><surname>Cang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Bu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group>. <article-title>The prevalence of drugs in motor vehicle accidents and traffic violations in Shanghai and neighboring cities</article-title>. <source>Accid Anal Prev</source> (<year>2010</year>) <volume>42</volume>:<fpage>2179</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1016/j.aap.2010.07.004</pub-id><pub-id pub-id-type="pmid">20728679</pub-id></mixed-citation></ref><ref id="B294"><label>294</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgetti</surname><given-names>R</given-names></name><name><surname>Marcotulli</surname><given-names>D</given-names></name><name><surname>Tagliabracci</surname><given-names>A</given-names></name><name><surname>Schifano</surname><given-names>F</given-names></name></person-group>. <article-title>Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability</article-title>. <source>Forensic Sci Int</source> (<year>2015</year>) <volume>252</volume>:<fpage>127</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.forsciint.2015.04.024</pub-id><pub-id pub-id-type="pmid">25981945</pub-id></mixed-citation></ref><ref id="B295"><label>295</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penning</surname><given-names>R</given-names></name><name><surname>Veldstra</surname><given-names>JL</given-names></name><name><surname>Daamen</surname><given-names>AP</given-names></name><name><surname>Olivier</surname><given-names>B</given-names></name><name><surname>Verster</surname><given-names>JC</given-names></name></person-group>. <article-title>Drugs of abuse, driving and traffic safety</article-title>. <source>Curr Drug Abuse Rev</source> (<year>2010</year>) <volume>3</volume>:<fpage>23</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="doi">10.2174/1874473711003010023</pub-id><pub-id pub-id-type="pmid">20088818</pub-id></mixed-citation></ref><ref id="B296"><label>296</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>MK</given-names></name><name><surname>Halkitis</surname><given-names>PN</given-names></name></person-group>. <article-title>Sexual risk taking and club drug use across three age cohorts of HIV-positive gay and bisexual men in New York City</article-title>. <source>AIDS Care</source> (<year>2011</year>) <volume>23</volume>:<fpage>1410</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1080/09540121.2011.565027</pub-id><pub-id pub-id-type="pmid">22022849</pub-id></mixed-citation></ref><ref id="B297"><label>297</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>QH</given-names></name><name><surname>Chu</surname><given-names>ZX</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YZ</given-names></name><etal></etal></person-group><article-title>Recreational drug use and risks of HIV and sexually transmitted infections among Chinese men who have sex with men: mediation through multiple sexual partnerships</article-title>. <source>BMC Infect Dis</source> (<year>2014</year>) <volume>14</volume>:<fpage>642</fpage>.<pub-id pub-id-type="doi">10.1186/s12879-014-0642-9</pub-id><pub-id pub-id-type="pmid">25443542</pub-id></mixed-citation></ref><ref id="B298"><label>298</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>A</given-names></name><name><surname>Vieira</surname><given-names>L</given-names></name><name><surname>McKay</surname><given-names>CA</given-names></name><name><surname>Bayer</surname><given-names>MJ</given-names></name></person-group>. <article-title>Ketamine abusers presenting to the emergency department: a case series</article-title>. <source>J Emerg Med</source> (<year>2000</year>) <volume>18</volume>:<fpage>447</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1016/S0736-4679(00)00162-1</pub-id><pub-id pub-id-type="pmid">10802423</pub-id></mixed-citation></ref><ref id="B299"><label>299</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>K</given-names></name><name><surname>Cottrell</surname><given-names>AM</given-names></name><name><surname>Corrigan</surname><given-names>AG</given-names></name><name><surname>Gillatt</surname><given-names>DA</given-names></name><name><surname>Mitchelmore</surname><given-names>AE</given-names></name></person-group>. <article-title>Ketamine-associated lower urinary tract destruction: a new radiological challenge</article-title>. <source>Clin Radiol</source> (<year>2010</year>) <volume>65</volume>:<fpage>795</fpage>–<lpage>800</lpage>.<pub-id pub-id-type="doi">10.1016/j.crad.2010.05.003</pub-id><pub-id pub-id-type="pmid">20797465</pub-id></mixed-citation></ref><ref id="B300"><label>300</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skeldon</surname><given-names>SC</given-names></name><name><surname>Goldenberg</surname><given-names>SL</given-names></name></person-group>. <article-title>Urological complications of illicit drug use</article-title>. <source>Nat Rev Urol</source> (<year>2014</year>) <volume>11</volume>:<fpage>169</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1038/nrurol.2014.22</pub-id><pub-id pub-id-type="pmid">24535583</pub-id></mixed-citation></ref><ref id="B301"><label>301</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yek</surname><given-names>J</given-names></name><name><surname>Sundaram</surname><given-names>P</given-names></name><name><surname>Aydin</surname><given-names>H</given-names></name><name><surname>Kuo</surname><given-names>T</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name></person-group>. <article-title>The clinical presentation and diagnosis of ketamine-associated urinary tract dysfunction in Singapore</article-title>. <source>Singapore Med J</source> (<year>2015</year>) <volume>56</volume>:<fpage>660</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.11622/smedj.2015185</pub-id><pub-id pub-id-type="pmid">26702160</pub-id></mixed-citation></ref><ref id="B302"><label>302</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>LK</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Shen</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>AT</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name></person-group><article-title>Evaluation of the extent of ketamine-induced uropathy: the role of CT urography</article-title>. <source>Postgrad Med J</source> (<year>2014</year>) <volume>90</volume>:<fpage>185</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">24443558</pub-id></mixed-citation></ref><ref id="B303"><label>303</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name></person-group>. <article-title>Lower urinary tract destruction due to ketamine: a report of 4 cases and review of literature</article-title>. <source>J Addict Med</source> (<year>2012</year>) <volume>6</volume>:<fpage>85</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/ADM.0b013e3182312863</pub-id><pub-id pub-id-type="pmid">21979820</pub-id></mixed-citation></ref><ref id="B304"><label>304</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Huang</surname><given-names>MC</given-names></name><name><surname>Lin</surname><given-names>SK</given-names></name></person-group>. <article-title>Gender differences in subjective discontinuation symptoms associated with ketamine use</article-title>. <source>Subst Abuse Treat Prev Policy</source> (<year>2014</year>) <volume>9</volume>:<fpage>39</fpage>.<pub-id pub-id-type="doi">10.1186/1747-597X-9-39</pub-id><pub-id pub-id-type="pmid">25245125</pub-id></mixed-citation></ref><ref id="B305"><label>305</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Sleeping problems in Chinese illicit drug dependent subjects</article-title>. <source>BMC Psychiatry</source> (<year>2015</year>) <volume>15</volume>:<fpage>28</fpage>.<pub-id pub-id-type="doi">10.1186/s12888-015-0409-x</pub-id><pub-id pub-id-type="pmid">25884573</pub-id></mixed-citation></ref><ref id="B306"><label>306</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costi</surname><given-names>S</given-names></name><name><surname>Dam</surname><given-names>NTV</given-names></name><name><surname>Murrough</surname><given-names>JW</given-names></name></person-group>. <article-title>Current status of ketamine and related therapies for mood and anxiety disorders</article-title>. <source>Curr Behav Neurosci Rep</source> (<year>2015</year>) <volume>2</volume>:<fpage>216</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1007/s40473-015-0052-3</pub-id><pub-id pub-id-type="pmid">26783510</pub-id></mixed-citation></ref><ref id="B307"><label>307</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>U</given-names></name></person-group>. <article-title>Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction</article-title>. <source>J Psychoactive Drugs</source> (<year>2015</year>) <volume>47</volume>(<issue>4</issue>):<fpage>276</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1080/02791072.2015.1072653</pub-id><pub-id pub-id-type="pmid">26317449</pub-id></mixed-citation></ref><ref id="B308"><label>308</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pender</surname><given-names>JW</given-names></name></person-group><article-title>Dissociative anesthesia</article-title>. <source>Calif Med</source> (<year>1970</year>) <volume>113</volume>(<issue>5</issue>):<fpage>73</fpage>.</mixed-citation></ref><ref id="B309"><label>309</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Stillman</surname><given-names>RC</given-names></name></person-group><article-title>Phencyclidine: an overview</article-title>. <source>NIDA Res Monogr</source> (<year>1978</year>) <volume>21</volume>:<fpage>1</fpage>–<lpage>17</lpage>.</mixed-citation></ref><ref id="B310"><label>310</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>CJ</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name></person-group>. <article-title>Acute and chronic effects of ketamine upon human memory: a review</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2006</year>) <volume>188</volume>(<issue>4</issue>):<fpage>408</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-006-0572-3</pub-id><pub-id pub-id-type="pmid">17006715</pub-id></mixed-citation></ref><ref id="B311"><label>311</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>A</given-names></name><name><surname>Hart</surname><given-names>N</given-names></name><name><surname>Trujillo</surname><given-names>KA</given-names></name></person-group>. <article-title>Differences between adolescents and adults in the acute effects of PCP and ketamine and in sensitization following intermittent administration</article-title>. <source>Pharmacol Biochem Behav</source> (<year>2017</year>) <volume>157</volume>:<fpage>24</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/j.pbb.2017.04.007</pub-id><pub-id pub-id-type="pmid">28442368</pub-id></mixed-citation></ref><ref id="B312"><label>312</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>HJ</given-names></name><name><surname>Tang</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>F</given-names></name><name><surname>Ungvari</surname><given-names>GS</given-names></name><name><surname>Tang</surname><given-names>WK</given-names></name></person-group>. <article-title>Ketamine users have high rates of psychosis and/or depression</article-title>. <source>J Addict Nurs</source> (<year>2015</year>) <volume>26</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1097/JAN.0000000000000060</pub-id><pub-id pub-id-type="pmid">25761158</pub-id></mixed-citation></ref><ref id="B313"><label>313</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JM</given-names></name><name><surname>Pepper</surname><given-names>F</given-names></name><name><surname>Fam</surname><given-names>J</given-names></name><name><surname>Furby</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>E</given-names></name><name><surname>Morgan</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2014</year>) <volume>231</volume>(<issue>10</issue>):<fpage>2107</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-013-3354-8</pub-id><pub-id pub-id-type="pmid">24264567</pub-id></mixed-citation></ref><ref id="B314"><label>314</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>RM</given-names></name><name><surname>Van Noorden</surname><given-names>MS</given-names></name><name><surname>Wannet</surname><given-names>W</given-names></name><name><surname>Beurmajer</surname><given-names>H</given-names></name><name><surname>Dijkstra</surname><given-names>BA</given-names></name><name><surname>Schellekens</surname><given-names>A</given-names></name></person-group><article-title>Pharmacological treatment in gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) dependence: detoxification and relapse prevention</article-title>. <source>CNS Drugs</source> (<year>2017</year>) <volume>31</volume>:<fpage>51</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1007/s40263-016-0402-z</pub-id><pub-id pub-id-type="pmid">28004314</pub-id></mixed-citation></ref><ref id="B315"><label>315</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carai</surname><given-names>MA</given-names></name><name><surname>Colombo</surname><given-names>G</given-names></name><name><surname>Reali</surname><given-names>R</given-names></name><name><surname>Serra</surname><given-names>S</given-names></name><name><surname>Mocci</surname><given-names>I</given-names></name><name><surname>Castelli</surname><given-names>MP</given-names></name><etal></etal></person-group><article-title>Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid</article-title>. <source>Eur J Pharmacol</source> (<year>2002</year>) <volume>441</volume>:<fpage>157</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/S0014-2999(02)01502-9</pub-id><pub-id pub-id-type="pmid">12063087</pub-id></mixed-citation></ref><ref id="B316"><label>316</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Irwing</surname><given-names>RD</given-names></name></person-group><source>NTP Summary Report on the Metabolism, Disposition and Toxicity of 1,4-Butanediol</source>. <publisher-loc>North Carolina</publisher-loc>: <publisher-name>USDoHaH Services</publisher-name> (<year>1996</year>).</mixed-citation></ref><ref id="B317"><label>317</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessman</surname><given-names>SP</given-names></name><name><surname>Fishbein</surname><given-names>WN</given-names></name></person-group><article-title>Gamma-hydroxybutyrate, a normal brain metabolite</article-title>. <source>Nature</source> (<year>1963</year>) <volume>200</volume>:<fpage>1207</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/2001207a0</pub-id><pub-id pub-id-type="pmid">14089913</pub-id></mixed-citation></ref><ref id="B318"><label>318</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snead</surname><given-names>OC</given-names><suffix>III</suffix></name><name><surname>Morley</surname><given-names>BJ</given-names></name></person-group>. <article-title>Ontogeny of gamma-hydroxybutyric acid. I. Regional concentration in developing rat, monkey and human brain</article-title>. <source>Brain Res</source> (<year>1981</year>) <volume>2227</volume>:<fpage>579</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1016/0165-3806(81)90010-9</pub-id><pub-id pub-id-type="pmid">7260659</pub-id></mixed-citation></ref><ref id="B319"><label>319</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engberg</surname><given-names>G</given-names></name><name><surname>Nissbrandt</surname><given-names>H</given-names></name></person-group>. <article-title>Gamma-hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source> (<year>1993</year>) <volume>348</volume>:<fpage>491</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/BF00173208</pub-id><pub-id pub-id-type="pmid">8114948</pub-id></mixed-citation></ref><ref id="B320"><label>320</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benavides</surname><given-names>J</given-names></name><name><surname>Rumigny</surname><given-names>JF</given-names></name><name><surname>Bourguignon</surname><given-names>JJ</given-names></name><name><surname>Cash</surname><given-names>C</given-names></name><name><surname>Wermuth</surname><given-names>CG</given-names></name><name><surname>Mandel</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>High affinity binding sites for gamma-hydroxybutyric acid in rat brain</article-title>. <source>Life Sci</source> (<year>1982</year>) <volume>30</volume>:<fpage>953</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/0024-3205(82)90624-5</pub-id><pub-id pub-id-type="pmid">7070203</pub-id></mixed-citation></ref><ref id="B321"><label>321</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snead</surname><given-names>OC</given-names><suffix>III</suffix></name></person-group>. <article-title>Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor</article-title>. <source>J Neurochem</source> (<year>2000</year>) <volume>75</volume>:<fpage>1986</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0751986.x</pub-id><pub-id pub-id-type="pmid">11032888</pub-id></mixed-citation></ref><ref id="B322"><label>322</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>LP</given-names></name><name><surname>Koek</surname><given-names>W</given-names></name><name><surname>France</surname><given-names>CP</given-names></name></person-group><article-title>Behavioral analyses of GHB: receptor mechanisms</article-title>. <source>Pharmacol Ther</source> (<year>2009</year>) <volume>121</volume>:<fpage>100</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.10.003</pub-id><pub-id pub-id-type="pmid">19010351</pub-id></mixed-citation></ref><ref id="B323"><label>323</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andresen</surname><given-names>H</given-names></name><name><surname>Aydin</surname><given-names>BE</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Iwersen-Bergmann</surname><given-names>S</given-names></name></person-group>. <article-title>An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results</article-title>. <source>Drug Test Anal</source> (<year>2011</year>) <volume>3</volume>:<fpage>560</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/dta.254</pub-id><pub-id pub-id-type="pmid">21381220</pub-id></mixed-citation></ref><ref id="B324"><label>324</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Liakoni</surname><given-names>E</given-names></name><name><surname>Dornbierer</surname><given-names>D</given-names></name><name><surname>von Rotz</surname><given-names>R</given-names></name><name><surname>Gachet</surname><given-names>MS</given-names></name><etal></etal></person-group><article-title>Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyrate in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source> (<year>2016</year>) <volume>81</volume>(<issue>5</issue>):<fpage>980</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1111/bcp.12863</pub-id><pub-id pub-id-type="pmid">26659543</pub-id></mixed-citation></ref><ref id="B325"><label>325</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schep</surname><given-names>LJ</given-names></name><name><surname>Knudsen</surname><given-names>K</given-names></name><name><surname>Slaughter</surname><given-names>RJ</given-names></name><name><surname>Vale</surname><given-names>JA</given-names></name><name><surname>Mégarbane</surname><given-names>B</given-names></name></person-group><article-title>The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol</article-title>. <source>Clin Toxicol (Phila)</source> (<year>2012</year>) <volume>50</volume>:<fpage>458</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="doi">10.3109/15563650.2012.702218</pub-id><pub-id pub-id-type="pmid">22746383</pub-id></mixed-citation></ref><ref id="B326"><label>326</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>EE</given-names></name><name><surname>Nelson</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>N</given-names></name></person-group>. <article-title>Oxidation of gamma-hydroxybutyrate to succinic semialdehyde by a mitochondrial pyridine nucleotide-independent enzyme</article-title>. <source>J Neurochem</source> (<year>1988</year>) <volume>51</volume>:<fpage>1079</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.1988.tb03071.x</pub-id><pub-id pub-id-type="pmid">3138385</pub-id></mixed-citation></ref><ref id="B327"><label>327</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abanades</surname><given-names>S</given-names></name><name><surname>Farre</surname><given-names>M</given-names></name><name><surname>Segura</surname><given-names>M</given-names></name><name><surname>Pichini</surname><given-names>S</given-names></name><name><surname>Barral</surname><given-names>D</given-names></name><name><surname>Pacifici</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics</article-title>. <source>Ann N Y Acad Sci</source> (<year>2006</year>) <volume>1074</volume>:<fpage>559</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1196/annals.1369.065</pub-id><pub-id pub-id-type="pmid">17105953</pub-id></mixed-citation></ref><ref id="B328"><label>328</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>OG</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Gertsch</surname><given-names>J</given-names></name><name><surname>von Rotz</surname><given-names>R</given-names></name><name><surname>Dornbierer</surname><given-names>D</given-names></name><name><surname>Gachet</surname><given-names>MS</given-names></name><etal></etal></person-group><article-title>Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone</article-title>. <source>Psychoneuroendocrinology</source> (<year>2015</year>) <volume>62</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.07.167</pub-id><pub-id pub-id-type="pmid">26209926</pub-id></mixed-citation></ref><ref id="B329"><label>329</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miotto</surname><given-names>K</given-names></name><name><surname>Darakjian</surname><given-names>J</given-names></name><name><surname>Basch</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Zogg</surname><given-names>J</given-names></name><name><surname>Rawson</surname><given-names>R</given-names></name></person-group>. <article-title>Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal</article-title>. <source>Am J Addict</source> (<year>2001</year>) <volume>10</volume>:<fpage>232</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1080/105504901750532111</pub-id><pub-id pub-id-type="pmid">11579621</pub-id></mixed-citation></ref><ref id="B330"><label>330</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Sassenbroeck</surname><given-names>DK</given-names></name><name><surname>De Neve</surname><given-names>N</given-names></name><name><surname>De Paepe</surname><given-names>P</given-names></name><name><surname>Belpaire</surname><given-names>FM</given-names></name><name><surname>Verstraete</surname><given-names>AG</given-names></name><name><surname>Calle</surname><given-names>PA</given-names></name><etal></etal></person-group><article-title>Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series</article-title>. <source>Clin Toxicol (Phila)</source> (<year>2007</year>) <volume>45</volume>:<fpage>533</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1080/15563650701365818</pub-id><pub-id pub-id-type="pmid">17503262</pub-id></mixed-citation></ref><ref id="B331"><label>331</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donjacour</surname><given-names>CE</given-names></name><name><surname>Aziz</surname><given-names>NA</given-names></name><name><surname>Overeem</surname><given-names>S</given-names></name><name><surname>Kalsbeek</surname><given-names>A</given-names></name><name><surname>Pijl</surname><given-names>H</given-names></name><name><surname>Lammers</surname><given-names>GJ</given-names></name></person-group>. <article-title>Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study</article-title>. <source>Sleep</source> (<year>2014</year>) <volume>37</volume>:<fpage>795</fpage>–<lpage>801</lpage>.<pub-id pub-id-type="doi">10.5665/sleep.3592</pub-id><pub-id pub-id-type="pmid">24899766</pub-id></mixed-citation></ref><ref id="B332"><label>332</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>AK</given-names></name><name><surname>Froestl</surname><given-names>W</given-names></name><name><surname>Weerts</surname><given-names>EM</given-names></name></person-group>. <article-title>Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2005</year>) <volume>180</volume>:<fpage>342</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-005-2165-y</pub-id><pub-id pub-id-type="pmid">15739078</pub-id></mixed-citation></ref><ref id="B333"><label>333</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>AM</given-names></name><name><surname>Ristanovic</surname><given-names>RK</given-names></name><name><surname>Bogan</surname><given-names>RK</given-names></name></person-group>. <article-title>Weight loss in narcolepsy patients treated with sodium oxybate</article-title>. <source>Sleep Med</source> (<year>2009</year>) <volume>10</volume>:<fpage>661</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1016/j.sleep.2008.05.012</pub-id><pub-id pub-id-type="pmid">19014899</pub-id></mixed-citation></ref><ref id="B334"><label>334</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottani</surname><given-names>A</given-names></name><name><surname>Leone</surname><given-names>S</given-names></name><name><surname>Vergara</surname><given-names>FB</given-names></name><name><surname>Tacchi</surname><given-names>R</given-names></name><name><surname>Loche</surname><given-names>A</given-names></name><name><surname>Bertolini</surname><given-names>A</given-names></name></person-group>. <article-title>Preference for palatable food is reduced by the gamma-hydroxybutyrate analogue GET73, in rats</article-title>. <source>Pharmacol Res</source> (<year>2007</year>) <volume>55</volume>:<fpage>271</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.phrs.2006.12.002</pub-id><pub-id pub-id-type="pmid">17240159</pub-id></mixed-citation></ref><ref id="B335"><label>335</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElroy</surname><given-names>SL</given-names></name><name><surname>Guerdjikova</surname><given-names>AI</given-names></name><name><surname>Winstanley</surname><given-names>EL</given-names></name><name><surname>O’Melia</surname><given-names>AM</given-names></name><name><surname>Mori</surname><given-names>N</given-names></name><name><surname>Keck</surname><given-names>PE</given-names><suffix>Jr</suffix></name><etal></etal></person-group><article-title>Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study</article-title>. <source>Int J Eat Disord</source> (<year>2011</year>) <volume>44</volume>:<fpage>262</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/eat.20798</pub-id><pub-id pub-id-type="pmid">20209489</pub-id></mixed-citation></ref><ref id="B336"><label>336</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapitány-Fövény</surname><given-names>M</given-names></name><name><surname>Mervó</surname><given-names>B</given-names></name><name><surname>Corazza</surname><given-names>O</given-names></name><name><surname>Kökönyei</surname><given-names>G</given-names></name><name><surname>Farkas</surname><given-names>J</given-names></name><name><surname>Urbán</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Enhancing sexual desire and experience: an investigation of the sexual correlates of gamma-hydroxybutyrate (GHB) use</article-title>. <source>Hum Psychopharmacol</source> (<year>2015</year>) <volume>30</volume>:<fpage>276</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1002/hup.2491</pub-id><pub-id pub-id-type="pmid">26216563</pub-id></mixed-citation></ref><ref id="B337"><label>337</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumnall</surname><given-names>HR</given-names></name><name><surname>Woolfall</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>JC</given-names></name><name><surname>Beynon</surname><given-names>CM</given-names></name></person-group>. <article-title>Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB)</article-title>. <source>Drug Alcohol Depend</source> (<year>2008</year>) <volume>92</volume>:<fpage>286</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2007.07.009</pub-id><pub-id pub-id-type="pmid">17766059</pub-id></mixed-citation></ref><ref id="B338"><label>338</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teltzrow</surname><given-names>R</given-names></name><name><surname>Bosch</surname><given-names>OG</given-names></name></person-group><article-title>Ecstatic anaesthesia: ketamine and GHB between medical use and self-experimentation</article-title>. <source>Appl Cardiopulm Pathophysiol</source> (<year>2012</year>) <volume>16</volume>:<fpage>309</fpage>–<lpage>21</lpage>.</mixed-citation></ref><ref id="B339"><label>339</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>OG</given-names></name><name><surname>Havranek</surname><given-names>MM</given-names></name><name><surname>Baumberger</surname><given-names>A</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>von Rotz</surname><given-names>R</given-names></name><name><surname>Herdener</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans</article-title>. <source>Eur Neuropsychopharmacol</source> (<year>2017</year>) <volume>27</volume>(<issue>4</issue>):<fpage>372</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.euroneuro.2017.02.006</pub-id><pub-id pub-id-type="pmid">28284776</pub-id></mixed-citation></ref><ref id="B340"><label>340</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamelak</surname><given-names>M</given-names></name><name><surname>Escriu</surname><given-names>JM</given-names></name><name><surname>Stokan</surname><given-names>O</given-names></name></person-group><article-title>Sleep-inducing effects of gammahydroxybutyrate</article-title>. <source>Lancet</source> (<year>1973</year>) <volume>2</volume>:<fpage>328</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(73)90839-8</pub-id></mixed-citation></ref><ref id="B341"><label>341</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>J</given-names></name><name><surname>Houghton</surname><given-names>WC</given-names></name></person-group>. <article-title>Sodium oxybate improves excessive daytime sleepiness in narcolepsy</article-title>. <source>Sleep</source> (<year>2006</year>) <volume>29</volume>:<fpage>939</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1093/sleep/29.7.939</pub-id><pub-id pub-id-type="pmid">16895262</pub-id></mixed-citation></ref><ref id="B342"><label>342</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>J</given-names></name><name><surname>Pardi</surname><given-names>D</given-names></name><name><surname>Hornfeldt</surname><given-names>CS</given-names></name><name><surname>Inhaber</surname><given-names>N</given-names></name></person-group>. <article-title>The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy</article-title>. <source>J Clin Sleep Med</source> (<year>2010</year>) <volume>6</volume>(<issue>6</issue>):<fpage>596</fpage>–<lpage>602</lpage>.<pub-id pub-id-type="pmid">21206549</pub-id></mixed-citation></ref><ref id="B343"><label>343</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaeth</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>RM</given-names></name><name><surname>Benson</surname><given-names>BA</given-names></name><name><surname>Wang</surname><given-names>YG</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Choy</surname><given-names>EH</given-names></name></person-group>. <article-title>Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial</article-title>. <source>Ann Rheum Dis</source> (<year>2012</year>) <volume>71</volume>:<fpage>935</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200418</pub-id><pub-id pub-id-type="pmid">22294641</pub-id></mixed-citation></ref><ref id="B344"><label>344</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimeńez</surname><given-names>F</given-names></name><name><surname>Lopez Timoneda</surname><given-names>F</given-names></name><name><surname>Nodal</surname><given-names>C</given-names></name><name><surname>Arrigain</surname><given-names>S</given-names></name></person-group><article-title>Neurophysiological study of the effects of gamma-OH at several doses in normal subjects</article-title>. <source>Arch Neurobiol (Madr)</source> (<year>1982</year>) <volume>45</volume>:<fpage>3</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">7125804</pub-id></mixed-citation></ref><ref id="B345"><label>345</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metcalf</surname><given-names>DR</given-names></name><name><surname>Emde</surname><given-names>RN</given-names></name><name><surname>Stripe</surname><given-names>JT</given-names></name></person-group><article-title>An EEG-behavioral study of sodium hydroxybutyrate in humans</article-title>. <source>Electroencephalogr Clin Neurophysiol</source> (<year>1966</year>) <volume>20</volume>:<fpage>506</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/0013-4694(66)90107-6</pub-id><pub-id pub-id-type="pmid">4143689</pub-id></mixed-citation></ref><ref id="B346"><label>346</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cauter</surname><given-names>E</given-names></name><name><surname>Plat</surname><given-names>L</given-names></name><name><surname>Scharf</surname><given-names>MB</given-names></name><name><surname>Leproult</surname><given-names>R</given-names></name><name><surname>Cespedes</surname><given-names>S</given-names></name><name><surname>L’Hermite-Balériaux</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men</article-title>. <source>J Clin Invest</source> (<year>1997</year>) <volume>100</volume>:<fpage>745</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1172/JCI119587</pub-id><pub-id pub-id-type="pmid">9239423</pub-id></mixed-citation></ref><ref id="B347"><label>347</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Rotz</surname><given-names>R</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name><name><surname>Dornbierer</surname><given-names>D</given-names></name><name><surname>Gertsch</surname><given-names>J</given-names></name><name><surname>Salomé Gachet</surname><given-names>M</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><etal></etal></person-group><article-title>Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers</article-title>. <source>Psychopharmacology (Berl)</source> (<year>2017</year>) <volume>234</volume>:<fpage>1957</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-017-4603-z</pub-id><pub-id pub-id-type="pmid">28429067</pub-id></mixed-citation></ref><ref id="B348"><label>348</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>OG</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Havranek</surname><given-names>MM</given-names></name><name><surname>Dornbierer</surname><given-names>D</given-names></name><name><surname>von Rotz</surname><given-names>R</given-names></name><name><surname>Staempfli</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Gamma-hydroxybutyrate increases resting state limbic perfusion and body and emotion awareness in humans</article-title>. <source>Neuropsychopharmacology</source>. (<year>2017</year>)<pub-id pub-id-type="doi">10.1038/npp.2017.110</pub-id>.</mixed-citation></ref><ref id="B349"><label>349</label><mixed-citation publication-type="book"><collab>EMCDDA</collab>. <source>GHB and Its Precursor GBL: An Emerging Trend Case Study</source>. <publisher-loc>Lisbon</publisher-loc>: <publisher-name>European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)</publisher-name> (<year>2008</year>).</mixed-citation></ref><ref id="B350"><label>350</label><mixed-citation publication-type="confproc"><collab>WHO</collab>. <article-title>Gamma-hydroxybutyric acid (GHB) critical review report</article-title>. <conf-name>WHO Expert Committee on Drug DependeNCE, ECOD – Thirty-fifth Meeting</conf-name><conf-loc>Hammamet, Tunisia</conf-loc> (<year>2012</year>).</mixed-citation></ref><ref id="B351"><label>351</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>LP</given-names></name><name><surname>Pardi</surname><given-names>D</given-names></name><name><surname>Gorsline</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse</article-title>. <source>Drug Alcohol Depend</source> (<year>2009</year>) <volume>104</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.04.012</pub-id><pub-id pub-id-type="pmid">19493637</pub-id></mixed-citation></ref><ref id="B352"><label>352</label><mixed-citation publication-type="book"><collab>USGPO</collab>. <source>Public Law 106–172 – Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000</source>. <publisher-name>U.S. Government Publishing Office</publisher-name> (<year>2000</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.gpo.gov/fdsys/pkg/PLAW-106publ172/content-detail.html">http://www.gpo.gov/fdsys/pkg/PLAW-106publ172/content-detail.html</uri></mixed-citation></ref><ref id="B353"><label>353</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>Z</given-names></name><name><surname>Kun</surname><given-names>B</given-names></name><name><surname>Demetrovics</surname><given-names>Z</given-names></name></person-group>. <article-title>The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review</article-title>. <source>J Psychopharmacol</source> (<year>2010</year>) <volume>24</volume>:<fpage>1281</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1177/0269881110363315</pub-id><pub-id pub-id-type="pmid">20488831</pub-id></mixed-citation></ref><ref id="B354"><label>354</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boscolo-Berto</surname><given-names>R</given-names></name><name><surname>Viel</surname><given-names>G</given-names></name><name><surname>Montagnese</surname><given-names>S</given-names></name><name><surname>Raduazzo</surname><given-names>DI</given-names></name><name><surname>Ferrara</surname><given-names>SD</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name></person-group>. <article-title>Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Sleep Med Rev</source> (<year>2012</year>) <volume>16</volume>:<fpage>431</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.smrv.2011.09.001</pub-id><pub-id pub-id-type="pmid">22055895</pub-id></mixed-citation></ref><ref id="B355"><label>355</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caputo</surname><given-names>F</given-names></name><name><surname>Mirijello</surname><given-names>A</given-names></name><name><surname>Cibin</surname><given-names>M</given-names></name><name><surname>Mosti</surname><given-names>A</given-names></name><name><surname>Ceccanti</surname><given-names>M</given-names></name><name><surname>Domenicali</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice</article-title>. <source>Eur Rev Med Pharmacol Sci</source> (<year>2015</year>) <volume>19</volume>:<fpage>1315</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">25912595</pub-id></mixed-citation></ref><ref id="B356"><label>356</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>IJ</given-names></name><name><surname>Perkins</surname><given-names>AT</given-names></name><name><surname>Michalek</surname><given-names>JE</given-names></name><collab>Oxybate SXB-26 Fibromyalgia Syndrome Study Group</collab></person-group>. <article-title>Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial</article-title>. <source>Arthritis Rheum</source> (<year>2009</year>) <volume>60</volume>:<fpage>299</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="doi">10.1002/art.24142</pub-id><pub-id pub-id-type="pmid">19116896</pub-id></mixed-citation></ref><ref id="B357"><label>357</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>IJ</given-names></name><name><surname>Holman</surname><given-names>AJ</given-names></name><name><surname>Swick</surname><given-names>TJ</given-names></name><name><surname>Alvarez-Horine</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>YG</given-names></name><name><surname>Guinta</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study</article-title>. <source>Pain</source> (<year>2011</year>) <volume>152</volume>:<fpage>1007</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.pain.2010.12.022</pub-id><pub-id pub-id-type="pmid">21397402</pub-id></mixed-citation></ref><ref id="B358"><label>358</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaeth</surname><given-names>M</given-names></name><name><surname>Alegre</surname><given-names>C</given-names></name><name><surname>Perrot</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guinta</surname><given-names>DR</given-names></name><name><surname>Alvarez-Horine</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia</article-title>. <source>Arthritis Res Ther</source> (<year>2013</year>) <volume>15</volume>:<fpage>R185</fpage>.<pub-id pub-id-type="doi">10.1186/ar4375</pub-id><pub-id pub-id-type="pmid">24286114</pub-id></mixed-citation></ref><ref id="B359"><label>359</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantrowitz</surname><given-names>JT</given-names></name><name><surname>Citrome</surname><given-names>L</given-names></name><name><surname>Javitt</surname><given-names>DC</given-names></name></person-group><article-title>A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia</article-title>. <source>Clin Ther</source> (<year>2009</year>) <volume>31</volume>(<issue>Pt 1</issue>):<fpage>1360</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.clinthera.2009.07.005</pub-id><pub-id pub-id-type="pmid">19698899</pub-id></mixed-citation></ref><ref id="B360"><label>360</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Perkins</surname><given-names>T</given-names></name><name><surname>Swick</surname><given-names>T</given-names></name><name><surname>Hull</surname><given-names>KL</given-names><suffix>Jr</suffix></name><name><surname>Jimenez</surname><given-names>JE</given-names></name><name><surname>Garris</surname><given-names>TS</given-names></name><etal></etal></person-group><article-title>Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study</article-title>. <source>Arch Neurol</source> (<year>2008</year>) <volume>65</volume>:<fpage>1337</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1001/archneur.65.10.1337</pub-id><pub-id pub-id-type="pmid">18852348</pub-id></mixed-citation></ref><ref id="B361"><label>361</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>H</given-names></name><name><surname>Uhl</surname><given-names>V</given-names></name><name><surname>Gantenbein</surname><given-names>AR</given-names></name><name><surname>Sándor</surname><given-names>PS</given-names></name><name><surname>Kallweit</surname><given-names>U</given-names></name></person-group>. <article-title>Efficiency of sodium oxybate in episodic cluster headache</article-title>. <source>Headache</source> (<year>2013</year>) <volume>53</volume>:<fpage>1490</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="doi">10.1111/head.12068</pub-id><pub-id pub-id-type="pmid">23463909</pub-id></mixed-citation></ref><ref id="B362"><label>362</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatami</surname><given-names>R</given-names></name><name><surname>Tartarotti</surname><given-names>S</given-names></name><name><surname>Siccoli</surname><given-names>MM</given-names></name><name><surname>Bassetti</surname><given-names>CL</given-names></name><name><surname>Sándor</surname><given-names>PS</given-names></name></person-group>. <article-title>Long-term efficacy of sodium oxybate in 4 patients with chronic cluster headache</article-title>. <source>Neurology</source> (<year>2011</year>) <volume>77</volume>:<fpage>67</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.0b013e31822313c6</pub-id><pub-id pub-id-type="pmid">21613599</pub-id></mixed-citation></ref><ref id="B363"><label>363</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>OG</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Seifritz</surname><given-names>E</given-names></name><name><surname>Wetter</surname><given-names>TC</given-names></name></person-group>. <article-title>Reconsidering GHB: orphan drug or new model antidepressant?</article-title><source>J Psychopharmacol</source> (<year>2012</year>) <volume>26</volume>:<fpage>618</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1177/0269881111421975</pub-id><pub-id pub-id-type="pmid">21926421</pub-id></mixed-citation></ref><ref id="B364"><label>364</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamelak</surname><given-names>M</given-names></name></person-group>. <article-title>Narcolepsy and depression and the neurobiology of gammahydroxybutyrate</article-title>. <source>Prog Neurobiol</source> (<year>2009</year>) <volume>89</volume>:<fpage>193</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="doi">10.1016/j.pneurobio.2009.07.004</pub-id><pub-id pub-id-type="pmid">19654034</pub-id></mixed-citation></ref><ref id="B365"><label>365</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>LP</given-names></name><name><surname>Richards</surname><given-names>BD</given-names></name><name><surname>Mintzer</surname><given-names>MZ</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group>. <article-title>Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB</article-title>. <source>Neuropsychopharmacology</source> (<year>2006</year>) <volume>31</volume>:<fpage>2537</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1038/sj.npp.1301146</pub-id><pub-id pub-id-type="pmid">16880774</pub-id></mixed-citation></ref><ref id="B366"><label>366</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>MY</given-names></name><name><surname>Kreutzer</surname><given-names>RA</given-names></name><name><surname>Dyer</surname><given-names>JE</given-names></name></person-group>. <article-title>Acute poisoning from gamma-hydroxybutyrate in California</article-title>. <source>West J Med</source> (<year>1992</year>) <volume>156</volume>:<fpage>380</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">1574880</pub-id></mixed-citation></ref><ref id="B367"><label>367</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>CF</given-names></name><name><surname>Feldman</surname><given-names>N</given-names></name><name><surname>Inhaber</surname><given-names>N</given-names></name><name><surname>Steininger</surname><given-names>TL</given-names></name><name><surname>Grzeschik</surname><given-names>SM</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing</article-title>. <source>Sleep Med</source> (<year>2010</year>) <volume>11</volume>:<fpage>38</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.sleep.2009.06.006</pub-id><pub-id pub-id-type="pmid">19897413</pub-id></mixed-citation></ref><ref id="B368"><label>368</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>OG</given-names></name><name><surname>Seifritz</surname><given-names>E</given-names></name></person-group><article-title>The behavioural profile of gamma-hydroxybutyrate, y-butyrolactone and 1,4-butanediol in humans</article-title>. <source>Brain Res Bull</source> (<year>2016</year>) <volume>126</volume>(<issue>Pt 1</issue>):<fpage>47</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.02.002</pub-id><pub-id pub-id-type="pmid">26855327</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/MusiqueCeltiqueV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001004 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001004 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= MusiqueCeltiqueV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.38. |  |